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Abstract  
 
Campylobacter is a major cause of acute bacterial gastroenteritis worldwide, with the 
highest number of infections being attributed to Campylobacter jejuni.  C. jejuni is a Gram 
negative, spiral, motile bacterium that belongs to the campylobacterales order and is 
related to both Helicobacter spp. and Wolinella sp..  It has long been established that 
proton pump inhibitors (PPIs) and other benzimidazole derivatives display anti-
Helicobacter activity in vitro.  PPIs have in the past been shown to affect Helicobacter 
pylori growth, survival, motility, morphology, adhesion/invasion potential and 
susceptibility to conventional antibiotics.   
PPIs are highly effective drugs that are well tolerated, safe for prolonged daily use and are 
therefore in high demand.  Both the PPIs omeprazole and lansoprazole featured in the top 
ten drugs prescribed in England in 2014.  In 2014 Campylobacter was also the most 
commonly diagnosed gastrointestinal infection in Scotland, in England and Wales and also 
in Europe.  It has previously been generally accepted that patients who are being treated 
with PPIs are more susceptible to enteric infections such as Campylobacter than people not 
taking PPIs.  The effect of PPI exposure on H. pylori has been investigated rigorously in 
the past.  A single previous study has hinted that PPIs may also be capable of affecting the 
related organism C. jejuni, but investigations have been extremely limited in comparison to 
those investigating the effect of PPIs on H. pylori.  This study has investigated the in vitro 
effects of direct contact with PPIs on the biology of C. jejuni.   
Exposure to the PPI pantoprazole was found to affect C. jejuni growth/survival, motility, 
morphology, biofilm formation, invasion potential and susceptibility to some conventional 
antibiotics.  Microarray studies showed that the cmeA and Cj0561c genes were 
significantly up-regulated in response to pantoprazole exposure and a CmeABC deficient 
mutant was found to be significantly more susceptible to killing by pantoprazole than was 
the parent strain.  Proteomic analysis indicated that the oxidative stress response of 
C. jejuni was induced following exposure to sub-lethal concentrations of pantoprazole.  
C. jejuni gene expression was assessed using qRT-PCR and the genes encoding for thiol 
peroxidase and GroEL co-chaperonin (both involved in the C. jejuni oxidative stress 
response) were found to be around four times higher in response to exposure to sub-lethal 
concentrations of pantoprazole.  Experiments using the oxidative stress inhibitors thiourea 
(a hydroxyl radical quencher) and bipyridyl (a ferrous iron chelator) showed that killing by 
pantoprazole was not mediated by hydroxyl radical production.    
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NaCl sodium chloride 
O2 oxygen 
O2
-
 superoxide 
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1 INTRODUCTION  
1.1 History of Campylobacter Discovery  
The first reported discovery of a pathogenic bacterium, which likely belonged in the genus 
currently known as Campylobacter, was in 1886.  A German bacteriologist named Theodor 
Escherich observed spiral shaped organisms in the colon and faeces of children that had 
died of enteric infection, which he was notably unable to culture (Kist, 1986).  Because he 
was unable to isolate the bacteria, the significance of the organism in patients with enteric 
infections was overlooked for many years.   
In 1913, John McFadyean and Stewart Stockman reported that they had observed 
peculiarly shaped organisms in the uterine mucus of sheep and cattle that had suffered 
abortions (Skirrow, 2006).  They classified them as vibrios because of their shape, but they 
had more than likely actually isolated Campylobacter fetus (C. fetus).  In 1919, Theobald 
Smith and Marian Taylor isolated spiral shaped bacteria, similar to those observed by 
McFadyean and Stockman, from aborted bovine foetuses and the species name Vibrio fetus 
was proposed to describe these organisms (Smith & Taylor, 1919).  The species name 
jejuni was first introduced by Jones et al in 1931 when they isolated a bacterium they 
called Vibrio jejuni (originally found in the jejunum), from calves with dysentery (Jones et 
al., 1931) and the species name coli was first introduced by Doyle in 1944 to describe 
organisms isolated from pigs.   
These difficult to isolate and culture organisms were considered pathogens of mainly 
veterinary importance for many years.  In 1946, AJ Levy reported that Vibrio jejuni was 
the likely causative agent in a milk-borne enteritis outbreak that had occurred in Illinois in 
1938 (Levy, 1946).  This signalled the initiation of interest in these organisms in relation to 
human disease.  In the 1950s, Elizabeth King noted that organisms isolated from the blood 
cultures of patients with diarrhoeal disease could be separated into two groups: those that 
grew best at 37°C and those that were thermophilic and grew best at 42°C.  She correctly 
hypothesised that the thermophilic organisms could be the cause of the diarrhoeal illness 
and that they might occur more commonly than their isolation from blood might suggest 
(King, 1957). 
In 1963, Sebald and Veron reported notable differences in the growth conditions of the 
organisms previously classified in the Vibrio genus.  Differences in the deoxyribonucleic 
acid (DNA) guanine and cytosine content were also observed and the new genus 
Campylobacter (from the Greek campylo; meaning curved) was proposed for a number of 
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the organisms (Sebald & Veron, 1963) including Vibrio fetus.  However, the complex 
growth requirements of the fastidious Campylobacter organisms were not fully understood 
and isolation and growth of the bacteria remained a challenge.   
In 1972, Dekeyser et al made their own growth media using thioglycolate-agar base with 
15% defibrinated ovine blood and the antibiotics novobiocin, bacitracin and polymixin B.  
They combined centrifugation and filtration techniques and were the first to report 
successful isolation of “related vibrios” from the stools of patients with enteritis (Dekeyser 
et al., 1972).  In 1977, a less “burdensome to laboratory staff” method of isolating 
campylobacters was developed by Skirrow (Skirrow, 1977).  A selective media that 
contained trimethoprim, vancomycin and polymixin B finally enabled widespread isolation 
of the organisms under laboratory conditions using “only a vacuum jar and an incubator set 
at about 43°C”.  The importance, in human gastrointestinal (GI) disease, of organisms 
within the Campylobacter genus soon became apparent.  Advances in culturing techniques 
and rising awareness have meant that Campylobacter is now recognised as the leading 
cause of human bacterial gastroenteritis in the world. 
1.2 Campylobacter Genus and Campylobacter jejuni  
The genus Campylobacter belongs to the epsilon class of Proteobacteria in the order 
campylobacterales.  The related genera Helicobacter and Wolinella are also included in the 
campylobacterales order.  The Campylobacter genus currently consists of seventeen 
species and six subspecies, of which the most frequently reported in human disease are 
Campylobacter jejuni subspecies jejuni (C. jejuni) and Campylobacter coli (C. coli) (Cody 
et al., 2013).  Other species such as Campylobacter lari (C. lari) and Campylobacter 
upsaliensis (C. upsaliensis) have also been, although much less frequently, isolated from 
patients with diarrhoeal disease (Kaneko et al., 1999, Couturier et al., 2012) and species 
such as C. fetus and Campylobacter hyointestinalis (C. hyointestinalis) remain mainly of 
veterinary importance.  C. jejuni causes around 90% of human infections, C. coli around 
8% and other species account for only around 2% of all human Campylobacter infections 
(Cody et al., 2013).  C. jejuni is therefore the most significant species with regard to 
human illness and is therefore the species used for the majority of experimental work 
detailed within this thesis. 
C. jejuni is a small (0.2-0.8 µm wide and 0.5-5.0 µm long) spiral-shaped, Gram negative 
bacterium.  It has a single unsheathed flagellum at one or both ends of the cell and exhibits 
a characteristic rapid darting or spinning motility.  It is microaerophilic and cannot 
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normally be grown in the laboratory under ambient gaseous atmospheric conditions; it 
grows best at around 5-10% oxygen (O2). 
C. jejuni has a comparatively small genome (around 1.6-1.8 megabases) which is rich in 
adenine and thymine (Fouts et al., 2005).  Having such a small genome may explain some 
of C. jejuni’s phenotypic properties e.g. their inability to metabolise carbohydrates or to 
degrade complex substances and their need for complex growth media (Dasti et al., 2010).  
C. jejuni has only a single superoxide dismutase (SOD) enzyme (SodB) and a single 
catalase enzyme (KatA) encoded for in its genome (Stead & Park, 2000).  The aerobic 
Gram negative enteric pathogen Escherichia coli (E. coli), in contrast, has three SODs and 
two catalase enzymes (Hwang et al., 2012).  C. jejuni is therefore extremely sensitive to 
the action of free radicals and superoxide, more so than some other aerobic enteric 
pathogens that are better equipped to manage oxidative stress.  Some strains of C. jejuni 
can grow in atmospheric oxygen if blood or pyruvate has been added to growth media, as 
these are able to scavenge oxygen.  Charcoal can also be added to agar used for the 
isolation of C. jejuni as it prevents the accumulation of reactive oxygen species (ROS) 
(John et al., 2011). 
1.3 Campylobacteriosis  
Human disease is often food or waterborne and occurs via the oral route, where ingested 
Campylobacter must survive the acid environment of the stomach and the activity of 
proteolytic enzymes in order to reach the intestines.  The surface of the intestinal tract is 
covered in a thick layer of mucus and Campylobacter must colonise the mucus layer in 
order to establish themselves in the colon and distal ileum.  Black et al demonstrated that 
an infectious dose of only 500-800 organisms was sufficient to cause human disease 
(Black et al., 1988). 
In Scotland in 2014 there were 6,636 cases of campylobacteriosis diagnosed (Health-
Protection-Scotland., 2015), which corresponds to an incidence of 124.6 cases per 100,000 
population (Browning et al., 2015).  In comparison, there were only 717 cases of 
salmonellosis reported in Scotland for the same time period (Health-Protection-Scotland, 
2015), with an incidence of only 13.5 cases per 100,000 population (Browning et al., 
2015).   
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Campylobacter was also by far the most common cause of GI illness for the same time 
period in England and Wales, causing more diagnosed infections than for Salmonella, 
Shigella, E. coli O157, Norovirus, Rotavirus, Giardia and Cryptosporidium combined (see 
Table 1).  Campylobacter is therefore the most common cause of acute bacterial 
gastroenteritis in the United Kingdom (UK) and is of great clinical importance.   
Table 1.  The most commonly diagnosed GI infections in England and Wales in 2013 
and 2014.   
 
Laboratory Reports for England and Wales 
GI Pathogen Cumulative Totals 2013 Cumulative Totals 2014 
Campylobacter 58,742 58,722 
Salmonella   7,255   6,672 
Norovirus   6,922   5,734 
Rotavirus 14,943   4,315 
Giardia   3,584   3,779 
Cryptosporidium   3,481   3,587 
Shigella sonnei     986   1,088 
E. coli O157     770     891 
 
Laboratory diagnosed infections listed in descending order for 2014.  Compiled using data 
from (Public-Health-England, 2015).   
 
C. jejuni has been the most commonly reported bacterial GI pathogen of humans in the 
European Union since 2005.  In 2014 the number of confirmed human campylobacteriosis 
cases reported was 236,851 with an incidence of 71 per 100,000 population, an increase of 
9.6% compared with the rate in 2013 (EFSA, 2015).  Salmonellosis was the second most 
commonly reported infection in the European Union with a total of 88,715 confirmed 
cases.  In the United States, Campylobacter is the second most common cause of food-
borne bacterial gastroenteritis (with Salmonella being the commonest) and in 2013 the 
incidence of campylobacteriosis was 13.73 cases per 100,000 population and for 
salmonellosis was 15.15 cases per 100,000 population (CDC, 2013).  In 2013 
Campylobacter resulted in fewer hospitalisations than Salmonella (1,028 versus 2,029) and 
resulted in fewer deaths than Salmonella (11 versus 30) in the United States.   
1.3.1 Symptoms and Management  
The incubation period can be long and quite variable (between 1 and 7 days) but is often 
between 1 and 3 days.  Symptoms can range from mild watery diarrhoea to severe bloody 
diarrhoea with fever and leukocytes in the stools (Yabe et al., 2010).  Patients may also 
experience malaise, fatigue, abdominal cramps, headaches or dizziness.  Vomiting is rare 
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but prolonged infections may result in weight-loss.  Campylobacter causes an 
inflammatory type diarrhoea that can lead to GI tissue damage but infections are usually 
self-limiting.  Symptoms often resolve after around 7 days and patients often do not require 
any treatment other than rehydration and replacement of electrolytes.   
1.3.2 Antibiotic Treatment of Campylobacter Infection  
Antibiotic treatment is not normally required, especially in the immunocompetent.  
Immunocompromised individuals, those with persistent disease, patients with severe 
bloody diarrhoea, paediatric cases and infections in the elderly may however benefit from 
antibiotic treatment in order to shorten the duration of symptoms.  Serious and systemic 
infections such as meningitis, endocarditis and bacteraemia can occur and also require 
antibiotic treatment, but they are rare and occur mostly in immunocompromised hosts.  As 
a result campylobacteriosis has a relatively low mortality rate (Yabe et al., 2010).  If 
required, campylobacteriosis can be treated with fluoroquinolones (e.g. ciprofloxacin) or 
macrolides (e.g. erythromycin).  Tetracycline may be considered as an alternative, 
although resistance rates can be high (for further information on the antibiotic resistance 
mechanisms of Campylobacter see Section 5.1.2).  In severe cases or in the case of 
systemic infection, intravenous treatment with an aminoglycoside (e.g. gentamicin) may be 
considered (Quinn et al., 2007). 
1.4 Complications Associated with Campylobacter jejuni Infection  
Occasionally, in the weeks or months following C. jejuni infection, “complications” can 
occur in some patients.  The severity, seriousness and duration of which, can be extremely 
variable.  These post-infectious complications can be easily divided into two groups: 
intestinal and extra-intestinal sequelae. 
1.4.1 Intestinal Sequelae  
Irritable bowel syndrome (IBS) is increasingly being implicated as a post-infectious 
complication of C. jejuni infection (Smith & Bayles, 2007, Spiller, 2007, Zilbauer et al., 
2008).  Patients with IBS suffer from abdominal pain, bloating and altered bowel habits.  
Although IBS is not life-threatening, it is life changing and can in some cases be life-long.   
C. jejuni has also been linked to inflammatory bowel diseases like Crohn’s disease (Weber 
et al., 1992, Berberian et al., 1994).  Crohn’s patients have inflamed lining of the digestive 
tract that can cause abdominal pain, diarrhoea, weight-loss and fatigue.  Crohn’s disease 
can again be a long-term condition, although patients may undergo periods of remission 
when they have mild or absent symptoms, followed by debilitating flare ups.  
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Campylobacteriosis is known to cause acute exacerbation of Crohn’s disease symptoms 
and can lead to these flare ups.  Although the intestinal sequelae linked with preceding 
C. jejuni infection are long-term complications, they are not life-threatening conditions.  
However, some of the extra-intestinal sequelae linked with preceding C. jejuni infection 
can be life-threatening. 
1.4.2 Extra-intestinal Sequelae  
Extra-intestinal complications that may result following C. jejuni infection are often, like 
campylobacteriosis, self-limiting.  However, they can occasionally result in serious long-
term deficits
 
in patients or be life-threatening (Wassenaar & Blaser, 1999).  Extra-intestinal 
complications that can occur following C. jejuni infection include Guillain-Barré syndrome 
(GBS), which is the most commonly reported, the related Miller Fisher syndrome (MFS) 
and reactive arthritis (Reuter et al., 2010). 
1.4.2.1 Guillain-Barré Syndrome  
GBS, which can occur around 7-21 days following C. jejuni infection, is an acute 
neurological disease caused by the demyelination of peripheral nerves.  This nerve 
demyelination leads to a rapidly progressing ascending weakness of the limbs, with feet 
and legs usually being the first to display acute flaccid paralysis.  If the paralysis ascends 
and reaches the respiratory muscles then mechanical ventilation may be required.  The 
worldwide annual incidence of GBS is 0.6-4 cases per 100,000 population (Nyati & Nyati, 
2013) and preceding C. jejuni infection is associated with around 20-40% of GBS cases 
(Nyati & Nyati, 2013).  GBS is normally self-limiting but can occasionally lead to a long-
term neurological deficit in some patients (due to irreversible nerve damage) and can be 
life-threatening if respiratory muscles are affected. 
GBS is the result of an auto-immune response which can develop when antibodies to the 
lipo-oligosaccharide (LOS) present on certain serotypes of C. jejuni attack gangliosides 
found on human nerve tissue.  Sialylated LOS structures of C. jejuni in particular are close 
mimics of human peripheral nerve gangliosides (Louwen et al., 2012) and the 
sialyltransferase of C. jejuni, cst-II is involved in the synthesis of the sialylated LOS 
structures that induce the production of the cross-reacting antibodies.  A cst-II knockout 
mutant which lacks the sialyltransferase and cannot sialylate LOS has been shown to be 
unable to induce the production of anti-ganglioside antibodies (Heikema et al., 2013). 
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1.4.2.2 Miller Fisher Syndrome  
MFS is an uncommon variant of GBS, which can also be caused by molecular mimicry, by 
certain strains of C. jejuni.  MFS is characterised by a descending paralysis, which is the 
opposite of that seen in GBS.  MFS often begins with paralysis of the eye muscles 
(ophthalmoplegia), progressing to facial asymmetry, slurred speech, general weakness and 
loss of motor co-ordination (Lo, 2007).  In some cases the paralysis can descend to the 
respiratory muscles, which occurs most often in children.  MFS can then be life-
threatening and mechanical ventilation may be required.  The annual incidence of MFS is 
low, at around 0.09 per 100,000 population (Lo, 2007).  The symptoms of MFS are again 
normally self-limiting, although plasmapheresis (whereby cross-reacting antibodies can be 
removed from the bloodstream) may shorten the duration of both GBS and MFS 
symptoms. 
1.4.2.3 Reactive Arthritis  
Reactive arthritis is a condition where painful joints can also be accompanied by 
conjunctivitis, urethritis, fatigue, fever, weight-loss and dermatology symptoms.  The 
arthritis occurs in the absence of antinuclear antibody or rheumatoid factor, affects 
multiple joints (knees and ankles being the most commonly affected) and is notably non-
symmetrical.  Reactive arthritis usually develops within 4 weeks of initial C. jejuni 
infection and symptoms persist for around 3-12 months, before spontaneously resolving 
(Wu & Schwartz, 2008).  Reactive arthritis is more likely to occur in adults than in 
children and is more common in males than in females (Mortensen et al., 2009). 
1.5 Epidemiology  
C. jejuni is the most common species of Campylobacter found in poultry, C. coli is the 
predominant species found in pigs, C. upsaliensis is commonly found in domestic pets and 
C. lari is the predominant species found in wild birds (particularly seagulls) and is also 
found in shellfish and crustaceans (Fouts et al., 2005).  Transmission of C. jejuni to 
humans is often the result of contact with, or consumption of, contaminated foodstuffs 
such as raw or undercooked chicken or unpasteurised dairy products.  C. jejuni can also be 
transmitted to humans via contaminated water.  Pork, veal and ham are significant sources 
of C. coli and C. upsaliensis can cause infections in humans that have been in contact with 
domestic pets, such as puppies or kittens, with diarrhoea.  Person-to-person spread of 
Campylobacter spp. is rare, even though large numbers of viable organisms are often shed 
in the faeces of infected patients and the infectious dose is low (Everest, 2002).  A notable 
exception to this is C. upsaliensis, which is rarely found in foodstuffs, but is transmittable 
18 | P a g e  
 
to people by pets and can also be transmitted via person-to-person spread (Fouts et al., 
2005). 
The self-limiting nature of campylobacteriosis contributes to the predicted true incidence 
of disease being much higher than reported (O'Brien et al., 2010) as many of those 
suffering from food-borne campylobacteriosis do not seek medical assistance.  Yet 
Campylobacter enteritis is one of the most common forms of acute bacterial enteritis in the 
developed world.  It affects people of all ages, but is most common in children less than 
5 years old and in 15-24 year old adults (Zilbauer et al., 2008).  In developing countries 
campylobacters are hyper-endemic in children under 2 years old (where they are also 
associated with significant mortality) and asymptomatic infections are common in adults 
(Nyati & Nyati, 2013).  Campylobacter enteritis is rarely seen in adults from areas where 
campylobacters are hyper-endemic, as immunity is usually acquired early in life due to 
frequent exposure (Konkel et al., 1996).  The high rate of asymptomatic infections seen in 
developing countries raised the question of whether Campylobacter strains isolated in 
developing countries should be considered pathogenic (Black et al., 1988).  However, 
many cases of campylobacteriosis are linked to foreign travel and the consumption of 
contaminated food or water in the areas visited.  As such Campylobacter is a significant 
cause of travellers’ diarrhoea and strains from developing areas are indeed pathogenic. 
1.6 Virulence Factors of Campylobacter jejuni  
C. jejuni is a very successful human pathogen and yet lacks many of the well-known 
virulence factors found in other successful human pathogens (Elmi et al., 2012).  Known 
virulence factors of C. jejuni include the production of cytolethal distending toxin (CDT), 
the presence of a polysaccharide capsule, the ability to invade cells and motility due to 
functioning flagella (Hendrixson et al., 2001, Karlyshev et al., 2002, Guerry, 2007).  These 
will be discussed in further detail in the sections below. 
1.6.1 Cytolethal Distending Toxin  
CDT is the only known, fully defined exotoxin produced by C. jejuni and it is an antigenic 
protein toxin (Parkhill et al., 2000).  CDT was first characterised in E. coli but is known to 
be produced by strains of C. jejuni as well as other enteric pathogens like Salmonella 
enterica and Shigella (Johnson & Lior, 1988, Dasti et al., 2010).  CDT was first identified 
in C. jejuni in 1987 and it is now known that C. jejuni makes more CDT than C. coli 
(Castillo et al., 2011).  CDT is made up of three subunits which are all membrane 
associated, CdtA, CdtB and CdtC.  CdtB is known to be the active component of the toxin 
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and has some similarity to DNase I-like proteins.  It is thought to act like a DNase by 
damaging DNA in the nucleus where it localises.  The specific functions of CdtA and CdtC 
are less well defined but they may play a role in host cell binding and delivery of the 
catalytic subunit CdtB into host cells (Young et al., 2007).  CDT interrupts the cell cycle 
and induces cell death (Ismaeel et al., 2005) because it causes elongation and swelling of 
cells.  CDT added to various cell lines in vitro induces apoptosis of the cells (Young et al., 
2007).  CDT also causes the production of interleukin 8 from intestinal epithelial cells, 
which recruits dendritic cells, neutrophils and macrophages to the site of C. jejuni infection 
and induces inflammation (Dasti et al., 2010).  Strains lacking CDT are however also 
capable of causing disease and there therefore exists a CDT-independent mechanism for 
eliciting interleukin 8 production and inflammatory diarrhoea (Elmi et al., 2012). 
1.6.2 Capsule  
C. jejuni has a number of hyper-variable regions (sometimes referred to as phase-variable) 
within its small genome which gain their variability as a result of slipped-strand 
mispairing.  Certain areas of the Campylobacter genome contain strands of single 
nucleotide repeats (or homopolymeric tracts).  These are prone to slipped-strand 
mispairing, which alters the length of the homopolymeric tract and can then influence the 
expression of downstream genes.  These homopolymeric tracts are often found in areas of 
the genome upstream of genes linked to flagella, capsule and LOS production and so the 
expression of flagella, capsule and LOS genes can be affected (Dasti et al., 2010).  This 
method of altering surface structures such as capsule contributes to antigenic variation in 
Campylobacter, which can be useful e.g. for evading host immune responses.   
The capsule of C. jejuni is thought to be a virulence factor and protects C. jejuni from 
environmental stress.  The capsule is made up of polysaccharides and it interacts with the 
extracellular environment of C. jejuni.  C. jejuni without a capsule have been shown to be 
less invasive, less virulent in ferrets, less able to colonise chickens and more sensitive to 
complement-mediated killing than C. jejuni with a capsule (Corcionivoschi et al., 2012).  
Capsular polysaccharide was suggested in one study to be important for C. jejuni survival 
of osmotic stress (Cameron et al., 2012).  The presence or absence of a capsule can also 
affect the autoagglutination (see Section 1.6.3) ability of different Campylobacter strains 
(Guerry, 2007). 
1.6.3 Flagella  
C. jejuni has a single polar flagella at one or both ends of the cell, which is unsheathed, 
glycosylated and is also immunogenic (Wassenaar & Blaser, 1999).
  
The flagella of 
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C. jejuni are used to penetrate the mucous layer of the gut and are also required for the 
adhesion to and invasion of epithelial cells (Guerry, 2007). 
 
Flagella are also used by 
C. jejuni to secrete non-flagellar proteins, which may play a role in invasion and 
autoagglutination (Almofti et al., 2011).
  
The flagella themselves are also important for 
autoagglutination and biofilm formation, which are both important for the survival of 
C. jejuni in the environment (Kalmokoff et al., 2006).  Flagella play an important role in 
the pathogenicity of C. jejuni and are essential for colonisation in animal models and for 
the colonisation of humans
 
(Tsutsui et al., 2000, Friis et al., 2005, Mills et al., 2012).   
1.6.3.1 Role of Flagella in Invasion and Adhesion  
It has long been acknowledged that entry into host cells provides a means for pathogenic 
bacteria to evade the host's immune system and gain access to a niche where the pathogen 
does not have to compete with other resident bacterial flora.  The human GI tract is lined 
with a continuously secreted layer of mucus which acts as a physical barrier to infection 
and contains a mixture of glycoproteins that are responsible for its viscosity (Wisessombat 
et al., 2010).  Colonic biopsies from patients with stool cultures positive for C. jejuni and 
suffering from colitis were shown to contain bacteria associated with the mucous layer as 
well as within the intestinal epithelial cells, suggesting that adherence and invasion of host 
epithelial cells is a hallmark of Campylobacter infection (van Spreeuwel et al., 1985).   
The in vivo findings of van Spreeuwel et al were later followed by the discovery that 
various C. jejuni isolates adhered to and invaded a variety of epithelial cell lines in vitro 
(Fauchere et al., 1986, Konkel & Joens, 1989, Everest, 2002).  Campylobacter adhesion 
protein A (CapA) is an autotransporter lipoprotein of C. jejuni and insertional mutagenesis 
of capA has been shown to significantly reduce the adhesion to and invasion of Caco-2 
cells and an inability to colonise or persist in chickens (Ashgar et al., 2007). 
1.6.3.2 Role of Flagella in Biofilm Formation  
Quorum sensing is important in autoagglutination but autoagglutination is mediated by the 
glycans which are found on the flagella of C. jejuni.  Biofilm formation requires flagella 
expression (Guerry, 2007).  Autoagglutination is often one of the first steps leading to 
microcolony formation and the start of biofilm formation.  Autoagglutination is affected by 
three major surface carbohydrates, the LOS core, the capsule and flagella.  The genes for 
these three carbohydrate structures are found in the hyper-variable regions of the C. jejuni 
genome (see Section 1.6.2) and this may explain why autoagglutination varies markedly 
between different strains.  Strains which readily autoagglutinate will associate in higher 
numbers to eukaryotic cells (Guerry, 2007).  Multiple non-motile mutant Campylobacter 
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strains have also been found to be deficient in both pellicle and aggregate type biofilm 
formation (Joshua et al., 2006).   
1.6.3.3 Role of Flagella in Translocation/Transcytosis  
The ability of selected pathogens to migrate across an intact cell barrier by invading cells 
can be an important virulence factor, as it allows access to underlying tissues as well as 
possible dissemination throughout the host.  C. jejuni can also translocate across the 
epithelial cell barrier via an alternative mechanism and can migrate from the intestinal 
mucosa to a variety of extra-intestinal sites, resulting in complications such as meningitis, 
endocarditis and bacteraemia.  This mechanism of translocation involves the bacteria 
moving down in between the host cells rather than being internalised by them. 
It has been reported that C. jejuni motility, as well as contributing to adherence and 
invasion ability also contributes to the translocation ability of different strains and that de 
novo protein synthesis is also required (Bras & Ketley, 1999).  Strains of C. jejuni which 
have a mutation in flaA, have a truncated flagella and the motility of these organisms is 
severely affected (Everest, 2002).  FlaA mutants of C. jejuni have been shown to be unable 
to cross epithelial cell monolayers and so FlaA and related motility must be required for 
translocation (Grant et al., 1993).  It has also been shown that strains of C. jejuni which 
express sialylated ganglioside-like LOS (see Section 1.4.2.1) translocate through epithelial 
cells with greater efficiency than strains lacking ganglioside-like LOS (Louwen et al., 
2012).   
1.7 Susceptibility to Campylobacter  
The human host has a number of defences against potential colonisation by enteric 
pathogens, these include: stomach acid released by parietal cells, resident bacterial flora, 
the action of gut peristalsis, presence of an intact epithelial barrier, local gut immunity and 
the secretion of mucus (Bavishi & DuPont, 2011).  Patients who have disturbed their 
resident bacterial flora (e.g. by taking antibiotics) can be more susceptible to enteric 
infections like campylobacteriosis, as can people with diabetes, people that have been in 
contact with pets or farm animals, people that have recently travelled internationally and 
those that have consumed unpasteurised dairy products like milk (Tam et al., 2009).  
Numerous strains of pathogenic bacteria secrete virulence factors which damage cells and 
disrupt the intact epithelial barrier of the gut, thereby increasing their survival in vivo (Elmi 
et al., 2012).   
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1.7.1 Proton Pump Inhibitors as a Risk Factor for Enteric Infection  
It is generally accepted that patients being treated with PPIs are more susceptible to enteric 
infections such as Campylobacter than patients not taking PPIs (Lodato et al., 2010, 
Bavishi & DuPont, 2011).  The stomach contents of patients taking PPIs will be less acidic 
than those not taking PPIs.  This is thought to result in increased survival of ingested 
bacteria that might not otherwise have survived the acidity of the stomach.  The infectious 
dose of enteric pathogens may therefore be less for people taking PPIs.  The taking of 
proton pump inhibitors (PPIs) is known to result in hypochlorhydria, which allows 
increased bacterial translocation across the epithelial cell barrier (Bavishi & DuPont, 
2011).  It has been proposed that severe diarrhoea in cases of campylobacteriosis could be 
a result of higher numbers of bacteria being endocytosed and translocating in between 
intestinal epithelial cells (Louwen et al., 2012).  The use of PPIs has also been associated 
with increased susceptibility to colonisation by Clostridium difficile (C. difficile) (Strachan 
et al., 2013).  Singh et al commented on the possibility that PPI use as a risk factor for 
C. difficile infection might be due to PPIs affecting the ability of normal resident bacterial 
flora to form protective biofilm in the GI tract, hence making it easier for C. difficile to 
colonise (Singh et al., 2012).   
1.8 Stomach Acid  
1.8.1 Acid Production  
H
+
/K
+
-ATPases (or proton pumps) can be found at rest within tubovesicles inside the 
parietal cells of the stomach.  When a parietal cell is stimulated, e.g. by histamine, gastrin 
or acetylcholine, the proton pumps migrate to the apical surface of the parietal cell and fuse 
with the plasma membrane.  This causes the intracellular membrane structure known as the 
canaliculus to undergo massive expansion, forming long microvilli and vastly increasing 
the secretory surface area of the parietal cell (Sachs et al., 1995).   
Hydrogen ions (H
+ 
or protons) and hydroxyl ions (OH
-
) are generated within parietal cells 
from the dissociation of water molecules (see Figure 1).  Carbon dioxide (CO2) diffuses 
into parietal cells from the bloodstream and reacts rapidly with these hydroxyl ions, via a 
carbonic anhydrase enzyme, to produce bicarbonate ions (HCO3
-
).  These bicarbonate ions 
are removed from the parietal cell via an anion exchanger, in exchange for incoming 
chloride ions (Cl
-
).  Chloride ions move quickly through the parietal cell to the area near 
the apical surface called the canaliculus.  The hydrogen ions left over from the water 
dissociation are pumped into the canaliculus, via the H
+
/K
+
-ATPase, as potassium ions 
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move inside the cell (Shin & Sachs, 2008).  Hydrochloric acid (HCl) is formed within the 
many canaliculi of parietal cells and then released into the stomach (Figure 1). 
 
 
Figure 1.  How hydrochloric acid is made and released from parietal cells.  Histamine 
release activates the H
+
/K
+
-ATPase via cyclic AMP (cAMP) to allow protons (H
+
)
 
into the 
canaliculus, where they react with chloride ions (Cl
-
)
 
to produce hydrochloric acid (HCl).  
HCl is then released from the canaliculus into the milieu of the stomach.  Activation of the 
H
+
/K
+
-ATPase can be blocked by the H2-receptor antagonist cimetidine.  Proton pump 
inhibitors (PPIs) can bind to and inhibit the activity of the H
+
/K
+
-ATPase, thereby also 
blocking the release of HCl, but at a later stage in the process.   
 
1.8.2 Excess Acid Production  
The acidic environment of the stomach is effective in preventing bacterial infections via 
the oral route, as many pathogenic bacteria do not survive exposure to the low pH in the 
stomach.  Stomach acid is also important for the digestion of foodstuffs, particularly 
protein and for the absorption of iron and calcium.  Excess production of stomach acid can 
however lead to the development of gastro-oesophageal reflux disease (GORD) or 
peptic/duodenal ulcers.  GORD occurs when the lower oesophageal sphincter muscle 
allows acid to leak out of the stomach and up into the oesophagus.  Patients often 
experience difficulty or pain when swallowing and feel a burning pain in their chest after 
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eating.  As recently as 50 years ago severe cases of excess acid production were sometimes 
life-threatening (Olbe et al., 2003).  Antacids could be given to temporarily neutralise 
stomach acid and offer symptom relief, but antacids were unable to block the continued 
production of acid.  Treatment options were therefore limited and surgical removal of 
stomach nerves or partial stomach resection were common interventions (Olbe et al., 
2003).   
Cimetidine was introduced in the 1970s and it was the first intervention capable of halting 
the production of stomach acid.  Cimetidine is a H2-receptor antagonist which blocks the 
release of histamine.  Histamine release is a trigger (by activating the H
+
/K
+
-ATPase) for 
stomach acid release from parietal cells and as such, cimetidine blocks stomach acid 
production via an indirect route (see Figure 1).   
1.9 Development of Proton Pump Inhibitors  
1.9.1 Benzimidazole Derivatives Inhibit Proton Pumps  
Throughout the 1960s a pharmaceutical company, then known as Astra, was searching for 
prospective treatments for excess acid production and in the 1970s they discovered the first 
compounds that inhibited the proton pumps of parietal cells (Olbe et al., 2003).  The 
compounds they found were derivatives of benzimidazole, which is a bi-cyclic compound 
that results from the fusion of benzene and imidazole (Figure 2).   
 
 
Figure 2.  Core benzimidazole structure.  Benzene fuses with imidazole to form the core 
bi-cyclic structure found in all benzimidazole derivatives. 
 
In 1973, Astra discovered that a non-toxic benzimidazole called H124/26 was able to block 
the secretion of hydrochloric acid, by inhibiting the H
+
/K
+
-ATPase of parietal cells.  Soon 
after, it was discovered that a sulphoxide metabolite of H124/26, called timoprazole 
(Figure 3a), was an even more potent inhibitor of the H
+
/K
+
-ATPase and of subsequent 
acid secretion.   
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Timoprazole Picoprazole 
a b 
 
 
Figure 3.  The chemical structures of timoprazole and picoprazole.  H124/26 was the 
first non-toxic benzimidazole found that inhibited proton pumps, but its sulphoxide 
metabolite timoprazole (a) was found to be a much more potent inhibitor of proton pumps.  
Timoprazole was however found to be toxic and picoprazole (b) was the chemically 
modified, non-toxic structure, which retained most inhibitory activity. 
 
However it was later found that timoprazole inhibited iodine uptake in the thyroid gland 
and caused thymus atrophy in animals and so it was unsuitable for clinical use.  The core 
structure of timoprazole, including the benzimidazole portion was retained, with different 
substitutions and side chain configurations being added and the resulting structures tested 
for H
+
/K
+
-ATPase inhibitory activity.  The most potent benzimidazole found, that did not 
inhibit iodine uptake, was called picoprazole (Figure 3b).   
1.9.2 Importance of the H+/K+-ATPase  
Around the same time it was becoming clear that the final step required for stomach acid 
production was the activation of the H
+
/K
+
-ATPase in parietal cells.  This active transport 
mechanism is required to move protons into the canalicular region of the parietal cell, 
where they then combine with chloride ions to produce the hydrochloric acid that is 
subsequently released into the stomach (Figure 1).  Without the H
+
/K
+
-ATPase activity, 
hydrochloric acid cannot be produced by parietal cells.  The H
+
/K
+
-ATPase of parietal 
cells was therefore an excellent prospective target for new anti-secretory therapies. 
There are also H
+
/K
+
-ATPases found in the kidneys, which the benzimidazole derivatives 
being developed by Astra could potentially also inhibit.  However, it was known that the 
canaliculi of parietal cells was the only area of the body that reaches a pH of ≤ 1.0 and this 
property was exploited during the drug design stages (Sachs et al., 1995).  Different 
substituents were systematically added to the pyridine ring (see Figure 2) of the 
benzimidazoles in an attempt to increase the pKa of the drugs and maximise their ability, 
as weak bases, to accumulate in the acidic canalicular compartments of parietal cells.  
There, they would be in close proximity to the proton pump they were being specifically 
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designed to inhibit.  Forming benzimidazole derivative structures with a low pKa would 
maximise their accumulation in parietal cells over the kidneys and reduce the likelihood of 
the wrong proton pumps being targeted.  In 1979, a chemical molecule, which would later 
become known as omeprazole (Figure 4a) was discovered and the first human clinical 
trials testing it, began in 1982 (Olbe et al., 2003). 
Omeprazole Pantoprazole 
a b 
 
 
Figure 4.  The chemical structures of omeprazole and pantoprazole.  Omeprazole (a) was 
the first commercially available PPI which has a core structure very similar to those of 
timoprazole and picoprazole.  Pantoprazole (b) is also a benzimidazole derivative and is 
the PPI used in this study. 
 
1.9.3 Omeprazole Trials  
Whilst the human trials were underway, animal studies were also being performed.  In 
1984, a long-term toxicology study using extremely high doses in rats resulted in endocrine 
tumour formation and all omeprazole human clinical trials were halted.  On further 
investigation it was found that the tumours were developing in entero-chromaffine-like 
(ECL) cells which are specific to rats and there was no similar risk to humans (Olbe et al., 
2003).  Human trials resumed and it was concluded that omeprazole was safe for human 
use and that omeprazole had a much longer duration of activity and was therefore superior 
to cimetidine.  Because omeprazole was so efficacious, it was requested by some 
physicians for patients with severe disease on the grounds of “compassionate-use”, even 
before it became commercially available (Klinkenberg-Knol et al., 2000).  Omeprazole 
was finally launched in Europe in 1988 and in the USA in 1990; over 15 years after Astra 
discovered the first benzimidazole derivative capable of inhibiting proton pumps. 
 
1.9.4 Extended Proton Pump Inhibitor Family  
1.9.4.1 Omeprazole  
Although omeprazole was extremely potent and safe for use, it was known that making 
chemical substitutions to the core benzimidazole structure could produce other structures 
that were able to inhibit the proton pumps of parietal cells and that the properties of such 
structures might be subtly different from those of omeprazole.  Omeprazole is almost 
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entirely eliminated through hepatic clearance (Ching et al., 1991) and there was therefore 
potential for interactions with other drugs that were metabolised by the same liver 
enzymes.  In 1987 the search for a PPI with increased bioavailability and therefore less 
liver clearance, was renewed by Astra.  This heralded the creation of a family of 
chemically related benzimidazole derivatives known as PPIs with lansoprazole being 
launched in 1991, pantoprazole (see Figure 4b) in 1994, rabeprazole in 1999 and 
esomeprazole in 2000. 
1.9.4.2 Lansoprazole  
Lansoprazole in its inactive pro-drug form (see Section 1.10) was first known as AG-1749 
and some of the most potent activated forms, capable of binding to and inhibiting proton 
pumps were known as AG-1789 and AG-2000 (Nagata et al., 1995).  Lansoprazole has a 
pKa around 4.0, which is similar to that of omeprazole and it therefore also preferentially 
accumulates in parietal cells rather than in the kidneys.  It undergoes acid activation at a 
similar rate to omeprazole but has the added advantage of being available as an oro-
dispersible tablet (Joint-Formulary-Committee., 2015).  Lansoprazole is however not very 
water soluble (Nguyen et al., 2005). 
1.9.4.3 Pantoprazole  
Pantoprazole has a similar potency to the first commercially available PPI omeprazole, but 
it interacts less with cytochrome P-450 (therefore has less potential for harmful interactions 
with other drugs metabolised by the same enzymes) than omeprazole and has a better pH 
dependent activation profile (Beil et al., 1992).  At a pH of 2.0 the half-life of pantoprazole 
is comparable with that of omeprazole at around 9 and 5 minutes respectively.  The PPIs 
have been specifically designed to act on the H
+
/K
+
-ATPase of parietal cells where the pH 
is low and therefore both PPIs have short half-lives at this low pH, as they are quick to 
become acid activated when they preferentially accumulate in parietal cells.  However the 
half-life of omeprazole at a pH of 5.0, where activation would be unwanted and potentially 
lead to targeting of the kidney cell H
+
/K
+
-ATPase rather than the parietal cell H
+
/K
+
-
ATPase, is around 55 minutes.  Pantoprazole was designed to be more stable at high pH 
and the half-life of pantoprazole at pH 5.0 was improved to > 90 minutes. 
1.9.4.4 Rabeprazole  
Rabeprazole was originally known as E-3810 and is the least stable PPI at neutral pH; it 
converts to its active form more quickly than the other PPIs at high pH (Besancon et al., 
1997).  Rabeprazole also differs from the other members of the PPI family, in that it has a 
pKa of around five, whereas the others have a pKa around four (Horn, 2000).  Rabeprazole 
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was however the first PPI to be recommended for “on demand” therapy regimes (Joint-
Formulary-Committee., 2015). 
1.9.4.5 Esomeprazole  
Esomeprazole is in fact the S-isomer of the original PPI launched by Astra, omeprazole.  
Omeprazole is now known to be a racemic composition of its two optical isomers,             
S-omeprazole (later known as esomeprazole) and R-omeprazole.  The S-isomer was found 
to inhibit gastric acid secretion to a greater degree than that of both the R-isomer and the 
original racemic mixture omeprazole (Andersson et al., 2001).  The S-isomer is also 
metabolised to a lesser degree and at a lower rate than the R-isomer and so has greater 
bioavailability and reaches higher peak plasma concentrations.  The S-isomer is also better 
tolerated by patients with impaired liver-function than other PPIs.  For these reasons, the 
omeprazole S-isomer alone was launched as esomeprazole by AstraZeneca, over a decade 
after the racemic mixture omeprazole was first launched.   
1.10 Chemistry of Proton Pump Inhibitor Activity  
PPIs are administered as tri-cyclic (see Figure 4) inactive pro-drugs (Andersson et al., 
2001) that are weak bases and have pKas (apart from rabeprazole) of around four 
(Besancon et al., 1997).  As such, they preferentially move inside the parietal cells of the 
stomach and accumulate in the canaliculus because the environment there is highly acidic 
as a result of the H
+
/K
+
-ATPase activity and the accumulation of protons.  The first step 
required for the activation of all PPIs is protonation (acid activation) and this occurs 
quickly in the acidic environment of the canaliculus where protons are freely available.  
The free nitrogen of the pyridine ring (see Figures 2, 3 and 4) becomes protonated (Shin et 
al., 1993) and a sulfenic acid is formed.  The sulfenic acid can undergo dehydration and 
the chemical structure rearranges quickly to form a tetra-cyclic sulfenamide (Olbe et al., 
2003).   
Both the sulfenic acid form and the tetra-cyclic sulfenamide are active forms of PPIs and 
as both of these forms are cationic, they are therefore both also fairly membrane 
impermeable.  Hence the sites of action available to activated PPIs are limited (Shin et al., 
2004).  The activated forms of PPIs form strong disulphide bonds with thiol groups on 
exposed cysteine residues of the H
+
/K
+
-ATPase of parietal cells (Shin et al., 1993).  This 
binding renders the proton pump inactive and the production of hydrochloric acid is 
blocked because protons are unable to move to the canaliculus and react with chloride ions 
to make hydrochloric acid (Beil et al., 1992).   
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The active PPI forms (the sulfenic acids and the tetra-cyclic sulfenamides) are highly 
reactive and are capable of self-reacting (Shin et al., 2004).  The stability of the activated 
forms is dependent on the pH and time.  Hence, if for example the pH changes and an 
active form remains unbound to a H
+
/K
+
-ATPase then it can be broken down into inactive 
sulphides or multiple other products (Besancon et al., 1997).  Benzimidazole derivatives, 
like the pro-drug forms of PPIs, are usually colourless but many of the activated 
benzimidazole intermediates, like sulfenic acids and sulfenamides are yellow in colour 
(Nguyen et al., 2005).  The compounds that may be generated by the break down of 
unbound activated PPI forms are more than can be accurately quantitated or identified 
(Shin et al., 2004). 
The binding and subsequent inactivation of the H
+
/K
+
-ATPase by sulfenic acids or tetra-
cyclic sulfenamides is irreversible and the production of hydrochloric acid only resumes 
when new proton pumps are synthesised by the parietal cells and these move to the plasma 
membrane (Ali et al., 2009).  The acid activated tetra-cyclic sulphenamide form is however 
known to be non-selective and is capable of binding to and inactivating the adenylate 
cyclase or Na
+
/K
+
-ATPase (see Figure 1) of parietal cells also (Beil et al., 1992). 
1.11 Proton Pump Inhibitor Uses and Dosages  
1.11.1 Proton Pump Inhibitor Use  
PPIs are frequently taken medications and are prescribed to treat common conditions such 
as GORD or peptic/duodenal ulcers.  They are also often prescribed prophylactically to 
prevent the development of ulcers in patients being treated with non-steroidal anti-
inflammatory drugs and in combination with antibiotics for the eradication of Helicobacter 
pylori (H. pylori).  Diseases such as Zollinger-Ellisson syndrome and Barrett's oesophagus 
are much rarer conditions and these require a much higher daily dose of PPI.  In Barrett's 
oesophagus the columnar epithelial cells in the lower oesophagus have become severely 
damaged, usually as a result of the long standing reflux of stomach acid and if left 
untreated, the cells can become cancerous.  Patients with Zollinger-Ellison Syndrome have, 
sometimes multiple, gastrin-secreting tumours (or gastrinomas) in the duodenum or 
pancreas which leads to hyperstimulation of the parietal cell H
+
/K
+
-ATPase and sustained 
hydrochloric acid release. 
1.11.2 The British National Formulary  
The British National Formulary (BNF) is used by prescribers, pharmacists and healthcare 
professionals for guidance on uses and the recommended doses of medicines available by 
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prescription in the UK (Shen et al., 2011).  Table 2 lists the daily dose of various PPIs 
recommended for the treatment of a variety of conditions according to the BNF.  Typical 
daily dosages range from 20-80 mg per day, usually taken as a single oral dose, but in 
complicated cases, PPIs may require to be taken before every meal (Shen et al., 2011).  In 
a report by Klinkenberg-Knol et al one exceptional patient required a daily dose of 120 mg 
omeprazole to manage their symptoms (Klinkenberg-Knol et al., 2000).   
Table 2.  Daily dosages of PPIs as recommended in the British National Formulary 
(Joint-Formulary-Committee., 2015).   
 
 
PPI 
Daily Dose (mg/ml) for Different Conditions 
BNF Indication 
Benign Ulcer Severe Ulcer 
Zollinger-Ellison 
Syndrome 
Omeprazole 20 40 20-120* 
Lansoprazole 30 30 60-160** 
Pantoprazole 40 80 80-160* 
Rabeprazole 20 20 60-120*** 
Esomeprazole 20 40 80-160* 
 
 
PPIs are listed in the table in the order in which they were licenced for use in the UK and 
the severity of symptoms increases towards the right-hand side of the table.  *Doses of 
omeprazole, pantoprazole or esomeprazole over 80 mg per day to be divided into two 
doses.  **Doses of lansoprazole over 120 mg per day to be divided into two doses.  
***Doses of rabeprazole over 100 mg per day to be divided into two doses. 
 
 
GORD and uncomplicated (or benign) ulcers are usually treated with the lowest 
recommended dose of PPIs.  Complicated (or severe) ulcers include ulcers which are 
actively bleeding and in such cases the recommended dose of PPIs often increases.  
Zollinger-Ellison syndrome is the most severe condition that PPIs may be prescribed to 
treat and the recommended PPI dose in such cases is often over 100 mg per day (Table 2).  
The maximum single dose that is recommended in the BNF for omeprazole, lansoprazole, 
rabeprazole or esomeprazole is 80, 120, 100 and 80 mg respectively.  Pantoprazole is the 
PPI used for the in vitro testing in this study (due to its superior ability to dissolve in water) 
and the maximum single dose of pantoprazole that is recommended is 80 mg.   
1.11.3 People Taking Proton Pump Inhibitors  
PPIs are very effective drugs, with few serious side effects and are available in the UK 
both by prescription and over the counter.  According to data published in April 2015 both 
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the PPIs omeprazole and lansoprazole featured in the top ten drugs prescribed in England 
in 2014 (Health and Social Care Information Centre).  Omeprazole was the third most 
commonly prescribed drug with 28.8 million items being prescribed and lansoprazole the 
tenth most commonly prescribed with 21.6 million items being prescribed in England in 
2014.  It is clear that in the UK there are a great number of people taking PPIs and the 
numbers are increasing (see Figure 5).  The numbers will likely be even higher than these 
data suggest, because data is unavailable for PPIs bought over the counter and taken 
without a prescription.  It has been noted that PPIs are amongst the most widely prescribed 
family of drugs worldwide and that more and more people throughout the world are taking 
PPIs (Ali et al., 2009, Bavishi & DuPont, 2011). 
 
 
Figure 5.  Quarterly data for PPI prescriptions in England.  Available from 
http://www.nhsbsa.nhs.uk/PrescriptionServices/Documents/PPDPrescribingAnalysisChart
s/Gastro_National_June_2014.pdf. 
 
1.11.4 Proton Pump Inhibitors in the Gastrointestinal Tract  
The PPI concentration which is clinically achievable in the mucous layer of the human gut 
is unknown (Megraud et al., 1991).  It has also been stated that the PPI concentration that 
can be found in the GI tract or stomach is unknown (Mirshahi et al., 1998, Trautmann et 
al., 1999).  In what is believed to be one of the only reports of its kind Caselli et al used 
high liquid chromatography to measure the lansoprazole concentration in gastric juice.  
A very small group of patients were given 15, 30 or 60 mg lansoprazole at around 10pm 
and blood samples were taken 2 hours later.  Peak plasma concentrations are reached 
around 2 hours post PPI dose and are dose dependent.  Twelve hours post dose, 1 ml of 
gastric juice was collected from the patients and the concentrations of lansoprazole found 
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in the juices were in the range 0.3-0.5, 1.2-2.0 and 2.9-3.4 µg/ml respectively for the 
different dosing regimes.  Following a 60 mg dose of lansoprazole, peak plasma 
concentration was reached 2 hours post dose and was found to be 1 µg/ml, but the 
concentration in gastric juice (12 hours post dose) was around three fold higher (2.9-
3.4 µg/ml).  The authors noted that rather than increasing linearly (as might be expected) 
the concentrations achieved in gastric juice appeared to increase “exponentially” with 
increasing PPI doses.   
It is noteworthy to point out that the peak plasma concentration was reached around 
2 hours post PPI dose, however, the lansoprazole concentration in gastric juice was 
measured many hours later, at 12 hours post dose, with no indication of why this time point 
was chosen or indeed what effect time-post-dose had on the concentrations detected in 
gastric juice.  This study nevertheless provides evidence that the residual PPI concentration 
in the GI tract may be higher than peak plasma concentrations suggest and that PPIs 
remain in the GI tract at detectable levels for a prolonged period of time post dose.   
It has been stated in another study that an acid activated form of rabeprazole can be 
detected in gastric juice (Ohara et al., 2001) but the reference for this information is 
“unpublished data”.  It has also been estimated that the concentration of PPI found in the 
luminal surface of parietal cells may be as high as 1,000 times that of the concentration 
found in the blood (Shin & Sachs, 2008).  The data on the PPI concentration that can be 
found in the GI tract or stomach is indeed scarce, perhaps at least in part due to the 
difficulties in acquiring samples of gastric juice from patients following PPI dosing 
regimes.  Peak plasma concentrations are conversely easy to determine, as blood samples 
can be easily collected from patients.  It is therefore difficult to ascertain the concentrations 
of PPI which are likely to be achieved in the human GI tract.   
Table 3 lists the concentrations of PPI that might theoretically be achieved in the stomach 
following different PPI doses taken on a full or empty stomach.  Results of calculations 
show that if all of the PPI remained in the stomach that the maximum achievable 
concentrations vary greatly depending on what dose is taken and whether on a full or 
empty stomach.  The maximum single dose of pantoprazole recommended in the BNF is 
80 mg and if taken on an empty stomach, the maximum achievable concentration might be 
around 1 mg/ml (or 1,000 µg/ml).  Of course, the whole PPI dose is unlikely to remain free 
floating in the juices of the GI tract and an unknown proportion would instead be expected 
to accumulate in canaliculi and bind to ATPases.  It is extremely difficult therefore to 
determine the concentrations of PPI that might be found in the GI tract, but they are likely 
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to be in the µg/ml range and (at least in the case of pantoprazole) unlikely to exceed 
1 mg/ml (or 1,000 µg/ml).  They are therefore likely to be present in higher concentrations 
than the concentrations of conventional antibiotics required to inhibit bacterial growth.  
The length of time that a concentration might be sustained for in the GI tract is also 
unknown.  Worth additional consideration is that the volume of stomach contents is 
unlikely to remain steady over a period of 24 hours. 
Table 3.  Concentrations of PPI that might be achieved in the stomach following 
different dosages.   
 
Daily Dose of PPI 
(mg) 
BNF Indication 
Concentration That Might Be Achieved 
(µg/ml) 
  Empty Stomach Full Stomach 
20 GORD    250 10 
40 Benign Ulcer    500 30 
80 Complicated Ulcer 1,000 50 
120 Exceptional Cases 1,500 80 
 
Calculations performed on the empty stomach containing 80 ml of residual fluid and a full 
stomach 1.5 l.  The highest single dose recommended for pantoprazole is 80 mg. 
 
1.12 The Anti-Helicobacter Activity of Proton Pump Inhibitors  
A summary of studies relevant to the anti-Helicobacter properties of PPIs can be found in 
Table 4 and selected details are discussed further in the sections below.   
1.12.1 Early Studies  
In 1964, Bishop et al were the first to report on the anti-bacterial activity of benzimidazole 
derivatives (Bishop et al., 1964).  In 1991, in the first report of its kind and only a few 
years after the global launch of omeprazole, Iwahi et al used both agar dilution and broth 
macrodilution to show that the PPIs omeprazole and lansoprazole inhibited the growth of 
H. pylori (Iwahi et al., 1991).  Exposure to lansoprazole in liquid media was shown to 
cause changes to H. pylori morphology and it was concluded that, at concentrations higher 
than those required to inhibit the growth of H. pylori, lansoprazole had a bactericidal 
effect.  Iwahi et al also reported in this early study that the bactericidal activity of the PPIs 
appeared to have a “taxonomic boundary” as up to 100 µg/ml, lansoprazole was unable to 
inhibit the growth of a wide range of laboratory standard bacterial strains and also of 
27 clinical isolates of C. jejuni (Iwahi et al., 1991). 
  
Table 4.  Chronological list summarising the results of studies investigating the anti-Helicobacter properties of various PPIs. 
 
Reference PPIs Tested Methods Employed Organisms Used Notable Results 
Iwahi 
(Iwahi et al., 1991) 
Omeprazole 
Lansoprazole 
Agar dilution 
Broth macrodilution 
H. pylori 
C. jejuni 
E. cloacae 
M. morganii 
Proteus spp. 
P. aeruginosa 
S. marcescens 
PPIs inhibited H. pylori growth 
Coccal forms and blebs seen in membranes of H. pylori 
No inhibition of growth of the other organisms tested up to 
100 µg/ml  
Megraud 
(Megraud et al., 1991) 
Omeprazole 
Lansoprazole 
Agar dilution H. pylori 
C. jejuni 
E. coli 
PPIs inhibited H. pylori growth 
Coccal forms of H. pylori seen 
No effect on C. jejuni or E. coli growth 
Suerbaum 
(Suerbaum et al., 1991) 
Omeprazole 
Pantoprazole 
Agar dilution 
Broth macrodilution 
H. pylori PPIs inhibited H. pylori growth 
 
Nagata 
(Nagata et al., 1993) 
Omeprazole 
Lansoprazole 
Broth microdilution H. pylori 
Proteus spp. 
PPIs inhibited H. pylori growth 
No inhibition of Proteus spp. up to 1,000 µM (around 350 µg/ml) 
Figura 
(Figura et al., 1994) 
Omeprazole Agar dilution H. pylori PPI inhibited H. pylori growth 
 
Hirai 
(Hirai et al., 1995) 
Omeprazole 
Lansoprazole 
Rabeprazole 
Agar dilution H. pylori PPIs inhibited H. pylori growth 
 
Nagata 
(Nagata et al., 1995) 
Omeprazole 
Lansoprazole 
Broth macrodilution H. pylori PPIs inhibited H. pylori growth 
 
Nakao 
(Nakao et al., 1995) 
Omeprazole 
Lansoprazole 
Agar dilution H. pylori Motility of H. pylori affected above the MIC 
PPI exposure affected adherence to Hep-2 cells 
Morphology affected with blebs seen 
Shibata 
(Shibata et al., 1995) 
Omeprazole 
Lansoprazole 
Agar dilution H. pylori PPIs inhibited H. pylori growth 
 
Sjostrom 
(Sjostrom et al., 1996) 
Omeprazole Broth dilution Helicobacter spp. 
Campylobacter spp. 
B. subtilis  
E. coli 
P. vulgaris 
P. aeruginosa 
S. aureus 
PPI inhibited H. pylori growth 
No inhibition of growth of the other organisms tested up to 
256 µg/ml 
  
Reference PPIs Tested Methods Employed Organisms Used Notable Results 
Bamba 
(Bamba et al., 1997) 
Omeprazole 
Lansoprazole 
Broth microdilution H. pylori PPIs inhibited H. pylori growth 
PPIs additive to some conventional antibiotics 
Midolo 
(Midolo et al., 1997) 
Omeprazole 
Lansoprazole 
Agar dilution H. pylori PPIs additive to some conventional antibiotics 
Mirshahi 
(Mirshahi et al., 1998) 
Omeprazole Agar dilution 
Broth macrodilution 
H. pylori PPI inhibited H. pylori growth 
 
Nakao and Malfertheiner 
(Nakao & Malfertheiner, 1998) 
Omeprazole 
Lansoprazole 
Pantoprazole 
Agar dilution 
Broth macrodilution 
H. pylori PPIs inhibited H. pylori growth 
Some PPIs were bactericidal 
Blebs seen on bacterial surface 
Vogt 
(Vogt & Hahn, 1998) 
Omeprazole 
Lansoprazole 
Agar dilution 
Broth macrodilution 
H. pylori PPIs inhibited H. pylori growth 
 
Woo 
(Woo et al., 1998) 
Omeprazole 
YJA20379* 
Agar dilution H. pylori PPIs inhibited H. pylori growth 
 
Trautmann 
(Trautmann et al., 1999) 
Lansoprazole Agar dilution 
Broth macrodilution 
H. pylori PPI inhibited H. pylori growth 
PPI additive to azithromycin killing 
Tsutsui 
(Tsutsui et al., 2000) 
Omeprazole 
Lansoprazole 
Rabeprazole 
Agar dilution  H. pylori 
Campylobacter spp. 
P. mirabilis 
S. enterica 
V. cholerae 
V. parahaemolyticus 
PPIs inhibited H. pylori growth 
No inhibition of growth of the other organisms tested up to 
256 µg/ml 
Inhibition of H. pylori and Campylobacter motility, but not of 
non-spiral organisms 
Ohara 
(Ohara et al., 2001) 
Omeprazole 
Lansoprazole 
Rabeprazole 
Agar dilution H. pylori Motility of H. pylori affected at sub-MIC levels 
Tanaka 
(Tanaka et al., 2002) 
Omeprazole 
Lansoprazole 
Pantoprazole 
Agar dilution H. pylori PPIs inhibited H. pylori growth 
PPIs additive or synergistic to conventional antibiotics 
Spengler 
(Spengler et al., 2004) 
TF18** Broth microdilution H. pylori PPI inhibited H. pylori growth 
Motility of H. pylori affected at sub-MIC levels 
 
*    YJA20379 = a newly synthesised PPI developed by Yung-Jin Pharmaceutical Company. 
**  TF18 = a trifluoromethyl ketone derivative (1-(2-benzoxazolyl)-3,3,3-trifluoro-2-propanone). 
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Also in 1991, agar dilution was used by Megraud et al to confirm that the PPIs omeprazole 
and lansoprazole inhibited the growth of H. pylori.  Bactericidal activity at concentrations 
higher than those required to inhibit growth and changes to H. pylori morphology were 
also confirmed (Megraud et al., 1991).  Suerbaum et al also confirmed in 1991 that the PPI 
omeprazole inhibited the growth of H. pylori and reported that the, as yet not clinically 
available, PPI pantoprazole also inhibited the growth of H. pylori (Suerbaum et al., 1991).  
They used a broth macrodilution method, with a short incubation period, to show that the 
acid activated forms of the PPIs were better able to inhibit the growth of H. pylori than the 
pro-drug forms were (Suerbaum et al., 1991).  The authors commented that inhibition of 
H. pylori growth, found when using agar dilution methods, was probably the result of PPI 
activation over the long incubation periods used (72-96 hours). 
1.12.2 Later Work  
In the years that followed, numerous studies confirmed that various PPIs were capable of 
inhibiting H. pylori growth (Nagata et al., 1993, Figura et al., 1994, Hirai et al., 1995, 
Nagata et al., 1995, Shibata et al., 1995, Sjostrom et al., 1996, Bamba et al., 1997, 
Mirshahi et al., 1998, Nakao & Malfertheiner, 1998, Vogt & Hahn, 1998, Woo et al., 
1998, Trautmann et al., 1999, Tsutsui et al., 2000, Tanaka et al., 2002, Spengler et al., 
2004), inducing morphological changes (Nakao et al., 1995, Nakao & Malfertheiner, 
1998), were bactericidal (Nakao & Malfertheiner, 1998) and that growth inhibition of other 
bacterial genera was not apparent (Nagata et al., 1993, Sjostrom et al., 1996, Tsutsui et al., 
2000).  In 1994, Figura et al suggested that inhibition of H. pylori growth by omeprazole 
might infer that PPIs were affecting bacterial ATPases (Figura et al., 1994).  They 
postulated that if this was indeed the case, then PPIs could theoretically affect anything 
which required energy production by the bacterium.  Bacterial motility is an energy 
requiring process, important for the pathogenicity of H. pylori, and yet Figura et al 
reported that the motility of H. pylori was not adversely affected at sub-inhibitory levels of 
PPI. 
1.12.3 Proton Pump Inhibitors Affect Bacterial Motility  
In disagreement with Figura et al, Nakao reported only 1 year later that the motility of 
H. pylori was adversely affected by exposure to PPIs at concentrations that affected 
bacterial growth (Nakao et al., 1995).  They noted that only slight motility was observed 
following exposure to the MIC of lansoprazole for 5 hours (MIC having been determined 
using agar dilution over 4 days).  A complete lack of motility was not observed until 
H. pylori had been exposed to four times the MIC for 4 hours.  Much later, in vitro 
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methods were improved and an adverse effect on H. pylori motility, at concentrations 
lower than those required to inhibit bacterial growth, were described by multiple authors 
(Tsutsui et al., 2000, Ohara et al., 2001, Spengler et al., 2004).  Of particular relevance to 
this study is the report by Tsutsui et al which showed that various PPIs (up to a 
concentration of 256 µg/ml) adversely affected the motility of both H. pylori and 
Campylobacter spp., even though no inhibition of Campylobacter spp. growth was 
observed (Tsutsui et al., 2000).   
1.13 Problems with Previous Research  
Many preceding studies make use of a single PPI, (Megraud et al., 1991, Figura et al., 
1994, Spengler et al., 2004)
 
whereas others use more than one (Iwahi et al., 1991, 
Suerbaum et al., 1991, Hirai et al., 1995, Tsutsui et al., 2000).  In studies where a single 
PPI has been used, the PPI in question is often different to those used in other similar 
studies (Megraud et al., 1991, Figura et al., 1994).  PPIs are known to be not very soluble 
in water (Shin et al., 2004, Nguyen et al., 2005) and the PPIs used in different studies have 
often been dissolved and in some cases further diluted in different liquids (Iwahi et al., 
1991, Figura et al., 1994).  Broth dilution
 
has been used by some authors (Suerbaum et al., 
1991, Spengler et al., 2004) and agar dilution by others (Iwahi et al., 1991, Megraud et al., 
1991, Figura et al., 1994, Hirai et al., 1995, Tsutsui et al., 2000) even though the stability 
of PPIs in different agars is unknown (Trautmann et al., 1999).  Hence it is very difficult to 
compare the results of relevant studies directly with one another.   
Suerbaum et al investigated the anti-bacterial properties of PPIs in pro-drug form, as well 
as in acid activated forms (Suerbaum et al., 1991).  Is it important to note that work carried 
out by Suerbaum et al, using acid activated PPIs, could only use very short incubation 
times (1 hour) and that acid activation of a PPI does not result in a single activated 
chemical structure, rather a number of different active forms can result (Iwahi et al., 1991, 
Suerbaum et al., 1991).  Also pertinent is that these different activated forms will have 
varied anti-bacterial activities themselves, based on their own specific chemical structures 
(Tsutsui et al., 2000).   
1.14 Other Bacteria and Proton Pump Inhibitors  
The majority of research into the anti-bacterial properties of PPIs has focused on H. pylori, 
but the activity of PPIs, and other benzimidazole derivatives, against other pathogenic and 
opportunistic bacteria have also been investigated.  A summary of relevant studies can be 
found in Table 5 and selected details are discussed further in the sections below. 
  
Table 5.  Chronological list summarising the results of studies investigating the properties of various PPIs against organisms other than Helicobacter 
and Campylobacter. 
 
Reference PPIs Tested Methods Employed Organisms Used Notable Results 
Bishop 
(Bishop et al., 1964) 
Various 
benzimidazoles 
Broth macrodilution E. coli 
K. aerogenes 
S. aureus 
S. pyogenes 
Inhibition of growth was observed in some cases 
The Gram positive organisms were more sensitive to inhibitory 
activity than Gram negative 
Problems with benzimidazole solubility were common 
Aeschlimann  
(Aeschlimann et al., 1999) 
Omeprazole 
Lansoprazole 
Broth microdilution S. aureus PPIs able to lower MIC and MBC of conventional antibiotics 
(ciprofloxacin and norfloxacin) 
PPIs increase killing by levofloxacin 
Nguyen 
(Nguyen et al., 2005) 
Omeprazole 
Lansoprazole 
Glass slide biofilm S. mutans PPIs found to be bactericidal against S. mutans 
PPIs also able to inhibit biofilm formation 
Vidaillac  
(Vidaillac et al., 2007) 
Omeprazole 
Omeprazole 
analogues 
Agar dilution 
Broth dilution 
S. aureus PPI MICs were > 512 µg/ml  
PPIs can reduce MIC of norfloxacin 
PPIs supplement killing by norfloxacin 
Sambanthamoorthy  
(Sambanthamoorthy et al., 2011) 
Omeprazole 
Lansoprazole 
ABC-1* 
Crystal violet staining K. pneumoniae 
P. aeruginosa 
S. boydii 
S. aureus 
V. cholerae 
ABC-1 did not to inhibit growth of the organisms tested 
ABC-1 did prevent biofilm formation 
ABC-1 was more potent at preventing biofilm formation than 
omeprazole 
Pre formed biofilm was not dispersed by ABC-1 
Singh  
(Singh et al., 2012) 
Esomeprazole Crystal violet staining P. aeruginosa 
S. aureus 
Exposure to PPI decreased ability to form biofilm 
PPI was able to supplement the killing by conventional antibiotics 
(meropenem and vancomycin) 
 
*  ABC-1 = antibiofilm compound 1, a novel low molecular weight benzimidazole similar in structure to omeprazole and lansoprazole. 
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1.14.1 Proton Pump Inhibitors Enhance Conventional Antibiotic Activity  
In 1999, Aeschlimann et al reported that the PPIs omeprazole and lansoprazole improved 
the in vitro activity of various fluoroquinolones against multiple strains of Staphylococcus 
aureus (S. aureus) (Aeschlimann et al., 1999).  Co-exposure to PPIs and the 
fluoroquinolones ciprofloxacin and norfloxacin lead to a reduction in the minimum 
inhibitory and minimum bactericidal concentrations (MBCs) of the fluoroquinolones and 
increased the killing of bacteria by the fluoroquinolone levofloxacin.  Further work 
investigating the activities of PPIs, and other benzimidazole derivatives, on S. aureus 
confirmed the ability to reduce the minimum inhibitory concentration (MIC) of 
conventional antibiotics and proposed a role for PPIs as potential inhibitors of bacterial 
efflux pumps (Vidaillac et al., 2007). 
In a later study Singh et al showed that pre-exposure to PPI enhanced killing of S. aureus 
by vancomycin and of Pseudomonas aeruginosa (P. aeruginosa) by meropenem (Singh et 
al., 2012).  They also reported that the PPI esomeprazole inhibited biofilm formation in 
both S. aureus and P. aeruginosa. 
1.14.2 Proton Pump Inhibitors Inhibit Biofilm Formation  
Susceptibility to conventional antibiotics and bacterial ability to form biofilm are linked.  It 
is well known that planktonic bacteria are (sometimes up to 1,000×) more susceptible to 
antibiotics than bacteria in biofilms are and most antibiotics are developed to target 
planktonic bacteria rather than those in biofilms (Sambanthamoorthy et al., 2011).  
In 2005, Nguyen et al reported that the PPIs omeprazole and lansoprazole inhibited biofilm 
formation in Streptococcus mutans (S. mutans) (Nguyen et al., 2005).  Later work by 
Sambanthamoorthy et al distinguished between the ability of PPIs, and other 
benzimidazole derivatives, to prevent biofilm formation but not to disrupt pre-formed 
biofilm (Sambanthamoorthy et al., 2011). 
1.15 Anti-parasitic Activity of Proton Pump Inhibitors  
Albendazole and mebendazole (Figure 6) are benzimidazole carbamate derivatives that are 
used to treat helminth infections.  They both have the same 2-ringed benzimidazole core 
structure that can be seen in Figure 2 and have adapted sidechain configurations that 
resemble the early structures in PPI development shown in Figure 3 and those of modern 
PPIs shown in Figure 4.   
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Albendazole Mebendazole 
a b 
 
Figure 6.  The chemical structures of albendazole and mebendazole.  Albendazole (a) 
and mebendazole (b) are benzimidazole carbamate derivatives which are used in the 
treatment of various helminth infections.   
 
In 1992, Cedillo-Rivera and Munoz reported that albendazole and mebendazole inhibited 
the growth of Giardia lamblia (G. lamblia) and, at even higher concentrations, the 
benzimidazoles were capable of killing the protozoan (Cedillo-Rivera & Munoz, 1992).  
They showed that the benzimidazoles were active at concentrations lower than that of the 
recommended treatment for G. lamblia infection (metronidazole) and suggested that 
tubulin was the target of the benzimidazoles.  The observation was however overlooked for 
a number of years following the publication and the search for new anti-parasitic 
treatments was thought by many to be of little importance as they were rather “neglected” 
infections (Perez-Villanueva et al., 2011).  However, resistance to recommended 
treatments began to emerge and interest was renewed in identifying potential novel targets 
for the treatment of parasitic infections and in identifying potential novel treatments.  The 
early 2000s saw a rush of articles being published, most of which focused on testing the 
anti-parasitic properties of newly synthesised or chemically modified benzimidazoles 
(a summary of relevant studies can be found in Table 6). 
Navarrete-Vazquez et al extended the range of parasites used in their experiments to 
include the protozoan Entamoeba histolytica (E. histolytica) and the helminth Trichinella 
spiralis (T. spiralis).  The major component of the cytoskeleton of G. lamblia and 
T. spiralis is tubulin but the major component of the cytoskeleton of E. histolytica is actin.  
Navarrete-Vazquez et al reported that albendazole was inactive against E. histolytica, but 
that some of the benzimidazole structures that they had created inhibited E. histolytica 
growth.  They determined that albendazole inhibited the polymerization of tubulin but that 
other benzimidazole structures had anti-parasitic properties that were independent of 
tubulin polymerisation and that these required further study. 
 
  
Table 6.  Chronological list summarising the results of studies investigating the anti-parasitic properties of benzimidazole derivatives. 
 
Reference Benzimidazoles 
Tested 
Methods Employed Organisms 
Used 
Notable Results 
Cedillo-Rivera 
(Cedillo-Rivera & Munoz, 
1992) 
Albendazole 
Mebendazole 
Broth macrodilution G. lamblia Inhibition of growth was observed as was killing 
Tubulin is likely target of benzimidazoles 
Navarrete-Vazquez 
(Navarrete-Vazquez et al., 
2001) 
Albendazole 
Benzimidazole 
derivatives 
Broth dilution G. lamblia 
E. histolytica 
T. spiralis 
Inhibition of G. lamblia  and T. spiralis growth was observed as was killing 
Albendazole was inactive against E. histolytica 
Albendazole inhibited tubulin polymerisation but other benzimidazoles did not 
Binding to tubulin is not required for all anti-parasitic activity 
Andrzejewska 
(Andrzejewska et al., 2002)  
Albendazole 
Benzimidazole 
derivatives 
Broth dilution G. intestinalis 
E. histolytica 
T. vaginalis 
Inhibition of G. intestinalis and T. vaginalis growth was observed 
Albendazole was inactive against E. histolytica 
Benzimidazole derivatives inhibited growth of E. histolytica 
Benzimidazole carbamates bind to tubulin and inhibit polymerisation. 
Cedillo-Rivera 
(Cedillo-Rivera et al., 2002) 
Albendazole 
 
Broth macrodilution G. intestinalis 
E. histolytica 
T. vaginalis 
Inhibition of G. intestinalis and T. vaginalis growth was observed 
Albendazole was inactive against E. histolytica 
Possible that benzimidazole induce changes to the plasma membrane 
Jiang  
(Jiang et al., 2002) 
Omeprazole 
 
Broth dilution L. donovani Inhibition of growth was observed 
Due to inhibition of the K
+
/H
+
-ATPase on the surface membrane 
Interferes with pH homeostasis ability and disrupts proton motive force 
Riel  
(Riel et al., 2002) 
Omeprazole 
Lansoprazole 
Pantoprazole 
Rabeprazole 
Broth microdilution P. falciparum Lansoprazole and rabeprazole were best at inhibiting growth 
Omeprazole and quinine were found to be synergistic 
A V-type H
+
-ATPase in the plasma membrane is unlikely to be the target 
Valdez 
(Valdez et al., 2002) 
Albendazole 
Benzimidazole 
derivatives 
Broth dilution G. lamblia 
E. histolytica 
T. spiralis 
Inhibition of G. lamblia  and T. spiralis growth by albendazole was observed 
Albendazole was inactive against E. histolytica 
Benzimidazole derivatives inhibited growth of E. histolytica 
Not all benzimidazole derivatives inhibited tubulin polymerisation 
  
Reference Benzimidazoles 
Tested 
Methods Employed Organisms 
Used 
Notable Results 
Kazimierczuk 
(Kazimierczuk et al., 2002) 
Albendazole 
Benzimidazole 
derivatives 
Broth microdilution G. duodenalis 
E. histolytica 
T. vaginalis 
Albendazole was inactive against E. histolytica and T. vaginalis (up to 200 µM) 
Benzimidazoles affect oxidative phosphorylation in mitochondria 
Issues with solubility and crystallisation were noted with some structures 
Navarrete-Vazquez 
(Navarrete-Vazquez et al., 
2003) 
Albendazole 
Mebendazole 
and their 
analogues 
Broth macrodilution G. lamblia 
T. vaginalis 
T. spiralis 
C. elegans 
Inhibition of growth was observed 
Not all benzimidazole derivatives inhibited tubulin polymerisation 
Other structures have a different mechanism of action 
Andrzejewska 
(Andrzejewska et al., 2004) 
Benzimidazole 
derivatives 
Broth macrodilution G. intestinalis 
T. vaginalis 
Inhibition of growth was observed 
Benzimidazoles inhibit protein kinases (CK1, CK2, and others)  
They may interfere with a wide spectrum of cell regulatory mechanisms 
Navarrete-Vazquez 
(Navarrete-Vazquez et al., 
2006) 
Benzimidazole 
derivatives 
Broth macrodilution 
Broth microdilution 
G. intestinalis 
T. vaginalis 
P. falciparum 
Inhibition of growth was observed 
 
Valdez-Padilla 
(Valdez-Padilla et al., 2009) 
Benzimidazole 
derivatives 
Broth dilution G. intestinalis 
T. vaginalis 
Inhibition of growth was observed 
 
Hernandez-Luis 
(Hernandez-Luis et al., 2010) 
Benzimidazole 
derivatives 
Broth macrodilution G. intestinalis 
E. histolytica 
T. vaginalis 
T. spiralis 
L. mexicana 
Inhibition of growth was observed 
Albendazole was inactive against E. histolytica 
 
Perez-Villanueva 
(Perez-Villanueva et al., 
2011) 
Omeprazole 
Lansoprazole 
Pantoprazole 
Rabeprazole 
Unknown G. intestinalis 
E. histolytica 
T. vaginalis 
 
Inhibition of growth was observed 
Pantoprazole showed good activity against all three protozoa 
PPIs may make good candidates for drug repurposing 
Mechanism of anti-protozoal activity is yet to be described 
 
The main component of the cytoskeleton of G. lamblia, G. intestinalis, G. duodenalis, T. spiralis and T. vaginalis is tubulin. 
The main component of the cytoskeleton of E. histolytica is actin. 
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In 2002, Jiang et al were the first to test a clinically used formulation of a PPI for 
antileishmanial activity (Jiang et al., 2002).  They noted that at pH 7.2 there was no 
adverse effect on the protozoan, but at pH 5.5 omeprazole inhibited the growth of 
Leishmania donovani (L. donovani).  They suggested that the prodrug form was therefore 
inactive and that the antileishmanial activity of omeprazole was due to one or more of the 
protonated active forms of PPI.  They also postulated that omeprazole was inhibiting the P-
type H
+
/K
+
-ATPase on the membrane surface of L. donovani.  This enzyme is known to be 
important for pH homeostasis and maintenance of the proton motive force across the 
membrane of L. donovani.   
It is known that acid activated forms of PPIs form strong disulphide bonds with thiol 
groups on exposed cysteine residues of the H
+
/K
+
-ATPase found in parietal cells and that 
acid activated tetra-cyclic sulphenamide forms can bind to and inactivate the adenylate 
cyclase or Na
+
/K
+
-ATPase of parietal cells (see Figure 1 and Section 1.10).  If acid 
activated forms of PPIs were present in the kidneys it is also known that binding to and 
inactivation of the kidney H
+
/K
+
-ATPases is also possible (see Section 1.9.2).  It is 
therefore proven that PPIs can bind to and inhibit a variety of enzymes that they encounter 
and therefore plausible that PPIs could bind to bacterial or parasitic enzymes (particularly 
perhaps ATPases).   
Riel et al also used clinically used formulations of PPIs to inhibit the growth of 
Plasmodium falciparum (P. falciparum) but they concluded that the V-type H
+
-ATPase in 
the plasma membrane of P. falciparum was not the target (Riel et al., 2002).  In 2011 it 
was reported that after around 20 years of research, the mechanism of the tubulin 
polymerisation independent anti-protozoal action of benzimidazoles was “yet to be 
described” (Perez-Villanueva et al., 2011).  The properties of structures containing the core 
benzimidazole backbone are therefore hugely diverse, with some reportedly also having 
anti-viral, anti-fungal and anti-cancer activities (Andrzejewska et al., 2002, Kazimierczuk 
et al., 2002, Navarrete-Vazquez et al., 2006).   
1.16 Proton Pump Inhibitors and Campylobacter  
Early studies reporting on the inhibitory effect of PPIs on H. pylori stated that PPIs had no 
similar inhibitory effect on C. jejuni (Iwahi et al., 1991, Megraud et al., 1991).  Almost a 
decade later, the first report of PPIs affecting both H. pylori and C. jejuni motility was 
published (Tsutsui et al., 2000).  C. jejuni is very acid sensitive (Lodato et al., 2010) and 
attempting to differentiate between the anti-bacterial properties of pro-drug versus acid 
 44 | P a g e  
 
activated forms of PPI by artificially manipulating the pH might therefore be problematic 
in the case of C. jejuni.  When Suerbaum et al attempted to do this with H. pylori they 
could only use short incubation times of 1 hour.  The standard measures of antimicrobial 
activity (MIC and MBC) are however usually expressed using 24 hours exposure for 
rapidly growing organisms.   
Considering that C. jejuni is one of the most important causes of bacterial gastroenteritis in 
the world (see Section 1.3); that there are increasing numbers of people taking PPIs 
worldwide (see Section 1.11.3 and Figure 5); that there is a proposed link between taking 
PPIs and increased susceptibility to enteric infections (see Section 1.7.1); and that it has 
been suggested that taking PPIs allows increased bacterial translocation across the 
epithelial cell barrier (see Section 1.6.3.3), it seems prudent to use methods similar to those 
employed previously by others to thoroughly investigate the effect of exposure to PPIs on 
C. jejuni.  If PPIs are truly able to affect C. jejuni motility as described by Tsutsui et al it 
therefore seems reasonable to suggest that the pathogenicity of the organism should also be 
adversely affected (see Section 1.6.3). 
1.17 Summary and Aims  
The exact method by which PPIs exert their anti-bacterial effect on Helicobacter and 
whether it is in fact a true bactericidal effect, are as yet unknown.  PPIs are benzimidazole 
derivatives and such compounds have been shown by others to affect H. pylori 
morphology (Ikeda & Karlyshev, 2012), H. pylori motility (Ohara et al., 2001), adherence 
of H. pylori to epithelial cells (Nakao et al., 1995) and biofilm formation in organisms such 
as S. mutans (Nguyen et al., 2005).  PPIs have also been shown by others to supplement 
the killing of organisms such as H. pylori by conventional antibiotics (Bamba et al., 1997).  
Previous work has hinted that PPIs may also be capable of affecting C. jejuni (Tsutsui et 
al., 2000), but investigations have been extremely limited in comparison to those 
investigating the effect of PPIs on the related organism H. pylori.  Indeed as 
Campylobacter and Helicobacter both belong in the campylobacterales order, adverse 
affects following exposure of C. jejuni to PPIs might in fact be expected.   
The project aims were to determine whether direct exposure to PPIs affected C. jejuni in 
ways similar to those reported by others using other bacterial genera.  Whether PPIs could 
affect C. jejuni growth/survival, motility, morphology, biofilm formation, adhesion and 
invasion of cultured epithelial cells and the effect of PPIs on the susceptibility to 
conventional antibiotics were investigated.   
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Microarrays, proteomics and metabolomics were used to investigate changes to C. jejuni 
gene expression, proteome and metabolome respectively, in response to PPI exposure.  
Selected C. jejuni genes were mutated to investigate the response to PPI exposure of 
deficient mutants in comparison to parent strains. 
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Chapter 2 
 
In Vitro Effects of PPI 
Exposure on Campylobacter 
jejuni   
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2 INTRODUCTION  
2.1.1 Helicobacter and Proton Pump Inhibitors  
It has been widely reported that exposure to PPIs affects the growth and survival of 
H. pylori in vitro.  The first study to report that exposure to PPIs inhibited the growth of 
H. pylori was published only a few years after the first PPI, omeprazole, was made 
commercially available (Iwahi et al., 1991).  The authors proposed that the anti-bacterial 
properties of PPIs were “selective” against H. pylori as 100 µg/ml had no inhibitory effect 
on Bacteroides fragilis, Bifidobacterium bifidum, C. jejuni, Citrobacter freundii, 
Clostridium perfringens, Enterobacter cloacae (E. cloacae), Enterococcus faecalis, E. coli, 
Eubacterium alactolyticum, Eubacterium limosum, Fusobacterium mortiferum, 
Fusobacterium nucleatum, Klebsiella pneumoniae (K. pneumoniae), Lactobacillus 
acidophilus, Morganella morganii (M. morganii), Peptostreptococcus anaerobius, Proteus 
mirabilis (P. mirabilis), Proteus vulgaris (P. vulgaris), P. aeruginosa, Serratia marcescens 
(S. marcescens), S. aureus, Streptococcus pneumoniae or Streptococcus pyogenes 
(S. pyogenes).   
This early study reported that, as well as inhibiting the growth of H. pylori, PPI exposure 
caused membrane blebbing and changes to the morphology of bacterial cells, with 
bacilliform and coccal forms of H. pylori being observed (Iwahi et al., 1991).  These 
reported changes to H. pylori morphology were supported by later studies (Megraud et al., 
1991, Nakao et al., 1995, Nakao & Malfertheiner, 1998).  Exposure to PPIs was also 
reported in some studies to affect the motility of H. pylori (Nakao et al., 1995, Tsutsui et 
al., 2000, Ohara et al., 2001, Spengler et al., 2004) and its ability to adhere to cultured 
cells (Nakao et al., 1995).   
Over the years, a number of proposed targets were investigated to explain the anti-
Helicobacter properties of PPIs.  These included the potent urease enzyme of H. pylori 
(Nagata et al., 1995, Logan, 1996), the organisms cytotoxin (Figura et al., 1994) and 
various bacterial ATPase enzymes (Belli & Fryklund, 1995, Park et al., 1996).  However, 
the target/s responsible for the in vitro activity of PPIs against H. pylori remained elusive 
even after over a decade of research (Mills et al., 2004), with urease, cytotoxin and specific 
ATPase enzymes all ruled out as targets.  A more comprehensive review of relevant 
literature can be found in Section 1.12 and in Table 4. 
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2.1.2 Campylobacter and Proton Pump Inhibitors  
Iwahi et al were also the first to test the PPIs omeprazole and lansoprazole for inhibitory 
activity against Campylobacter sp. (Iwahi et al., 1991).  They tested 27 clinically isolated 
strains of C. jejuni and reported that no inhibition of growth was observed up to a 
concentration of 100 µg/ml of PPIs.  This observation was supported by later studies 
reporting that the growth of Campylobacter spp. was not inhibited up to 256 µg/ml of 
omeprazole, lansoprazole or rabeprazole (Megraud et al., 1991, Sjostrom et al., 1996, 
Tsutsui et al., 2000).  However in one crucial study, where PPI exposure was found to 
affect the survival and motility of H. pylori, PPI exposure was reported to affect 
Campylobacter motility even though no effect on Campylobacter survival was found 
(Tsutsui et al., 2000).   
Motility is considered an important virulence factor (see Section 1.6.3) of C. jejuni (van 
Alphen et al., 2012) and is required for host colonisation (Cullen et al., 2013), for biofilm 
formation (Guerry, 2007) as well as for attachment to and invasion of epithelial cells (Mills 
et al., 2012).  In 1988, Black et al reported that after using a mixture of motile and non-
motile Campylobacter strains in experimental human infections only motile strains were 
recovered from stools (Black et al., 1988).  Therefore, if exposure to PPIs can indeed 
adversely affect C. jejuni motility then adverse effects on the ability to form biofilm and to 
adhere to and invade epithelial cells could also result following PPI exposure.  As 
discussed previously having an adverse effect on C. jejuni motility could have serious 
implications for the pathogenicity of the organism and its ability to cause disease. 
2.1.3 Other Bacteria and Proton Pump Inhibitors  
Whilst the bactericidal activity of PPIs seems to be mostly limited to H. pylori it seems 
likely that the bacterial target for PPIs would be an ATPase, or multiple ATPase enzymes, 
with the possibility of hampering any process which requires energy production (Figura et 
al., 1994).  It is therefore possible that energy requiring processes, in other bacteria, might 
also be affected by exposure to PPIs.  A more comprehensive review of relevant literature 
can be found in Section 1.14 and in Table 5.  A number of studies concluded that PPIs, or 
structurally similar benzimidazoles, inhibit biofilm formation in various Gram positive and 
Gram negative bacteria (Nguyen et al., 2011, Sambanthamoorthy et al., 2011, Singh et al., 
2012).  Co-exposure to PPIs and conventional antibiotics was also shown to increase 
bacterial killing and reduce MICs and MBCs (Aeschlimann et al., 1999). 
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2.1.4 Chapter Aims  
It is generally accepted that patients being treated with PPIs are more susceptible to all 
enteric infections (including campylobacteriosis and C. difficile) than patients who are not 
taking PPIs (Bavishi & DuPont, 2011).  The numbers of people taking PPIs worldwide is 
also ever increasing.  The link between PPI use and susceptibility to enteric infections has 
been investigated in countries including the Netherlands (Doorduyn et al., 2010, Bavishi & 
DuPont, 2011, Bouwknegt et al., 2014).  The effect of PPI exposure on H. pylori has been 
investigated rigorously in the past, but the effect on C. jejuni remains unclear.  With 
C. jejuni being the most common cause of acute bacterial gastroenteritis in the UK and in 
Europe it may prove useful to study the effects that direct contact with PPIs has on the 
pathogen. 
Experiments presented in this chapter were performed to determine whether exposure to 
PPI had any effects on Campylobacter.  Methods similar to those used in various H. pylori 
studies were employed to investigate if in vitro exposure to PPI inhibited the growth of, or 
indeed was bactericidal to C. jejuni.  Any changes to C. jejuni motility, morphology, 
ability to form biofilm and ability to adhere to or invade epithelial cells were also 
investigated.  Selected experiments were also performed using the Gram negative enteric 
pathogen Salmonella enterica, subsp enterica, serovar Typhimurium (S. Typhimurium) 
and a mouse commensal strain of Lactobacillus to investigate whether the in vitro effects 
of PPI exposure are likely “selective” and limited to the spiral Gram negative enteric 
pathogens.   
This study has utilised the PPI pantoprazole, due to its superior ability to dissolve in water 
and give accurate concentrations, compared to other PPIs like omeprazole or lansoprazole 
(personal observations).  Pantoprazole is also generally prescribed at a higher dose than 
some of the other PPIs (see Table 2) and the resulting concentration that might be 
physically achievable in the GI tract is therefore likely to be higher for pantoprazole than 
for other PPIs (see Table 3).   
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2.2 Materials and Methods  
2.2.1 Bacterial Strains and Culture Conditions  
The C. jejuni, S. Typhimurium and Lactobacillus strains used in this chapter of the study 
are listed in Table 7.  All strains were stored at -80°C on Microbank™ beads (Prolab).  To 
revive strains from frozen stocks, beads were thawed on ice and one bead removed and 
streaked onto a plate to obtain single colonies.  After 48 hours, one or more colonies were 
re-streaked onto a fresh plate and this was termed passage number one.  Strains were 
routinely passaged onto a fresh plate every 2-3 days, up to a maximum passage of ten.  
Strains from overnight growths were used in all individual experiments.  Strains were 
routinely grown on either Mueller-Hinton agar (MHA; Oxoid) or MHA with 7% horse 
blood (MHA + B; see Appendix 1).  C. jejuni incubations were carried out at 37°C, in a 
variable-atmosphere incubator (VAIN; Don Whitley Scientific) in an atmosphere of 
5% H2, 5% CO2, 5% O2 and 85% N2.  S. Typhimurium and Lactobacillus sp. incubations 
were carried out in a standard aerobic incubator at 37°C.  The Lactobacillus strain was 
isolated from a 6-8 week old healthy C57BL/6 (Harlan Laboratories) control mouse and 
was identified using 16S ribosomal DNA typing. 
Table 7.  Bacterial strains used in this chapter. 
 
Strain Features Origin/Reference 
C. jejuni 
11168-O 
Minimally passaged strain, 
first C. jejuni to later have 
its genome sequenced 
(Gaynor et al., 2004) 
C. jejuni 
81-176 
Human clinically isolated 
strain 
(Korlath et al., 1985) 
C. jejuni 
81116 
Human clinically isolated 
strain 
(Palmer et al., 1983) 
S. Typhimurium 
SL1344 
Pathogenic laboratory 
strain 
(Hoiseth & Stocker, 1981) 
Lactobacillus sp. Normal gut flora strain Isolated from a healthy 
C57BL/6 mouse 
 
2.2.2 Proton Pump Inhibitor  
Unless otherwise stated the PPI pantoprazole sodium hydrate powder (Sigma) was 
dissolved in sterile water and sterilised using a 0.2 µm syringe filter (Sartorius).  When 
required, PPI was further diluted in sterile water to achieve desired concentrations.  Neat 
PPI solution and the most dilute concentration (in the case of serial dilutions) were 
routinely cultured aerobically and microaerophillicaly on MHA to check for sterility. 
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2.2.3 Growth on Solid Agar  
C. jejuni colonies from an overnight plate growth were harvested into Mueller-Hinton 
broth (MHB; Oxoid) and around 1×10
8
 CFU/ml added to 10 ml molten soft top agar (STA; 
see Appendix 1) and poured over the surface of an MHA plate.  After cooling, prepared 
concentrations of pantoprazole (20-0 mg/ml or 20,000-0 µg/ml) were spotted onto the 
surface and plates incubated for 24 hours before being checked for inhibition of growth. 
2.2.4 Pantoprazole Minimum Inhibitory Concentration and Minimum 
Bactericidal Concentration  
MIC and MBC experiments were performed using a broth microdilution method in sterile 
96 well microtitre plates (Corning).  Campylobacter or Salmonella colonies from an 
overnight plate growth were harvested into MHB or minimal essential media (MEM; 
Invitrogen); Dulbecco’s modified eagle media with GlutaMAXTM (DMEM; Invitrogen) or 
tryptic soy broth (TSB; LabM) to around 5×10
5
 CFU/ml.  An equal volume of this 
bacterial suspension was added to the same volume of PPI (at concentrations ranging from 
40-0 mg/ml or 40,000-0 µg/ml).  The microtitre plate was covered with a sterile lid before 
being incubated for 4 or 24 hours.  The microtitre plate was then placed in an automatic 
plate reader (BMG LabTech-FluoStar-Optima), shaken and the optical density at 600 nm 
(OD600) measured.  MIC was also assessed visually using a light box.  10 µl aliquots were 
taken from each well and spotted onto MHA + B plates and plates incubated for 24 hours 
before being examined for the growth of Salmonella or 48 hours before being examined for 
the growth of Campylobacter.  PPI was replaced with an equal volume of sterile water for 
controls.  Controls were also performed to ensure the sterility of water, MHB, MEM, 
DMEM, TSB and PPI.  In a similar manner Lactobacillus colonies from an overnight 
MHA plate growth were harvested into MHB and pantoprazole MBC determined 
following exposure to pantoprazole for 4 or 24 hours by culturing 10 µl aliquots on MHA 
+ B plates for 24 hours. 
Following exposure to varying concentrations of PPI for 4 or 24 hours, aliquots were 
removed from the wells and inoculated into fresh broths containing no PPI.  These were 
then incubated for a further 24 hours before aliquots were removed and plated onto MHA 
+ B to determine if live bacteria could be revived in the absence of PPI following 
exposures to specific PPI concentrations. 
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2.2.5 Survival Studies  
Following exposure to varying concentrations of PPI for 4 or 24 hours in a broth 
microdilution method similar to that used in Section 2.2.4, aliquots were serially diluted in 
phosphate buffered saline (PBS; Invitrogen) and remaining viable bacteria were 
enumerated by viable plate surface colony counting and calculating CFU/ml.   
2.2.6 Motility Testing  
Semi-solid agar (SSA, see Appendix 1) was prepared once weekly and plates refrigerated 
until required.  Campylobacter or Salmonella colonies from an overnight plate growth 
were harvested into MHB to 1×10
7
 CFU/ml.  Aliquots of this suspension were added to an 
equal volume of PPI (at concentrations ranging from 5-0 mg/ml or 5,000-0 µg/ml).  These 
were then incubated for either 4 or 24 hours before 1 µl aliquots were stabbed into the 
centre of SSA plates.  Plates were then incubated for 24 (for Salmonella) or 48 hours (for 
Campylobacter) and the diameter of the zones of spread were measured in mm.  Following 
each of the exposure times serial dilutions were made in PBS and spotted onto plates to 
monitor bacterial survival at the different concentrations of PPI tested.  These plates were 
incubated for 24 (for Salmonella) or 48 hours (for Campylobacter) and surviving CFU/ml 
calculated. 
2.2.7 Biofilm Formation  
25cm
2
 flasks (Corning) containing 10 ml MHB were primed overnight in the VAIN.  They 
were then inoculated with a few colonies from an overnight plate growth of 
Campylobacter and incubated overnight.  Cultures were pelleted (Sigma 4K15 centrifuge) 
at 4,500 × g for 10 minutes at 4
o
C and resuspended to an OD600 of 0.6 using an Eppendorf 
Biophotometer.  Equal volumes of this were aliquoted into 5 ml Eppendorf tubes (Starlab) 
and PPI, or water for no PPI controls, added to final concentrations of 500, 250, 125 and 
0 µg/ml.  The Eppendorf tubes were vortexed and incubated in the VAIN with loose lids 
for 2 hours.  To remove the PPI, Eppendorf tubes were centrifuged as described above and 
bacterial pellets washed with 1 ml PBS, vortexed and re-centrifuged.  The remaining 
bacteria were resuspended in MHB to an OD600 of 0.3.  200 µl of these suspensions was 
added to replicate wells of a 96 well microtitre plate before being covered with a lid and 
incubated in the VAIN to allow biofilm to form for 1, 2, or 3 days.   
Following 1, 2 or 3 days incubation selected wells, covering a range of PPI concentrations, 
were observed using an inverted microscope (Zeiss Axiovert 25) at 400× magnification.  
5 µl was taken from selected wells onto glass microscopy slides, stained using Live/Dead® 
BacLight
TM
 (Invitrogen) and viewed using fluorescent microscopy (Axio Imager.A1) at 
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400× magnification.  In both cases images were captured using Axiovision release 4.7.1 
software (Carl Zeiss, Germany).  Aliquots were removed, plated on MHA and incubated 
aerobically to check for contamination.  The remaining media was removed from all wells 
and wells washed four times with PBS, plates inverted and dried in a 42°C incubator for 15 
minutes.  1% crystal violet was added to wells and the plates placed on a rotary shaker 
(Stuart Scientific S03) at room temperature for 10 minutes at 180 revolutions per minute 
(rpm).  Crystal violet was then removed and wells washed four times with PBS.  Plates 
were again inverted and dried for 15 minutes before 70% ethanol was added to wells to 
elute the crystal violet stain and plates placed again on a rotary shaker for 10 minutes.  
OD600 was then measured using a BMG LabTech-FluoStar-Optima plate reader.  If values 
were above the maximum detected by the plate reader, then 1:2 and 1:5 dilutions were 
made in water from appropriate wells, the values corrected according to the dilution factor 
and the average of both dilutions taken as the final result.   
2.2.8 Adhesion and Invasion  
In all of the references stated below, DMEM was supplemented with 10% foetal calf serum 
(FCS; Gibco).  C. jejuni 81-176 was harvested from overnight plate growths into DMEM 
and the suspension diluted as required in fresh DMEM (see below).  Pantoprazole for use 
in these experiments was dissolved and further diluted, when required, in PBS with PBS 
alone being used for no PPI controls.   
Caco-2 cells were grown in DMEM.  The cells were grown routinely in vented cap tissue 
culture flasks (Corning) at 37°C in a 5% CO2 humidified atmosphere.  For all assays, 
12 well tissue culture plates (Corning) were seeded with approximately 5×10
5
 cells per ml, 
and incubated until fully confluent (usually around 48 hours).  Before infection with 
C. jejuni the monolayers were covered with 1 ml fresh DMEM.  Approximately 1×10
7
 
CFU/ml of C. jejuni in DMEM was added to monolayers with pantoprazole or PBS alone 
being added to a final concentration of 1,000, 500, 250 or 0 µg/ml.  The infected 
monolayers were incubated for 4 hours before 5 µl aliquots were stabbed into SSA and 
motility following exposures to varying PPI concentrations assessed as described in 
Section 2.2.6.  Serial dilutions were also prepared from the wells to ensure PPI exposure 
concentrations tested did not significantly alter the CFU/ml surviving the PPI exposures.   
For measurement of adhesion, the infected monolayers were incubated for 4 hours and then 
gently washed three times with PBS, before being lysed using 1% (v/v) Triton X-100 
(Sigma) in water and ten fold serial dilutions made in PBS.  Ten µl aliquots of each 
dilution were plated on MHA + B and agar plates incubated for 48 hours in the VAIN to 
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enumerate and calculate CFU/ml.  For measurement of invasion, the infected monolayers 
were incubated for 4 hours as for the adhesion assay and then gently washed three times 
with PBS, before adding DMEM containing gentamicin (Sigma) 200 μg/ml for 2 hours to 
kill any extracellular bacteria.  Following incubation with gentamicin the infected 
monolayers were gently washed, lysed and serial dilutions plated as described for the 
adhesion assay.   
The total number of bacteria associated with the monolayers (adhered and internalised) 
was determined using the method described first above and internalised only bacteria 
determined by using gentamicin in the invasion assay.  The difference between the total 
number of associated bacteria and the number of intracellular bacteria was calculated to 
obtain the number of adherent C. jejuni.  One mg/ml (or 1,000 µg/ml) final concentration 
of pantoprazole, dissolved in PBS and added to wells containing fully confluent Caco-2 
cells in DMEM, for 12 hours looked microscopically indistinguishable from Caco-2 cells 
not exposed to PPI.  So the presence of PPI in the assay over 4 hours likely did not affect 
the cell morphology. 
2.2.9 Electron Microscopy  
Following exposure, for 24 hours, of C. jejuni to various concentrations of pantoprazole, 
50 µl aliquots were removed and fixed for 1 hour at room temperature, in 2.5% 
glutaraldehyde in 0.1 M phosphate buffer.  They were then rinsed three times, for 
5 minutes each, with 0.1 M phosphate buffer.  Specimens were then fixed for 1 hour in 1% 
osmium tetroxide.  After three 10 minute washes with distilled water, specimens were 
dehydrated through an ascending series of acetone solutions (30, 50, 70, 90 and 100%) 
twice for 10 minutes each.  Specimens were then dried in a critical point dryer (Polaron 
E3000) for 80 minutes and mounted on stubs using double-sided copper tape and silver 
paint.  A Polaron SC515 SEM coating system was used to coat the specimens with gold–
palladium (20 nm thickness) and they were viewed on a JEOL 6400 scanning electron 
microscope. 
2.2.10 Replicates and Data Analysis  
Each assay was conducted in triplicate and was independently repeated at least twice.  
Results are expressed as means +/- standard deviations (SD; error bars) of all replicate 
experiments.  The unpaired Students t test was used to determine statistical significance.  A 
P value of > 0.01 but < 0.05 was considered significant (*) and a P value of < 0.01 highly 
significant (**).  
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2.3 Results  
2.3.1 Growth on Solid Agar  
Various prepared concentrations of pantoprazole were spotted onto plates inoculated with a 
lawn of C. jejuni to visually determine whether the PPI pantoprazole was able to inhibit the 
growth of Campylobacter.  At a concentration of 20 mg/ml pantoprazole (or 20,000 µg/ml) 
a clear zone of inhibition was visible in the agar (Figure 7a) and zones of inhibition were 
observed down to 8 mg/ml (or 8,000 µg/ml) pantoprazole (Figure 7b), with the edges of 
the zones becoming progressively less clearly defined as the PPI concentration was 
lowered.  At 4 mg/ml pantoprazole (or 4,000 µg/ml) no inhibition was observed and the 
growth of C. jejuni was undisturbed (Figure 7b) as it was for the no PPI control.  The PPI 
appeared not to diffuse through the agar and inhibition was limited to the area of direct 
exposure. 
     
a            b 
 
Figure 7.  The PPI pantoprazole inhibits the growth of C. jejuni.  Pantoprazole solution, 
at the concentrations (mg/ml) indicated in white text above the relevant spots, was spotted 
onto a lawn of C. jejuni strain 81-176.  Plates were then incubated for 24 hours before 
being inspected for zones of inhibition. 
 
Similar results were observed, with mg/ml concentrations of PPI inhibiting the growth of 
C. jejuni strains 11168-O and 81116 (data not shown).  Direct inhibition of the growth of 
multiple strains of C. jejuni, observed using simple spot testing, prompted further 
investigation using standard methods for MIC and MBC determination. 
2.3.2 Pantoprazole Minimum Inhibitory Concentration and Minimum 
Bactericidal Concentration  
A standard MIC is determined by visually inspecting broth cultures, at various drug 
concentrations, for the lowest concentration at which growth inhibition can be observed, 
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indicated by the lack of turbidity caused by bacterial growth (van Alphen et al., 2012).  
In some cases, a more objective result can be obtained by using an automatic plate reader 
to measure the optical density (OD) (Bamba et al., 1997).  Broth microdilution was used to 
try and determine the pantoprazole MIC for various strains of C. jejuni.  The maximum 
achievable pantoprazole concentration in water was 40 mg/ml (personal observations) 
hence the maximum final PPI concentration in a standard broth MIC or MBC experiment, 
where equal volumes of bacterial suspension are mixed with an equal volume of the test 
agent, was 20 mg/ml.  Results in Figure 8 show that an MIC cannot be accurately 
determined for pantoprazole.  Instead of turbidity increasing as the drug concentration 
decreases (as is normally the case in an MIC experiment) the opposite is true and the 
presence of the PPI itself causes an increase in turbidity. 
  a 
Final Pantoprazole Concentration per Well (mg/ml) 
20 10 5 2.5 1.25 0.63 0.31 0.16 0.08 0 
  b 
Figure 8.  Turbidity cannot be used to determine the MIC of pantoprazole for wild-type 
C. jejuni strains.  C. jejuni strain 11168-O was exposed to halving dilutions of PPI, in a 
broth microdilution experiment, for 24 hours, before OD600 was determined (a).  
Pantoprazole above 10 mg/ml comes out of solution after prolonged incubation and above 
1.25 mg/ml a yellow colour develops, making it difficult to determine where lack of 
turbidity is due to lack of bacterial growth (b). 
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It was found that, following 24 hours incubation at ≥ 1.25 mg/ml (or 1,250 µg/ml) 
pantoprazole, a yellow colour developed within the wells and at ≥ 10 mg/ml (or 
10,000 µg/ml) problems with solubility developed (Figure 8).  This made it difficult to 
determine a MIC by visual inspection or by reading the OD spectrophotometrically as 
cloudiness in the wells occurred at high PPI concentrations.  Results show that ODs are 
much higher at high concentrations of PPI than even for the no PPI positive control.   
In order to determine if the turbidity at high concentrations of PPI was due to solubility 
issues in MHB, the same test method was employed substituting MHB with MEM, DMEM 
or TSB.  In all cases the results were similar to those achieved using MHB (data not 
shown) and an MIC could not be reliably determined either using an automatic plate reader 
or by visually inspecting wells.  For this reason, MHB continued to be used for subsequent 
bacterial growth experiments, including MBC determinations. 
The MBC is the concentration at which > 99.9% of a bacterial population are killed and 
this can be determined by exposing strains to varying concentrations of a drug and then 
plating aliquots onto agar which is free from the drug being tested (van Alphen et al., 
2012).  MBC results obtained using broth microdilution for various strains of C. jejuni are 
shown in Table 8.   
Table 8.  The MBC of the PPI pantoprazole for different strains of C. jejuni falls within 
a similar range.   
 
C. jejuni 
Strain 
Pantoprazole MBC (mg/ml) 
4 Hour Exposure 24 Hour Exposure 
Mean +/- SD Range Mean +/- SD Range 
11168-O 3.30 +/- 1.30 4.50-2.00 0.83 +/- 0.32 0.63-1.25 
81-176 2.90 +/- 1.00 4.00-2.00 0.93 +/- 0.34 0.63-1.25 
81116 3.30 +/- 1.30 4.50-2.00 0.99 +/- 0.42 0.63-1.25 
 
Following exposure to PPI in MHB for 4 or 24 hours in an MIC experiment, 10 µl aliquots 
were removed from the wells and spotted onto MHA + B plates to determine the MBC. 
 
These data support the observation in Figure 7 that direct contact between C. jejuni and 
the PPI pantoprazole is deleterious to Campylobacter survival.  The PPI MBC following 
4 hours exposure was found to be 3.3 mg/ml (or 3,300 µg/ml) for two of the C. jejuni 
strains tested and 2.9 (or 2,900 µg/ml) for another (Table 8).  The concentration required 
to kill lowers when the exposure time is extended, such that following 24 hours exposure, 
around 1 mg/ml (or 1,000 µg/ml), is bactericidal to C. jejuni strains (Table 8). 
 58 | P a g e  
 
Following exposure to concentrations of PPI above 1.25 mg/ml (or 1,250 µg/ml) for 
24 hours, no live Campylobacter could be revived when aliquots were removed and 
inoculated into fresh broths containing no PPI and incubated for another 24 hours in the 
absence of PPI.   
Neither S. Typhimurium or Lactobacillus sp. demonstrated any susceptibility to PPI 
(Table 9) and the bacterial populations were able to survive exposures up to 20 mg/ml (or 
20,000 µg/ml) pantoprazole, which is over 20× the MBC for C. jejuni.  A similar number 
of colonies were isolated from 10 µl aliquots that had been exposed to 20 mg/ml (or 
20,000 µg/ml) pantoprazole for 24 hours as were isolated from the no PPI control 
(Figure 9).   
Table 9.  The PPI pantoprazole does not kill S. Typhimurium or Lactobacillus.   
 
Strain 
Pantoprazole MBC (mg/ml) 
4 Hour Exposure 24 Hour Exposure 
S. Typhimurium SL1344 > 20 > 20 
Lactobacillus sp. > 20 > 20 
 
Following exposure to PPI in MHB for 4 or 24 hours in an MIC experiment, aliquots were 
removed from the wells and spotted onto MHA + B plates to determine the MBC. 
 
 
 
Figure 9.  Lactobacillus displays no susceptibility to pantoprazole up to a concentration 
of 20 mg/ml (or 20,000 µg/ml).  Lactobacillus sp. in MHB were exposed to varying 
concentrations of pantoprazole (as indicated in µg/ml in the white text above individual 
spots) for 24 hours before 10 µl aliquots were removed and plated onto MHA + B.  Plates 
were incubated aerobically for 24 hours before being examined for the presence of 
Lactobacillus and photographed using a Gel Doc system.  
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        313         156            78 
 
 
           39       20         0 
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2.3.3 Survival Studies  
To investigate if exposure to PPI at concentrations lower than the MBC had an effect on 
C. jejuni survival, samples were diluted in PBS and remaining viable bacteria were 
enumerated, following exposure to various concentrations of PPI for 4 or 24 hours.  
Results in Figure 10a show that following 4 hours PPI exposure there was more variability 
in the susceptibility of C. jejuni strains, but following 24 hours exposure, multiple strains 
of C. jejuni show very similar susceptibility patterns (Figure 10b).  At the higher 
concentrations of pantoprazole tested, there are fewer C. jejuni surviving than at lower 
concentrations (Figure 10a and b).  In Figure 10b where strains had been exposed to the 
PPI for 24 hours there was no bacterial survival above 1.25 mg/ml (or 1,250 µg/ml) for any 
of the three C. jejuni strains tested and this was to be expected as this exceeds the MBC.   
Having determined that C. jejuni was killed by exposure to mg/ml concentrations of PPI, 
experiments were performed using S. Typhimurium to investigate whether another, non-
spiral, Gram negative enteric pathogen might be similarly affected.  Results in Figure 11 
show that, even following 24 hours exposure to concentrations of PPI four times higher 
than those required to kill C. jejuni, no effect on S. Typhimurium survival was evident.  
This is in support of the MBC data in Section 2.3.2, where the MBC of pantoprazole was 
> 20 mg/ml (or 20,000 µg/ml) pantoprazole for S. Typhimurium.  
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  a 
  b 
Figure 10.  Exposure to the PPI pantoprazole affects C. jejuni strain survival in a dose 
dependent manner.  Aliquots were removed, serially diluted and surviving bacteria were 
calculated following exposure in MHB to varying concentrations of PPI for 4 hours (a) or 
24 hours (b).  
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Figure 11.  Exposure to the PPI pantoprazole does not affect S. Typhimurium survival.  
Aliquots were removed, serially diluted and surviving bacteria were calculated following 
exposure to varying concentrations of PPI for 24 hours. 
 
2.3.4 Motility Testing  
Experiments were performed using soft agar motility to determine whether exposure to sub 
lethal levels of PPI could interfere with the motility of C. jejuni.  Results in Figure 12 
confirm that exposure to PPI does inhibit the motility of C. jejuni strains as motility 
decreases as the PPI concentration increases.   
At the same time as the testing was performed to assess the motility of C. jejuni strains, 
serial dilutions were made to determine the numbers of bacteria surviving the exposures to 
the various PPI concentrations.  In Figure 10a, the log CFU/ml counts for strain 11168-O 
(shown in blue) remains quite steady from the concentration 0 to 313 µg/ml.  Yet when the 
motility of these surviving bacteria was measured (Figure 12) a highly significant 
difference in the motility of 11168-O exposed to 313 µg/ml was seen compared to the no 
PPI exposed control (P =.0.0046).  Following exposure of 11168-O to 625, 313 and 
156 µg/ml pantoprazole for 4 hours, the average zone diameter was found to be 0, 5.3 and 
13.3 mm respectively whilst the remaining viable CFU/ml were 1.5×10
7
, 3.0×10
7
 and 
3.5×10
7
 respectively.    
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a     b     c 
  d 
  e 
 
Figure 12.  Exposure to the PPI pantoprazole adversely affects C. jejuni motility.  
C. jejuni strain 11168-O was exposed to PPI at 1,000 (a), 500 (b) and 0 µg/ml (c) for 
4 hours before aliquots were stabbed into 0.4% SSA.  Three strains of C. jejuni were 
exposed to various concentrations of the PPI pantoprazole for 4 (d) or 24 hours (e) before 
having 1 μl aliquots stabbed into SSA.  Plates were then incubated for 48 hours before the 
diameters of the zones were measured in mm and mean +/- SD plotted.  Levels of 
significance, as indicated by * (P value > 0.01 but < 0.05) or ** (P value < 0.01) relate to 
the individual test conditions compared to the no PPI control for the same strain.   
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Similar experiments performed using Salmonella in contrast, found that Salmonella 
motility was not affected by exposure to PPIs (Figure 13). 
 
a     b     c 
 
  d 
Figure 13.  Exposure to the PPI pantoprazole does not affect the motility of 
S. Typhimurium.  S. Typhimurium strain SL1344 was exposed to PPI at 1,000 (a), 500 (b) 
and 0 µg/ml (c) for 4 hours before aliquots were stabbed into SSA.  SL1344 was exposed to 
various concentrations of the PPI pantoprazole for 24 hours (d) before having 1 μl 
aliquots stabbed into SSA.  Plates were then incubated for 24 hours before the diameter of 
the zones was measured in mm and mean +/- SD plotted. 
 
2.3.5 Biofilm Formation  
Crystal violet assays were used to assess the ability of C. jejuni (pre-exposed to PPI for 
2 hours) to then form biofilms.  Microscopy was also used to visualise the biofilm, with 
and without staining.  Results in Figure 14 show that in the absence of PPI, C. jejuni 
produced more biofilm at 48 hours than at 24 hours and still more at 72 hours (the blue, 
red and green bars on the far right of the graph).  At 24 hours there was no significant 
difference in the ability to form biofilm at any of the concentrations of PPI tested (blue 
bars), but the biofilm formed in only 24 hours was quite small, even for the no PPI control.  
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At 48 hours however (red bars), compared to the no PPI control, pre-exposure to 500, 250 
and 125 µg/ml PPI for 2 hours significantly reduced ability to form biofilm (P = 0.005, 
P = 0.003 and P = 0.011 respectively).  At 72 hours (green bars), pre-exposure to 
500 µg/ml PPI for 2 hours was the only concentration to significantly decrease biofilm 
(P = 0.021)  Similar results were seen for C. jejuni 11168-O and 81-176, with pre-exposure 
to some PPI concentrations affecting ability to form biofilm (data not shown).  
 
 
Figure 14.  Effect of pre-exposure to the PPI pantoprazole on the ability of C. jejuni to 
form biofilm.  C. jejuni strain 81116 was exposed to varying concentrations of PPI in 
MHB for 2 hours before PPI was removed by pelleting and washing bacteria.  Samples 
were then resuspended in fresh broth and corrected to the same OD600 before being 
allowed to form biofilm in wells of 96 well microtitre plates for 24, 48 or 72 hours.  Levels 
of significance, as indicated by * (P value > 0.01 but < 0.05) or ** (P value < 0.01) relate 
to the individual test conditions compared to the no PPI control for the same incubation 
time.  
 
Results in Figure 14 indicate that biofilm formation at 48 hours was most affected by pre-
exposure to PPI and Figure 15 shows that these results were confirmed using microscopy.  
The no PPI control shows a dense structured biofilm using fluorescent microscopy 
(Figure 15f) and multiple patches of heavily clumped bacteria using inverted light 
microscopy (Figure 15e).  C. jejuni pre-exposed to 250 µg/ml displays disruption to the 
biofilm with fewer patches of heavily clumped bacteria and large spaces between clumps 
(Figure 15c and d).  C. jejuni pre-exposed to 500 µg/ml shows no apparent biofilm 
structure with individual bacterial cells rather than clumps or structured biofilm 
(Figure 15a and b).    
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Figure 15.  Pre exposure to the PPI pantoprazole for 2 hours affects C. jejuni ability to 
form biofilm at 48 hours.  C. jejuni 81-176 was exposed to 500 (a and b), 250 (c and d) 
and 0 µg/ml (e and f) pantoprazole in MHB for 2 hours before being allowed to form 
biofilm in wells of 96 well microtitre plates for 48 hours.  Biofilms were viewed using a 
normal inverted light microscope at x400 magnification (a, c and e) and stained with 
LIVE/DEAD® BacLight™ stain then viewed using a fluorescent microscope (b, d and f) at 
x400 magnification. 
 
2.3.6 Adhesion and Invasion  
Gentamicin protection assays were used to determine if exposure to PPI affected ability of 
C. jejuni to adhere to and/or invade Caco-2 cells.  Caco-2 cells originated from a human 
colonic adenocarcinoma (Louwen et al., 2012) and form polarised monolayers (Friis et al., 
2005) which can be used as models for the absorptive epithelial cells of the gut 
(MacCallum et al., 2005).  Results in Figure 16 show that the decrease in adherent 
C. jejuni on exposure to pantoprazole does not reach statistical significance.  The reduction 
in invasion of Caco-2 cells was highly significant at all concentrations of PPI tested 
(Figure 16).  The P values for 250, 500 and 1,000 µg/ml pantoprazole exposed versus the 
no PPI exposed invasion control were 0.00009, 0.00008 and 0.00006 respectively.   
f e 
d c 
a b 
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Figure 16.  Exposure to the PPI pantoprazole significantly decreases invasion of Caco-2 
cells by C. jejuni.  Fully confluent monolayers of Caco-2 cells were infected with C. jejuni 
81-176 at varying concentrations of PPI for 4 hours before adherent and invaded 
organisms were quantified.  Levels of significance, as indicated by ** (P value < 0.01) 
relate to the individual test conditions compared to the relevant no PPI control. 
 
2.3.7 Electron Microscopy  
Results in Figure 17a show that prolonged exposure to concentrations of pantoprazole 
well above the MBC causes C. jejuni to change into atypical coccal forms which have lost 
their flagella.  At around two times the MBC (Figure 17b) we see the population is a 
mixture of cells in typical spiral morphology, some with intact long smooth flagella and we 
also see atypical coccal forms which have shortened or absent flagella.  In some cells we 
see evidence of membrane blebbing (indicated by a white arrow in Figure 17b).  When the 
PPI concentration that C. jejuni has been exposed to, is lowered to below the MBC 
(Figure 17c), we find that most of the population is in typical spiral morphology with a 
few coccal forms also being present.  C. jejuni cells which have not been exposed to PPI 
(Figure 17d) appear spiral, with intact flagella and smooth, bleb free membranes.  Similar 
results were also obtained for strains 81-176 and 81116 (data not shown). 
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Figure 17.  Prolonged exposure 
to high concentrations of PPI 
affects C. jejuni morphology.  
C. jejuni 11168-O in MHB was 
exposed to 10,000 (a), 2,000 (b), 
600 (c) and 0 µg/ml (d) 
pantoprazole for 24 hours.  
Morphology switches from 
atypical coccal forms following 
exposure to high concentrations 
of PPI to more typical spiral 
morphology at low PPI 
concentrations.  A white arrow 
is used to highlight membrane 
blebbing. 
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2.4 Discussion  
2.4.1 Growth on Solid Agar  
Spotting of pantoprazole onto solid agar clearly shows that direct application of PPI 
inhibits the growth of C. jejuni at mg/ml concentrations (Figure 7).  It is however worth 
noting that the concentrations of conventional antibiotics generally required to inhibit 
bacteria are usually within the µg/ml range and so the concentrations of PPI shown here to 
inhibit growth are much higher than those required for conventional antibiotics.  Other 
authors have concluded in the past that PPIs were not able to kill Campylobacter spp. 
(Iwahi et al., 1991, Megraud et al., 1991, Sjostrom et al., 1996, Tsutsui et al., 2000), but 
the maximum documented concentration previously tested was 0.256 mg/ml (or 
256 µg/ml).  Results obtained by direct spotting, suggest that the concentration required to 
inhibit C. jejuni growth is much higher than the concentration previously tested by others.   
The molecular weight of pantoprazole is 383 and the molecular weight of the pantoprazole 
sodium hydrate used in this study is 405 and this is comparable with conventional 
antibiotics that commonly diffuse through agar.  However results in Figure 7 make it clear 
that the PPI does not diffuse through the agar and C. jejuni inhibition is limited to areas of 
direct contact.   
It is thought that agar dilution methods may be less accurate than broth microdilution 
(Klancnik et al., 2010) in determining inhibitory concentrations and that broth culture more 
closely resembles the in vivo environment (Trautmann et al., 1999).  The stability of PPIs 
in agar has also been questioned (Trautmann et al., 1999).  Agar dilution also requires far 
greater quantities of drug than broth microdilution and is therefore not often used when the 
cost of the drug is high, as is the case with pantoprazole sodium hydrate.  For these reasons 
MIC and MBCs were performed using broth microdilution in this study. 
2.4.2 Pantoprazole Minimum Inhibitory Concentration and Minimum 
Bactericidal Concentration  
Dimethyl sulfoxide (DMSO) has been used extensively by others in the past, as the solvent 
for PPIs, with some researchers further diluting in DMSO (Trautmann et al., 1999) and 
others diluting in water (Midolo et al., 1997).  The use of DMSO is unlikely to closely 
mimic the in vivo environment as prescription drugs are likely to be taken with water.  This 
study has utilised the PPI pantoprazole (due to its superior ability to dissolve in water and 
give accurate concentrations) but in other anti-bacterial studies it is one of the least 
commonly tested PPIs (see Tables 4 and 5).   
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PPIs such as pantoprazole are prodrugs that undergo acid activation to form sulfenic acids 
and subsequent dehydration to form cyclic sulfenamides (Shin et al., 2004).  The 
conversion occurs more quickly at acidic pH than at neutral pH, but can occur in vitro at 
neutral pH given time (Sachs et al., 1995).  The sulfenic acids and cyclic sulfenamides are 
highly reactive and change form quickly to generate more compounds than can be 
quantitated accurately (Shin et al., 2004).  Acid activated PPIs at high concentrations are 
not very soluble in water (Shin et al., 2004).  Acid activation of the prodrug probably 
occurs in vitro during long incubation periods (Suerbaum et al., 1991). 
It is known that a number of the intermediates that PPIs become converted to, upon 
protonation, are yellow in colour (Nguyen et al., 2005).  At high in vitro (and therefore in 
the absence of parietal cell H
+
/K
+
-ATPases to bind to) concentrations of PPI presumably 
more of the PPI is converted to yellow coloured intermediates and this caused the problems 
with determining MIC using visual inspection or automated OD detection as shown in 
Figure 8.  The insolubility of pantoprazole and its acid activated intermediates at very high 
concentrations also contributed to the difficulty in determining the MIC.  MIC has been 
determined by others by inoculating an actively growing culture onto agar plates 
containing a range of PPI concentrations (Suerbaum et al., 1991, Shibata et al., 1995), but 
for reasons discussed at the end of Section 2.4.1 agar dilution was not used in this study 
and MBC was investigated instead. 
Whether the anti-bacterial activity of PPIs was bacteriostatic (Megraud et al., 1991), 
bactericidal (Midolo et al., 1997) or both (Mirshahi et al., 1998) for H. pylori has been 
heavily disputed.  Results presented here demonstrate that an accurate MBC can be 
determined and pantoprazole was found to be bactericidal, at 24 hours, to multiple strains 
of C. jejuni at around 1 mg/ml (or 1,000 µg/ml) (Table 8).  It is likely that the activity of 
PPIs is indeed truly bactericidal as attempts to revive any live C. jejuni from broths 
containing concentrations of PPI higher than the cidal level, repeatedly failed to produce 
any live bacteria.  No killing, inhibition of S. Typhimurium growth or motility was 
observed using the same methods used for C. jejuni up to a maximum concentration of 
20 mg/ml (or 20,000 µg/ml).  A strain of Lactobacillus isolated from a young C57BL/6 
healthy mouse also demonstrated no susceptibility to the bactericidal action of 
pantoprazole.   
2.4.3 Motility Testing  
When the motility of 11168-O exposed to 625 µg/ml pantoprazole is compared to the same 
strain exposed to 313 µg/ml pantoprazole, where surviving CFU/ml remains fairly steady, 
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we find that bacteria exposed to the lower PPI concentration for 4 hours are highly 
significantly more motile than those exposed to the higher PPI concentration (P = 0.005).  
The reduction in the zone diameters seen in Figure 12 is therefore not merely a reflection 
of the number of live bacteria present in the 1 μl aliquot being stabbed into the semi-solid 
agar, but rather a display of reduced bacterial motility.  We also see in Figure 12 that 
strains 81-176 and 81116 are naturally more motile than strain 11168-O.  Results indicate 
that the motility of C. jejuni strains is severely affected following exposure to pantoprazole 
for 4 or 24 hours.  The effect is more pronounced the higher the PPI concentration present, 
with no growth at all being observed at concentrations above the MBC.  For all three 
strains tested, as the PPI concentration decreases, motility increases.  It is possible that the 
energy dependent motion of the flagellar motor is being targeted by the pantoprazole and 
that is why motility decreases as PPI concentration rises or exposure time increases.  The 
minimum pantoprazole concentration which consistently significantly reduced bacterial 
motility in all three of the C. jejuni strains tested was 625 µg/ml following 4 hours 
pantoprazole exposure and 313 µg/ml following 24 hours pantoprazole exposure. 
Tsutsui et al reported that the PPIs lansoprazole, omeprazole and rabeprazole adversely 
affected the motility of Campylobacter strains, at a concentration of 16 µg/ml (Tsutsui et 
al., 2000).  This study has demonstrated that the PPI pantoprazole is also able to adversely 
affect the motility of Campylobacter strains and that this effect becomes more pronounced 
with exposure to even higher concentrations of PPI than were tested by Tsutsui et al.   
2.4.4 Biofilm Formation  
The ability of short pre-exposures to PPI to affect biofilm formation were most apparent 
following 48 hours of biofilm formation (Figure 15).  Exposure to concentrations of PPI as 
low as 125 µg/ml was shown to significantly reduce ability to form biofilm.  C. jejuni 
forms biofilms on the surfaces of chicken meat and biofilm formation is known to be 
important for survival in the environment (Gundogdu et al., 2011).  Some bacteria exist in 
the colon in biofilms (Slonczewski et al., 2009) where they are protected and better able to 
persist.  Motility is known to be important for biofilm formation (Kalmokoff et al., 2006) 
and defects in motility are known to cause defects in biofilm formation (Reuter et al., 
2010).  Results in Figure 12 show that the motility of C. jejuni was adversely affected by 
exposure to sub-lethal concentrations of PPI and it is therefore unsurprising that biofilm 
formation was also found to be impaired.  Loss of biofilm formation ability may also 
suggest that pantoprazole exposure affects the quorum sensing ability of C. jejuni.   
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2.4.5 Adhesion and Invasion  
Nakao et al reported in 1995 that exposure to even sub-MIC levels of lansoprazole for 
1 hour resulted in a decreased ability of H. pylori to adhere to HEp-2 cells (Nakao et al., 
1995).  Motility is required by C. jejuni for invasion of epithelial cells (Everest, 2002) and 
we have already demonstrated that PPI exposure affects the motility of C. jejuni 
(Figure 12).  Results in Figure 16 show that ability of C. jejuni to adhere to Caco-2 cells is 
not significantly affected by PPI exposure but that the ability to invade them was.  The 
reduction in invasion of Caco-2 cells was highly significant at all concentrations of PPI 
tested, even as low as 250 µg/ml.  The ability of C. jejuni to invade cells is considered a 
virulence factor (Zilbauer et al., 2008), with some strains being notably more invasive than 
others and highly invasive strains are considered more pathogenic (Pesci et al., 1994).  It 
has also been suggested that severity of disease following infection with C. jejuni may be 
linked to differences in strain ability to invade epithelial cells (Friis et al., 2005, Dasti et 
al., 2010).  It is clear that, even at sub lethal levels, the invasion potential of C. jejuni, and 
therefore also its pathogenicity or ability to cause invasive disease, is significantly 
diminished in the presence of PPIs. 
2.4.6 Electron Microscopy  
Results suggest that at concentrations of pantoprazole well above the MBC, cell lysis 
occurs as far fewer cells could be detected per field compared to the no PPI exposed 
control and those samples exposed to low concentrations of pantoprazole.  Bacteriolysis 
can be indicated by a loss of turbidity and/or an increase in viscosity in broth cultures 
(Iwahi et al., 1991) but due to issues with colour, insolubility and turbidity at 
concentrations of pantoprazole well above the MBC (Figure 8) this was unable to be 
confirmed.  The only cells which can be seen at concentrations of pantoprazole around 10× 
the MBC are atypical coccal forms, which are thought to be degenerate forms of 
Campylobacter (Ikeda & Karlyshev, 2012). 
In studies using Helicobacter, changes in morphology following PPI exposure (Megraud et 
al., 1991, Nakao et al., 1995) were noted as well as membrane blebbing (Iwahi et al., 1991, 
Nakao & Malfertheiner, 1998).  We have shown similar effects in the related Gram 
negative spiral pathogen C. jejuni (Figure 17a and b). 
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2.5 Summary and Conclusions  
Direct spotting of a PPI solution, at a concentration of ≥ 8 mg/ml (or 8,000 µg/ml) onto the 
surface of agar plates inoculated with C. jejuni results in inhibition of growth.  Broth 
microdilution shows the PPI pantoprazole is bactericidal at 24 hours to multiple strains of 
C. jejuni at a concentration of around 1 mg/ml (or 1,000 µg/ml).  Inhibition of C. jejuni 
growth by pantoprazole occurs at concentrations lower than the bactericidal concentration 
and anti-Campylobacter activity is both concentration and time dependent.  Motility testing 
indicates that the motility of C. jejuni strains is affected in a dose dependent manner 
following exposure to sub lethal concentrations of PPI.  No inhibition of S. Typhimurium 
growth or motility was observed using the same methods.  No growth inhibition or killing 
was observed for a strain of Lactobacillus isolated from a healthy mouse.  Pre-exposure to 
sub lethal concentrations of PPI affects the ability of C. jejuni to produce biofilm.  
Gentamicin protection assays show that C. jejuni exposed to sub lethal concentrations of 
PPI were significantly less able to invade Caco-2 cells than the no PPI exposed control.  
EM analysis shows that exposure to lethal concentrations of PPI leads to a change from 
C. jejuni typical spiral morphology to atypical coccal forms, often lacking flagella.   
C. jejuni virulence is dependent on a number of factors including the flagella, related 
motility and ability to adhere to and/or invade epithelial cells (Wassenaar & Blaser, 1999).  
We have shown that the PPI pantoprazole is bactericidal to multiple strains of C. jejuni and 
that motility of the organism is reduced, even at sub lethal levels of PPI.  It is possible that 
the PPI affects the energy dependent mechanism of the flagellar motor of C. jejuni, thereby 
affecting C. jejuni motility.  The reduction in motility seen was also found to affect the 
ability of C. jejuni to form biofilm and invade epithelial cells.  Exposure to high 
concentrations of PPI has been shown to result in a loss of flagella and conversion to 
degenerate coccal forms of C. jejuni.  We have postulated that the concentrations required 
to achieve these outcomes might be achievable in the human stomach, especially in those 
patients taking higher doses of PPIs for severe disease on an empty stomach (see Table 3).  
It is therefore important to further investigate the interactions between PPIs and C. jejuni 
as these data suggest the pathogenicity of the organism might be affected by exposure to 
PPIs.  People taking PPIs are reportedly at higher risk of developing enteric infections like 
campylobacteriosis (Tam et al., 2009).  However, our results suggest that some people may 
be protected from developing campylobacteriosis due to the bactericidal action of PPIs on 
the organism or sub-inhibitory effects on motility and invasion.  Crucially, this would 
depend on the concentrations and duration of exposure encountered by the organism.  
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Chapter 3 
 
Investigation of the Possible 
Mechanisms of 
Pantoprazole Action on 
Campylobacter jejuni 
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3 INTRODUCTION  
Proton pumps are ATPases, which break down ATP (in an energy dependent process) to 
regulate the movement of ions across the cell wall.  Bacteria have a variety of proton 
pumps on their cell surface that act to control processes like turgor pressure, intracellular 
pH and the proton motive force.  Disruption of the proton motive force affects the rotation 
of bacterial flagella and subsequently affects motility (Manson et al., 1977).  Exposure to 
pantoprazole has been shown in Chapter 2 to affect C. jejuni motility.   
PPIs are known to covalently bind to sulfhydryl groups on accessible cysteine residues 
found on the H
+
/K
+
-ATPase of parietal cells.  The urease of H. pylori has four cysteine 
residues in its sequence.  PPIs are known to inhibit the urease enzyme of H. pylori and it 
has been suggested that this may be the result of PPIs targeting these cysteines and thereby 
inhibiting the urease (Park et al., 1996).  However, it is now known that targeting of the 
urease by PPIs is not responsible for the growth inhibition and/or killing of H. pylori by 
PPIs as urease negative strains of H. pylori are also susceptible to the anti-bacterial activity 
of PPIs (Nagata et al., 1995, Logan, 1996, Mirshahi et al., 1998).   
C. jejuni has a number of ATPases on its surface with available cysteines that may be 
potential targets for PPIs.  It is of course possible that PPIs have multiple C. jejuni targets 
(as appears to be the case for H. pylori), which may or may not include bacterial ATPases.  
A variety of experiments were therefore performed to investigate intracellular changes to 
C. jejuni in response to pantoprazole exposure. 
3.1.1 Use of Proteomic Analysis  
Protein production is vital to all living organisms and the term proteomics is used to 
describe the large scale study of proteins.  One of the most common methods of analysing 
all of an organisms proteins (the proteome) is by using two dimensional (2D) gel 
electrophoresis.  Diverse proteins will have specific isoelectric points depending on their 
own specific mass and structure (i.e. the numbers of positively charged and negatively 
charged side chains present in the sequence) and at all pH values other than their own 
isoelectric point, proteins will be either positively or negatively charged (depending on 
their own individual properties).  A protein sample can therefore be applied to a gel strip 
which has been impregnated with an immobilised pH gradient.  Then an electric current 
can be applied and used to separate proteins along the length of the strip where individual 
proteins with the same isoelectric point will migrate to the point where they are neither 
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negatively nor positively charged.  This is commonly referred to as the first dimension of 
the protein separation. 
The proteins on the gel strip can then be treated with sodium dodecyl sulfate (SDS) which 
denatures the proteins and proteins with a large mass will unfold into long molecules and 
proteins with a small mass will unfold into shorter molecules.  The number of SDS 
molecules that bind to a protein is proportional to the length (and therefore the original 
mass) of a protein.  So a protein with a large mass, will denature to a long strand and bind 
many SDS molecules and a protein with a small mass, will denature into a short strand and 
bind fewer SDS molecules.  However, because the number of SDS molecules that bind to a 
protein is dependent on the length of the protein, then all proteins (large and small) will 
essentially have an equal mass-to-charge ratio.   
SDS molecules are negatively charged and a gel strip containing the pH gradient from a 
first dimension separation experiment can then be applied to an electrophoresis gel where 
the now negatively charged proteins can be separated according to relative size when a 
second electric current is applied.  Large proteins will move through the gel more slowly 
than smaller proteins.  This is commonly referred to as the second dimension of the protein 
separation and is useful because it is unlikely that different proteins with the same 
isoelectric point will also be of identical size.  Therefore by separating proteins using 2D 
methods, better separation is achieved.  2D proteomics has previously been used to 
investigate changes in the C. jejuni proteome in response to bile exposure (Fox et al., 
2007) and to growth in a low oxygen environment (Liu et al., 2012).  Examination of the 
proteome of C. jejuni following exposure to pantoprazole may therefore prove useful in an 
effort to define the bactericidal mechanism of action. 
3.1.2 Transcriptomics  
The production of cellular proteins is determined by the preceding processes of 
transcription and translation.  A DNA sequence may first be transcribed into ribonucleic 
acid (RNA), which is then translated into protein.  Transcriptomics is therefore the study of 
the complete set of RNA transcripts produced by a particular genome.  Microarrays are a 
commonly used method of studying the expression levels of a large number of genes 
simultaneously.  Total transcribed RNA can be harvested from cells and converted to 
complementary DNA (cDNA) which is labelled with a fluorescent dye (e.g. cyanine III 
(Cy3) or cyanine IV (Cy5)).  An array of unique short DNA sequences (probes) are 
arranged on a solid surface where the position of each probe (and the gene of which it is a 
part) is known.  Hybridisation of samples to the probes allows the binding of 
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complementary sequences.  If a particular gene was therefore being transcribed under test 
conditions, then the corresponding RNA would be harvested and converted to labelled 
cDNA, labelled cDNA would be bound by the corresponding probe and the confirmation 
of gene expression obtained by detecting fluorescence in the position of the specific probe.  
Microarrays have previously been used to investigate the differences in C. jejuni gene 
expression in response to varying growth conditions (Corcionivoschi et al., 2009, John et 
al., 2011, Mills et al., 2012) and following exposure to the highly alkaline compound 
trisodium phosphate (Riedel et al., 2012).   
3.1.3 Chapter Aims 
Exposure to pantoprazole has been shown in Chapter 2 to have an effect on C. jejuni 
growth, motility, biofilm formation, invasion potential and morphology.  Prolonged 
exposure to mg/ml quantities of pantoprazole has also been shown to be bactericidal.  2D 
gel proteomics experiments presented in this chapter were performed to determine whether 
exposure to pantoprazole caused significant changes to the C. jejuni proteome.  The 
predicted roles of proteins which were identified as differentially present under 
pantoprazole exposed and control conditions were researched in anticipation that a protein 
or proteins that might be essential for bacterial survival might be identified that could 
account for the killing of C. jejuni by pantoprazole.  The up-regulation of selected genes 
(as indicated from proteomic analysis) was confirmed using qRT-PCR.  Microarray 
experiments were performed to identify any changes in gene expression following 
exposure to pantoprazole.  Insertional mutation of a component gene for an ATPase that 
was thought to be a prospective target for PPIs was also performed to assess if there was 
any change in the susceptibility to pantoprazole for the mutant. 
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3.2 Materials and Methods  
3.2.1 Bacterial Strains and Culture Conditions  
The C. jejuni and E. coli strains used in this chapter of the study are listed in Table 10.  All 
strains were stored at -80°C, revived, cultured and incubated as detailed in Section 2.2.1.  
E. coli used in cloning experiments was grown either in lysogeny broth (LB) broth with 
shaking at 200 rpm or on LB agar plates in an aerobic 37°C incubator.  Strains from 
overnight growths were used in all individual experiments unless otherwise stated.   
Table 10.  Bacterial strains used in this chapter. 
 
Strain Features Origin/Reference 
C. jejuni 
11168-H 
Hypermotile derivative of 
strain 11168 
(Karlyshev et al., 2002) 
C. jejuni 
81-176 
Human clinically isolated 
strain 
(Korlath et al., 1985) 
C. jejuni 
81116 
Human clinically isolated 
strain 
(Palmer et al., 1983) 
E. coli XL-2-Blue Competent cells Stratagene 
 
3.2.2 Antibiotics and Pantoprazole  
Pantoprazole sodium hydrate was prepared as described in Section 2.2.2.  Ampicillin 
(Sigma) and kanamycin (Sigma) were dissolved in water, sterilised using a 0.2 µm syringe 
filter and added to agar plates at final concentrations of 100 and 50 µg/ml respectively, 
when required. 
3.2.3 Proteomics 1  
The details of many of the solutions used during proteomic analyses are provided in 
Appendix 1.  A suspension of C. jejuni 81-176 in MHB was prepared from 48 hour plate 
cultures and corrected to an OD595 of 0.35.  9.5 ml of this was added to 0.5 ml pantoprazole 
to give a final pantoprazole concentration of 2 mg/ml (or 2,000 µg/ml).  This was mixed 
well and placed in a sterile universal with the cap loosened before incubating for 2 or 
4 hours.  Samples were then centrifuged at 3,000 × g for 15 minutes, supernatant was 
removed, the pellet re-suspended in 5 ml PBS and centrifuged again at 3,000 × g for 
15 minutes.  The pellet was again re-suspended in 5 ml PBS and centrifuged at 3,000 × g 
for 15 minutes before all of the supernatant was removed and the inside of the tube dried 
completely.  Samples were then stored overnight at -20°C. 
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Samples were defrosted and all cells were lysed and acetone precipitated (three washes) 
and made up to approximately 250 μl in lysis buffer.  The amount of protein in each 
sample was then measured and adjusted so that they were approximately equal.  Samples 
were then added to individual 2D gel strips and run overnight to accumulate a total of 
between 70 and 80,000 vhrs.  Strips were then washed in DTT and IOA and 2D-PAGE 
gels run overnight at 1 W per strip.  Gels were then fixed and stained using colloidal 
coomassie before being scanned and visually examined.  Seventeen gel spots were selected 
for identification using mass spectrometry.  Fourteen spots were thought to be present 
under PPI free control conditions but absent from the PPI exposed sample and three spots 
were thought to be present under PPI exposed conditions but absent from the PPI free 
control.  Excised gel bands were placed in 1.5 ml Eppendorf tubes and washed with 
100 mM ammonium bicarbonate for 30 minutes at room temperature on a rotary shaker 
(100 rpm).  Ammonium bicarbonate was then removed and 50% acetonitrile/100 mM 
ammonium bicarbonate added.  Eppendorfs were again placed on a rotary shaker and left 
at room temperature for 35 minutes.  The wash solvent was removed from the tubes and 
50 μl acetonitrile added for 10 minutes to shrink gel slices.  Gel slices were dried for 
30 minutes in a vacuum centrifuge.  Gel slices were rehydrated with trypsin in 25 mM 
ammonium bicarbonate.  The proteins were digested at 37°C for 24 hours.  Liquid was 
then removed from the Eppendorfs and added to 96 well plates.  5% FA was added to the 
remaining gel slices and incubated at room temperature on a rotary shaker for 20 minutes.  
Two times volume of acetonitrile was then added and tubes incubated on a rotary shaker 
for an additional 20 minutes.  All the liquid was collected and pooled in the original 
96 well plate.  The 96 well plate was dried in a vacuum centrifuge to concentrate the 
samples.  Proteins were identified by MALDI-TOF-MS.  Experiments were performed at 
each exposure time and pantoprazole concentration (0 and 2 mg/ml) only once.   
3.2.4 Proteomics 2  
3.2.4.1 Determining Pantoprazole Exposure Conditions  
Experiments were first performed to determine the time and concentration of pantoprazole 
exposure to be used.  Colonies were harvested into DMEM to an OD600 of 1.0 from 
overnight plate growths of C. jejuni strain 81-176.  Bacterial suspensions were then split 
into two equal volumes in sterile bijous and sterile water or pantoprazole (to give final 
concentrations of 1, 1.5 or 2 mg/ml) added.  Bijous, with the caps loosened, were then 
incubated and serial dilutions performed each hour for a total of 6 hours incubation and 
CFU/ml calculated.  This experiment was carried out only once in triplicate. 
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3.2.4.2 Preparation of Protein Extracts  
Proteomics experiments were carried out at a final pantoprazole concentration of 1 mg/ml 
(or 1000 µg/ml) for 2 hours.  Overnight growths of C. jejuni strain 81-176 were harvested 
from MHA + B plates into DMEM to an OD600 of 1.2.  This was then divided equally 
between two sterile vented cap 25 cm
2
 tissue culture flasks (Corning) and pantoprazole or 
sterile water (for the no pantoprazole control) added.  Flasks were mixed gently and 
incubated in the VAIN for 2 hours before the entire contents of the flasks were transferred 
into cooled sterile 15 ml falcon tubes (Corning).  Aliquots were removed and serially 
diluted to calculate surviving CFU/ml.  Falcon tubes were centrifuged at 3,000 × g for 
15 minutes at 4°C, supernatant removed, and the pellets resuspended in ice cold fresh 
DMEM.  Falcon tubes were again centrifuged at 3,000 × g for 15 minutes at 4°C, 
supernatant removed and the pellets resuspended in 5 ml ice cold fresh DMEM.  Falcon 
tubes were centrifuged for a third time at 3,000 × g for 15 minutes at 4°C, supernatant 
removed and the inside of the tubes dried with a sterile swab. 
Harvested pellets under both pantoprazole exposed and control conditions were stored at    
-80°C until all three replicates of the experiment had been performed.  Proteomics 2 
experiments were therefore performed in biological triplicate but only one technical 
replicate of 2D gels were performed.  Samples were transported from the University of 
Glasgow to Moredun Research Institute on dry ice.  All of the work described in the 
remaining Proteomics 2 sections below was carried out by me at the Moredun Research 
Institute with the help of those named in the Acknowledgements section. 
Protein pellets were thawed and resuspended in extraction buffer at room temperature for 
30 minutes, vortexed and then transferred into fresh 1.5 ml Eppendorfs.  Tubes were 
centrifuged at 1,500 × g for 10 minutes and supernatant removed into fresh Eppendorfs.  
The protein content of all six samples was measured at 480 nm on a Novaspec II Visible 
Spectrophotometer (GE Healthcare) using 2-D Quant Kit (GE Healthcare) according to the 
manufacturer’s instructions and adjusted to 400 μg/ml.  Proteins were precipitated using 
Precipitant and Co-precipitant, vortexed and centrifuged at 1,800 × g for 5 minutes.  The 
supernatant was removed and protein pellets stored at -20°C.   
3.2.4.3 Two Dimensional Polyacrylamide Gel Electrophoresis and Image 
Acquisition 
Pellets were removed from the freezer and air dried at room temperature for 5 minutes and 
then resuspended in extraction buffer.  Tubes were vortexed for 30 seconds each to fully 
dissolve the protein pellet and samples were then centrifuged at 1,800 × g for 5 minutes.  
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Samples were cleaned using 2-D Clean-Up Kit (GE Healthcare) according to the 
manufacturer’s “Procedure A” guidelines.  After step 11 of the protocol, samples were 
stored overnight at -20°C (as indicated in the instructions).  450 μl of rehydration solution 
(with IPG pH 4-7 buffer; GE Healthcare) was added to each protein sample in the last step 
of the protocol.  
Each of the six samples was then applied evenly along the length of six individual 
Immobiline DryStrip pH 4-7 (GE Healthcare) strips in a DryStrip Reswelling Tray (GE 
Healthcare) and left overnight at room temperature.  The following morning proteins were 
separated on the gel strips according to relative charge (first dimension of separation) at the 
same time, under identical test conditions.  Isoelectric focusing was performed at 20°C for 
7 hours at 500 volts (V), then 1000 V for 1 hour, a gradient from 1000-8000 V over a 
period of 3 hours and then a final 5 hours at 8000 V (Ettan IPGphor 3 Isoelectric Focusing 
Unit; GE Healthcare).  Following isoelectric focusing the strips were placed in individual 
equilibration tubes and first equilibrated using equilibration buffer with DDT on a gentle 
rocker for 15 minutes.  Buffer was removed and strips were additionally equilibrated using 
equilibration buffer with iodoacetamide on a gentle rocker for 15 minutes.   
Strips were removed from equilibration tubes, rinsed with double-distilled water then 
mounted onto precast 12.5% polyacrylamide gels cross-linked with bisacrylamide (GE 
Healthcare) and the second dimension of separation (according to protein size) also carried 
out in the same gel tank (Ettan DALTsix Electrophoresis Unit), under identical test 
conditions for all six samples.  The unit was first set at 15 W for 1 hour to allow the 
proteins to transfer off the strip and onto the gel and then the setting adjusted to 100 W and 
separation of proteins allowed to run overnight.  Gels were then transferred into individual 
trays for fixing and staining.  All six gels were fixed in the same manner, for equal lengths 
of time (two repeats of 1 hour) in 500 ml fresh fixative each time, then rinsed five times in 
double-distilled water for 15 minutes each time, stained using Colloidal Coomassie Blue 
working solution (see Section 7.2) overnight and then washed twice for 30 minutes each 
time in double-distilled water before being scanned using a high sensitivity scanner under 
the same brightness and contrast conditions.  Tagged Image File (TIF) files were then 
uploaded into the ImageMaster 2D Platinum software programme (GE Healthcare) for 
analysis. 
3.2.4.4 Identification of Proteins by Mass Spectrometry 
For identification of proteins by MALDI-TOF-MS each gel spot indicated as differentially 
present under the PPI exposed and control conditions by ImageMaster 2D Platinum was 
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excised from the gel and subjected to standard in-gel destaining and trypsinolysis 
procedures (Shevchenko et al., 1996).  Tryptic peptides were applied to a steel MALDI 
target plate in a solution of 10 mg/ml α-cyano-4-hydroxycinnamic acid (CHCA) in 
0.1% trifluoroacetic acid and 50% ACN.  Mass spectra were obtained using an Ultraflex II 
TOF/TOF instrument (Bruker Daltonics) operated in the reflectron mode.  The instrument 
was calibrated using known peptide standards (Bruker Daltonics PepMix 2).  Each 
spectrum was produced by accumulating data from 10 × 100 consecutive laser shots.  
Peptides were identified by matching the measured monoisotopic masses to theoretical 
monoisotopic masses generated using the MASCOT search engine (peptide mass 
fingerprinting, PMF).  Selected peptides from proteins that remained unidentified by PMF 
were fragmented in MS/MS mode.  The search parameters were: maximum of one missed 
cleavage by trypsin, variable modification of oxidation of methionine, modification of 
cysteine by propionamidation and carbamidomethylation, peptide tolerance of ±50 ppm.  
Using these parameters and searching the NCBI database, Mascot scores greater than 87 
were considered significant (P < 0.05). 
3.2.5 Quantitative Real-time Polymerase Chain Reaction 
To further assess if the operons for selected proteins were subject to induction by exposure 
to pantoprazole, C. jejuni was exposed to 1 mg/ml (or 1,000 µg/ml) pantoprazole, for 1 or 
2 hours.  The rpoA gene was used for normalization.  The qRT-PCR experiments were 
repeated three times, using RNA samples prepared from three independent experiments. 
3.2.5.1 Primers 
Primers were designed using the Primer3Plus programme (available online) using the 
parameters: product size range (100-300), minimum primer size (17), optimum primer size 
(20), maximum primer size (22), minimum melting temperature (57°C), optimum melting 
temperature (59°C), maximum melting temperature (62°C), minimum GC% (30), optimum 
GC% (50) and maximum GC% (70).  A BLAST search was used to ensure primers 
targeted only the selected region within the Campylobacter genome.  Primer sequences 
were selected from the available lists to minimize primer dimer formation.  Primers were 
obtained from Eurofins and first adjusted to 100 pmol/µl in nuclease free water.  1 in 10 
dilutions of these were prepared and stored at -20°C as working stock solutions.  A list of 
primers used in these experiments is provided in Table 11.   
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Table 11.  Oligonucleotide primers used in this section. 
 
Primer Name Sequence (5’→ 3’) Product Size (nucleotides) 
ATPase-F TGGTGCAGGTGTTGGTAAA 
201 
ATPase-R CTTGCTCCTGGTGGTTCATT 
GroEL-F CCAAGAGGACGCAATGTTTT 
266 
GroEL-R TCCATACCGCGTTTTACCTC 
rpoA-F CGAGCTTGCTTTGATGAGTG 
109 
rpoA-R TCCCACAGGAAAACCTATGC 
Thiol Perox-F GCCAGTTACAATGGTGCTGA 
195 
Thiol Perox-R CACAAATACGGCACGAGCTA 
 
Genomic DNA was extracted from overnight cultures of C. jejuni strain 81-176 according 
to the manufacturer’s instructions (four replicates) using DNeasy Blood & Tissue Kit 
(Qiagen).  The four selected genes were each amplified using 2× concentrate PCR Master 
Mix (ThermoFisher) in 23 µl volumes containing 20 µl PCR Master Mix, 1 µl of stock 
forward primer, 1 µl of stock reverse primer and 1 µl genomic DNA in 0.2 ml PCR tubes 
(only once).  Negative controls were included which used 1 µl of nuclease free water in 
place of genomic DNA.  Tubes were heated to 94°C for 5 minutes then subjected to 30 
cycles of 94°C for 30 seconds, 50°C for 2 minutes, 72°C for 1 minute, followed by an 
extension at 72°C for 10 minutes.  The PCR products were visualised on 1% agarose gels 
(1 g agarose (Sigma) in 100 ml 1× Tris EDTA acetate) incorporating 10,000× GelRed
TM
 
Nucleic Acid Gel Stain (Biotium).  DNA fragment sizes were estimated by using 1 Kb Plus 
DNA Ladder (ThermoFisher).  In all four cases only one product was seen on the gel at the 
expected position (see Table 11 for product sizes) for each primer set, confirming that the 
design of the primers was correct and that only the selected genes were amplified from 
C. jejuni genomic DNA (data not shown).  To check that the products (of the expected 
size) that had been amplified by the primers was indeed the gene of interest, bands were 
carefully removed from the gel using a scalpel and DNA extracted from them using 
QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer’s guidelines (only 
once).  Extracted DNA was sequenced by Source Bioscience, using the relevant primers 
and resulting nucleotide sequences analysed using CLC Genomics Workbench (Qiagen).  
All four sequences showed > 95% homology with the relevant genes in the C. jejuni        
81-176 genome sequence. 
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3.2.5.2 Campylobacter jejuni Pantoprazole Exposure  
C. jejuni strain 81-176 was harvested from overnight MHA + B plate cultures into DMEM 
to an OD600 of 1.6 before being split into equal volumes and added to sterile vented cap 
25 cm
2
 tissue culture flasks.  Pantoprazole was prepared as described in Section 2.2.2 and 
was added to one flask to give a final concentration of 1 mg/ml (or 1,000 µg/ml) with 
sterile water being added to the other flask to act as the no pantoprazole control.  
Following incubation for 1 hour, half of sample volumes were transferred from the flasks 
into cooled sterile 15 ml falcon tubes.  Flasks were then returned to the VAIN and 
incubated for a further hour.  Falcon tubes were centrifuged at 4,500 × g for 15 minutes at 
4°C, supernatant removed, 1 ml of the RNA stabilising reagent RNAprotect (Qiagen) 
added, vortexed and then stored on ice.  At the end of the 2 hour incubation the remaining 
samples were transferred from the flasks into cooled sterile 15 ml falcon tubes and 
prepared in the same manner. 
3.2.5.3 Ribonucleic Acid Extraction  
The 1 ml of RNAprotect was vortexed and added to a 1.2 ml Lysing Matrix B tube (MP) 
containing 0.1 mm silica beads and mixed vigorously using a FastPrep®-24 machine (MP) 
for 40 seconds.  Tubes were then centrifuged at 13,000 × g for 5 minutes at 4°C.  Around 
750 µl was removed from the top of the tubes and placed in fresh 1.5 ml sterile Eppendorfs 
and left at room temperature for 5 minutes.  300 µl chloroform was added and tubes then 
vortexed.  After a further 5 minutes at room temperature, tubes were centrifuged at 
13,000 × g for 5 minutes at 4°C.  The upper phase of the supernatant was removed and 
placed again in fresh Eppendorfs.  The centrifugation was repeated at 13,000 × g for 
5 minutes at 4°C and the upper phase again removed into fresh Eppendorfs.  Chilled 100% 
ethanol was added to tube and then vortexed.  Tubes were placed in a -20°C freezer for 
1 hour before being centrifuged at 13,000 × g for 15 minutes at 4°C.  Supernatant was 
removed and white RNA pellets washed gently with 75% ethanol.  Ethanol was removed 
and the pellets allowed to air dry at room temperature for 5 minutes.  Samples with large 
RNA pellets were dissolved using 100 µl of nuclease free water (ThermoFisher) and 
smaller pellets using 80 µl.  Tubes were vortexed, left at room temperature for 5 minutes 
and then vortexed again. 
To eliminate residual DNA contamination, which would interfere with the quantitative 
real-time polymerase chain reaction (qRT-PCR), samples were treated according to the 
manufacturer’s guidelines using Turbo DNA-freeTM Kit (Ambion).  Total RNA was 
quantified using a NanoDrop 2000 and the 260/280 nm ratio checked to be above 1.95.  
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3.2.5.4 Complementary Deoxyribonucleic Acid Synthesis  
Samples which were found to have total RNA concentrations below 1000 ng/µl were 
designated as (low RNA concentration) and a higher volume of extracted RNA was used 
during first strand cDNA synthesis than was used from samples which had over 1000 ng/µl 
RNA.  Random primers (Invitrogen), 10 mM dNTP mix (Invitrogen), extracted RNA 
samples (see Section 3.2.5.3) and nuclease free water were mixed in the volumes shown in 
Table 12 in 0.2 ml PCR tubes.  Tubes were heated at 65°C for 5 minutes and then placed 
on ice for 2 minutes.   
Table 12.  First strand cDNA synthesis reaction volumes. 
 
 Volume Required (µl) 
High RNA  Low RNA  
Random Primers 1.5 1.5 
dNTP Mix 1.0 1.0 
Extracted RNA 6.5 10.0 
Nuclease Free Water 11.0 7.5 
Total 20.0 20.0 
 
SuperScript® III reverse transcriptase (Invitrogen) was used to make cDNA according to 
the manufacturer’s instructions.  The concentration of cDNA in the samples was measured 
using a NanoDrop 2000 and were normalised to a concentration of 50 ng/µl using TE 
buffer (Ambion).  To check that the reverse transcription step had worked the four selected 
genes were each amplified using 2× concentrate PCR Master Mix in 0.2 ml PCR tubes 
(only once) as described in Section 3.2.5.1.  Negative controls were included which used 
1 µl of nuclease free water in place of genomic DNA and positive controls which used 
genomic DNA in place of reverse transcribed cDNA.  PCR thermocycling conditions were 
the same as before and the PCR products were again visualised on a 1% agarose gel.  In all 
four cases, only one product was seen on the gel at the expected position (data not shown).  
cDNA was then stored at -20°C. 
3.2.5.5 Quantitative Real-time Polymerase Chain Reaction 
Analyses were conducted using ECO
TM
 Real-Time PCR System (Illumina) according to 
the manufacturer’s specifications with KAPA SYBR® FAST (KAPA Biosystems).  No 
template controls (nuclease free water in place of cDNA) were included in each qRT-PCR 
analysis to detect nucleic acid contamination and primer dimer formation.  No reverse 
transcriptase controls (extracted RNA in place of cDNA) were also included in each qRT-
PCR analysis.  qRT-PCR master mixes were mixed according to the volume required 
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immediately prior to use.  Volumes used in a typical experiment are listed in Table 13 and 
individual reactions were performed using a total volume of 20 µl (19.5 µl of master mix 
and 0.5 µl of prepared cDNA).  At the end of each qRT-PCR a melt curve was performed 
from 50-95°C and 10 µl aliquots removed from each well and analysed for the presence of 
DNA on 1% agarose gels (see Section 3.2.5.1).  The expected melting temperature of the 
four gene products was determined using the online Oligo Calc:  Oligonucleotide 
Properties Calculator programme (available at http://biotools.nubic.northwestern.edu/Oligo 
Calc. html).  The primer sets used to detect the transcription levels of ATP synthase F1, 
GroEL co-chaperonin and thiol peroxidase can be seen in Table 11 as can the primer set 
for the internal control gene rpoA.  The rpoA gene has been identified as a suitable internal 
control for use in experiments investigating the stress response of C. jejuni (Ritz et al., 
2009). 
Table 13.  qRT-PCR master mix preparation. 
 
Component Volume (µl) 
SYBR® FAST (at 2× concentrate) 180 
Forward Primer (at 10 µM)    2 
Reverse Primer (at 10 µM)    2 
Nuclease Free Water 176 
 
3.2.6 Microarrays  
C. jejuni strain 81-176 (at around 1×10
8 
CFU/ml) was cultured in 2 ml DMEM with or 
without pantoprazole (at a final concentration of 2 mg/ml or 2,000 µg/ml) 
microaerophillicaly for 2 hours.  350 μl of bacterial suspension was then removed and 
added to 700 μl of RNA protect.  RNA was extracted using Qiagen RNeasy Mini Kit 
(Qiagen) according to the manufacturer's instructions.  RNA was eluted in 30 μl of 
molecular grade water (Sigma) and concentrations checked by NanoDrop.  Samples from 
four independent biological replicates were standardised to 2 μg of RNA in 9 μl of 
molecular grade water.  Labelled cDNA was prepared from 700 ng total RNA using Cy3-
dCTP (GE Healthcare) and SuperScript II reverse transcriptase with random hexamer 
primers (Life Technologies – Invitrogen).  Labelled cDNA was purified by Qiagen 
MinElute column, combined with 10× CGH blocking agent and 2× Hi-RPM hybridisation 
buffer (Agilent) and heated at 95°C for 5 minutes prior to loading onto microarray slides.  
Slides were then incubated overnight in an Agilent rotating oven at 65°C, 20 rpm.  After 
hybridization, slides were washed for 5 minutes at room temperature with CGH Wash 
Buffer 1 (Agilent) and for 1 minute at 37°C with CGH Wash Buffer 2 (Agilent) then 
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scanned immediately (using an Agilent High Resolution Microarray Scanner, at 2 µm 
resolution, 100% PMT).  Scanned images were quantified using Feature Extraction 
software v 10.7.3.1.  Results for microarray experiments are notably representative of four 
separate biological replicates.   
3.2.7 Making the kdpB Mutant  
3.2.7.1 Recombinant Deoxyribonucleic Acid Methods  
All of the work described in the kdpB mutant sections below was carried out in the 
laboratories of the LSHTM.  NEBcutter was used to search the nucleotide sequence of the 
different subunits of Kdp for existing restriction enzyme sites.  The kdpA and kdpC genes 
were found to have no existing restriction enzyme sites within their sequence, whereas 
kdpB and kdpD respectively had sites for BclI+BglII and BclI only within their sequence.  
KdpB is known to be the largest subunit and forms the functional part of the Kdp and so 
the kdpB gene was selected for insertional mutation. 
E. coli XL-2-Blue (Stratagene) was used for recombinant plasmid transformation to make 
a C. jejuni 11168-H kdpB insertional mutant.  The cloning vectors used were pGEM®-T 
Easy (Promega) for PCR product cloning and C. jejuni 11168-H mutagenesis, and 
pJMK30, a Campylobacter compatible plasmid containing a gene encoding resistance to 
kanamycin (kan
R
; an aminoglycoside 3’-phosphotransferase) for insertional mutagenesis.   
Genomic DNA was isolated from C. jejuni strain 81116 according to the manufacturer’s 
guidelines (QIAamp DNA Mini Kit; Qiagen).  Gene specific forward (kdpB GS-F) and 
reverse (kdpB GS-R) primers were obtained from Invitrogen, the sequences of which can 
be found in Table 14.  The genome sequence of the kdpB gene, which was used to design 
the primers, can be found in Section 8.1.  These were used to amplify a fragment within 
the coding region of the kdpB gene.  The PCR product was cloned into pGEM®-T Easy (to 
give construct pI).  pI was transformed into E. coli XL-2-Blue competent cells and 
transformants selected on LB agar with ampicillin and kanamycin after 48 hours growth.  
Transformants were screened for the presence of pI and frozen stocks of E. coli containing 
pI were made using Microbank™ beads and stored at -80°C. 
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Table 14.  Oligonucleotide primers used in this section. 
 
Primer Name Sequence (5’→ 3’) 
kdpB GS-F TAATGCCATAAAAGGAGC 
kdpB GS-R ATTCTAAGTATCCAAGC 
kan
R
 F-out TGGGTTTCAAGCATTAGTCCATGCAAG 
kan
R
 R-out GTGGTATGACATTGCCTTCTGCG 
 
Restriction digestion at the unique BglII site allowed a 1.4-kb BamHI restriction fragment 
from pJMK30, containing the kan
R
, to be ligated to pI and give construct pIK.  To ensure 
that the kan
R
 had inserted in the correct position, the plasmid was analysed by restriction 
digestion with EcoRI, and by standard PCR with the original template primers (kdpB GS-F 
and kdpB GS-R) and a set of primers designed for amplification of the kan
R
 (kan
R
 F-out) 
and reverse kan
R
 R-out), the sequences of which can be found in Table 14.  The genome 
sequence of the kan
R
, which was used to design the primers, can be found in Section 8.2.  
To confirm that the kan
R
 had inserted in the same orientation as the insert and that the 
possibility of polar effects were minimised, pIK was amplified with combinations of 
template and kan
R
 primers, kdpB GS-F and kan
R
 F-out and, kdpB GS-R and kan
R
 R-out.  
Plasmids containing the correct insertional mutation were used to transform C. jejuni 
11168-H via electroporation.  SOC broth (Sigma) was added to the electroporation cuvette 
immediately, mixed well and left in the VAIN for 1 hour.  Electroporated bacteria were 
then plated onto MHA + B plates and incubated in the VAIN for 24 hours.  Campylobacter 
colonies were harvested into PBS and 200 µl aliquots plated onto MHA + B + kan agar 
and incubated for 48 hours for isolation of insertional mutants.  A number of single 
colonies were selected to check that the observed kanamycin resistance was in the 
chromosome.  The colonies were analysed using PCR with kdpB GS-F and kdpB GS-R. 
pGEM®-T Easy was used for mutagenesis in C. jejuni 11168-H because it has an E. coli 
origin of replication.  All known vectors with an E. coli origin of replication are unable to 
replicate in Campylobacter, and can therefore be used as suicide vectors (Van Vliet et al., 
1998).  When mutant constructs of Campylobacter DNA in E. coli vectors are introduced 
into Campylobacter, a double crossover event occurs which leads to the elimination of 
vector sequences and the replacement of the wild-type gene with the disrupted copy from 
the vector (Van Vliet et al., 1998). Therefore, transformation of C. jejuni 11168-H with 
pIK would result in incorporation of the disrupted kdpB gene and the loss of pGEM®-
T Easy.   
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3.2.7.2 Polymerase Chain Reaction Conditions  
Crude cell lysates were amplified using Taq polymerase (Gibco) in 20 µl volumes 
containing 0.1 µg primers and DNA at 94°C for 1 minute, 25 cycles of 94°C for 
45 seconds, 50°C for 45 seconds, 72°C for 2 minutes, followed by an extension at 72°C for 
7 minutes.  The PCR products were analysed on 1% agarose gels. 
3.2.7.3 Minimum Bactericidal Concentration  
The MBC was determined at 4 and 24 hours for the kdpB mutant and the parent strain 
using a broth microdilution method as described in Section 2.2.4 where around 5×10
5
 
CFU/ml in MHB was mixed with an equal volume of pantoprazole in water.  Pantoprazole 
was tested at final concentrations ranging from 10-0 mg/ml (or 10,000-0 µg/ml). 
3.2.8 Replicates and Data Analysis  
Unless otherwise stated each assay was conducted in triplicate and was independently 
repeated at least three times.  Results are expressed as means +/- standard deviations (SD; 
error bars) of replicate experiments.  The unpaired Students t test was used to determine 
statistical significance.  A P value of > 0.01 but < 0.05 was considered significant (*) and a 
P value of < 0.01 highly significant (**).  qRT-PCR data were analysed according to the 
2
ΔΔCT
 method (Livak & Schmittgen, 2001) with target gene expression normalised to rpoA 
expression.  ΔΔCT was calculated as (CT (target gene, no PPI exposure) - CT (reference 
gene, no PPI exposure)) - (CT (target gene, PPI exposed) - CT (reference gene, PPI 
exposed)). 
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3.3 Results  
3.3.1 Proteomics 1  
Experiments were performed to determine whether exposure to pantoprazole caused 
significant changes to the C. jejuni proteome.  Seventeen gel spots were selected from 
individual 2D gels and the identifications for the proteins following mass spectrometry are 
listed in Table 15 together with whether the protein was thought to be up- or down-
regulated in response to pantoprazole exposure and the role of the protein.  There appeared 
to be more proteins present on the control gels, than there were for C. jejuni exposed to 
pantoprazole for 2 or 4 hours.  Hence most of the proteins identified appeared to be down-
regulated in their production following pantoprazole exposure rather than up-regulated (see 
Table 15).  Most protein spots were identified as being differentially present following the 
4 hour exposure (Figure 18).  Only one gel spot was excised and identified from the 2 hour 
exposure experiment and the gel pictures have been omitted. 
A number of proteins identified as differentially present in pantoprazole exposed gels 
versus those for the no pantoprazole controls are involved in the oxidative stress response 
of C. jejuni (proteins 6, 7, 11 and 15 in Table 15).  Of these proteins three appeared to be 
down-regulated in response to pantoprazole exposure and one up-regulated.  The role of 
oxidative stress in the killing of C. jejuni by pantoprazole will be further investigated in 
Chapter 4.   
A number of proteins identified as differentially present in pantoprazole exposed gels 
versus those for the no pantoprazole controls are involved in the synthesis of LPS or the 
bacterial cell membrane (proteins 8, 10 and 17 in Table 15).  Of these proteins two appear 
to be down-regulated in response to pantoprazole exposure and one up-regulated.  The 
effect of pantoprazole exposure on the outer membrane of C. jejuni will be further 
discussed in Chapter 5.    
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Table 15.  List of protein identifications for the 17 gel spots excised from gels in the 
proteomics 1 experiment.   
 
Gel 
Spot 
Up/ 
Down 
2/4 
Hour 
Identification Role 
1 Down 4 Phosphate Acetyltransferase  Acetate Metabolism 
2 Down 4 3-Oxoacyl-(Acyl-Carrier-Protein) 
Synthase II 
Fatty Acid Synthesis 
3 Down 4 OorA Electron Transport 
Chain 
4 Down 4 2,3,4,5-Tetrahydropyridine-2-
Carboxylate N-Succinyltransferase 
Lysine Biosynthesis 
5 Down 4 Aspartate-Semialdehyde 
Dehydrogenase  
Amino Acid 
Biosynthesis 
6 Down 4 UDP-GlcNAc/Glc 4-Epimerase  Nucleotide Metabolism 
7 Down 4 Pyridine Nucleotide-Disulphide 
Oxidoreductase Family Protein 
Oxidoreductase 
Activity 
8 Down 4 ADP-L-Glycero-D-Manno-
Heptose-6-Epimerase 
LPS Biosynthesis 
9 Down 4 Hypothetical Protein CJE0806 Unknown 
10 Down 4 3-Deoxy-D-Manno-Octulosonate 
Cytidylyltransferase 
LPS Biosynthesis 
11 Down 4 Superoxide Dismutase Oxidative Stress 
12 Down 4 OorC  Electron Transport 
Chain 
13 Down 4 P19 Protein Iron Transport 
14 Down 4 P19 Protein Iron Transport 
15 Up 4 Anti-oxidant AhpCTSA Family 
Protein  
Oxidative Stress 
16 Up 4 2-Component Regulator  Unknown 
17 Up 2 Peptidoglycan-Associated 
Lipoprotein Omp18 
Antigenic Outer 
Membrane Protein 
 
The table indicates whether proteins appeared to be up-regulated or down-regulated, 
following PPI exposure at 2 mg/ml (or 2,000 µg/ml) for 2 (spot 17) or 4 hours (spots 1-16).  
Proteins listed in green have been identified as possible targets for novel antimicrobials, 
proteins listed in red are thought to be essential for survival and proteins listed in orange 
are thought to be involved in the oxidative stress response. 
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  a 
  b 
Figure 18.  2D gels from proteomics 1 experiments.  C. jejuni strain 81-176 was grown in 
MHB in the absence of pantoprazole (a) and in the presence of 2 mg/ml pantoprazole (b) 
for 4 hours.  Spots 1-14 (a) were thought to be missing from the corresponding gel (b) and 
spots 15 and 16 (b) were thought to be missing from the corresponding gel (a) and were 
excised for identification using MS. 
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3.3.2 Proteomics 2  
3.3.2.1 Determining Pantoprazole Exposure Conditions  
It was thought that the concentration of pantoprazole used in the proteomics 1 experiments 
may have been too high.  Basic experiments were therefore first performed to determine 
the pantoprazole concentration and duration of exposure to be used for more rigorous 
triplicate proteomic analyses.  Results in Table 16 show that there was a 1 log reduction in 
C. jejuni numbers following exposure to 2 mg/ml pantoprazole for 2 hours and a 3 log 
reduction in C. jejuni numbers following exposure to 2 mg/ml pantoprazole for 4 hours 
(the conditions used in proteomics 1 experiments, see Section 3.2.3).   
Table 16.  Killing of C. jejuni by pantoprazole is both time and concentration dependent.   
 
Time (hours) 
Pantoprazole Concentration (mg/ml) 
0.0 1.0 1.5 2.0 
1 2.6×10
9
 2.1×10
9
 2.7×10
9
 2.1×10
9
 
2 2.6×10
9
 1.6×10
9
 3.0×10
9
 3.7×10
8
 
3 2.5×10
9
 2.5×10
9
 1.9×10
9
 1.6×10
7
 
4 2.4×10
9
 1.0×10
9
 1.5×10
8
 1.2×10
6
 
5 3.2×10
9
 1.0×10
8
 3.0×10
7
 1.8×10
4
 
6 2.8×10
9
 1.6×10
7
 2.8×10
5
 < 100 
 
C. jejuni strain 81-176 was grown in DMEM in the absence of pantoprazole and in the 
presence of various pantoprazole concentrations for 6 hours with aliquots being removed, 
serially diluted and surviving bacteria calculated each hour.   
 
Proteomic analysis was to be used to detect specific changes in the proteome of C. jejuni 
induced by exposure to pantoprazole, but not to detect non-specific changes in the 
proteome indicative of dying bacteria.  The possibility that the lack of proteins detected 
following exposure to pantoprazole being linked to the overall loss of bacterial cells was 
also taken into consideration.  It was decided that triplicate proteomic analysis would 
therefore be performed following exposure to 1 mg/ml pantoprazole for 2 hours. 
3.3.2.2 Proteomics  
Before bacteria were collected for 2D gel analysis, aliquots were serially diluted and 
CFU/ml in the samples calculated.  The average CFU/ml recovered from the no 
pantoprazole control samples and for the pantoprazole exposed samples were 4.2×10
9 
and 
4.5×10
9 
respectively.  Hence, as was desired, exposure to pantoprazole at 1 mg/ml (or 
1000 µg/ml) for 2 hours did not cause a significant loss of live bacterial cells.  
Representative examples of 2D gels under both control and pantoprazole exposed 
conditions are shown in Figure 19.   
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  b 
Figure 19.  Examples of 2D gels from proteomics 2 experiments.  C. jejuni strain 81-176 
was grown in DMEM in the absence of pantoprazole (a) and in the presence of 1 mg/ml 
pantoprazole (b) for 2 hours.  Gel pictures shown under each test condition are 
representative examples from triplicate experiments. 
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Image Master 2D Platinum software allowed the grouping of triplicate gel pictures for the 
control samples and grouping of triplicate gel pictures for the pantoprazole exposed 
samples.  The software identified every spot in the series of six pictures and a number of 
well-defined proteins, which were easily identifiable in all six replicates were highlighted 
as anchor points, from which the relative positions of all other gel spots were compared 
(see highlighted proteins 1 and 2 in green and blue in Figure 20).  A numerical value was 
assigned to each spot depending on the size and the intensity of the spot and these values 
compared between the two different test conditions. 
A P value was generated by the software following the comparison for the pantoprazole 
exposed and control groups.  A three dimensional (3D) image was produced of individual 
gel spots showing relative size and intensity to allow comparison of individual replicates of 
the experiment for particular proteins (Figure 21).  Ten proteins were determined to be 
differentially present under pantoprazole exposed and control conditions (see Figure 22) 
and these were removed from the gels and identified using mass spectrometry.  The 
identifications of the proteins are listed in Table 17 together with the P values generated 
by ImageMaster 2D Platinum, whether the protein was up- or down-regulated in response 
to pantoprazole exposure and the role of the protein. 
Table 17.  List of protein identifications for the ten gel spots excised from gels in the 
proteomics 2 experiments.   
 
Gel 
Spot 
P 
Value 
Up/ 
Down 
Identification Role 
1 0.037 Down NifU Family Protein Nitrogen Fixation 
2 0.042 Down Acetyl-CoA Carboxylase Fatty Acid Metabolism 
3 0.004 Up 
Phosphoribosylformylglycinamidine 
Synthase II 
Purine Metabolism 
4 0.004 Up Thiol Peroxidase Oxidative Stress 
5 0.008 Up DnaK Chaperone Protein 
Chaperone and 
Oxidative Stress 
6 0.008 Up Nonheme Iron-Containing Ferritin Iron Storage 
7 0.020 Up GroEL Co-chaperonin 
Chaperone and 
Oxidative Stress 
8 0.023 Up Putative Bacterioferritin  
Oxidative Stress and 
Iron Storage 
9 0.033 Up Nucleoside Diphosphate Kinase Purine Metabolism 
10 0.035 Up ATP Synthase F1 Proton Pump 
 
 
  
 
 
 
Figure 20.  Protein spot 
analysis using Image 
Master 2D Platinum 
software.  In this 
example protein spots 
found in triplicate 
pantoprazole exposed 
experiments have been 
compared to the control.  
The size and intensity of 
the spots is assessed by 
the software and each 
spot is assigned a 
numerical value.  The 
average values for each 
spot under the two 
conditions (pantoprazole 
exposed (P) and control 
(C) seen in the table at 
the bottom of the figure) 
are compared and a 
P value assigned.  
Protein spots that have 
been identified as 
significantly different 
can then be selected for 
further analysis (see 
Figure 21 overleaf). 
  
   a    b 
Figure 21.  Individual gel spot analysis.  ImageMaster 2D Platinum software indicates the 
position of individual proteins (red arrows) which have been identified as differentially present 
between pantoprazole exposed (P1, P2 and P3) and control (C1, C2 and C3) test conditions 
(a).  Spot size and intensity data can be used to produce a 3D image of the protein spots, 
which shows clearly in this example that the protein is present in greater quantities in the 
pantoprazole exposed samples than in the control samples (b). 
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Figure 22.  Positions of the ten protein spots identified as differentially present under 
pantoprazole exposed and control conditions.  The positions of the proteins listed in Table 
17 are shown on a single gel. 
 
Protein 9 in Table 17 was up-regulated in response to pantoprazole exposure and is known 
to be involved in purine metabolism.  The metabolite xanthine (also linked to purine 
metabolism) was also detected in greater than two fold increase (see Table 28) following 
exposure to pantoprazole in metabolomics experiments which are detailed in Appendix 3.   
In the second round of proteomics experiments, where experiments were performed in 
triplicate and computer software was used to identify proteins that were differentially 
present in the gels, four proteins which play roles in the oxidative stress response of 
C. jejuni were identified as being differentially present (proteins 4, 5, 7 and 8 in Table 17).  
All four of these proteins were found to be up-regulated in response to pantoprazole 
exposure. 
A number of proteins were also identified as differentially present in proteomics 1 
experiments, under pantoprazole exposed conditions versus the no pantoprazole controls, 
which were involved in the oxidative stress response of C. jejuni.  Validation of the 
differential presence of selected oxidative stress proteins following exposure to 
pantoprazole was performed using qRT-PCR.  qRT-PCR was also used to investigate the 
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effect of pantoprazole (an inhibitor of the H
+
/K
+
-ATPase) exposure on the ATP Synthase 
F1 portion of the C. jejuni proton pump (protein 10 in Table 17). 
3.3.3 Quantitative Real-time Polymerase Chain Reaction 
SYBR green is a fluorescent DNA binding dye that emits a fluorescent signal when it 
binds to double stranded DNA (dsDNA) and hence in qRT-PCR SYBR green can be used 
as a measure of the amount of primer specific dsDNA products.  The rpoA gene of 
C. jejuni encodes for the alpha subunit of DNA-directed RNA polymerase was has 
previously been identified as a highly stable housekeeping gene that can be used to study 
gene expression variations between different stress conditions (Ritz et al., 2009).  
Expression of rpoA was measured following exposure to 1 mg/ml pantoprazole for 1 or 
2 hours and in the absence of pantoprazole exposure (also at 1 or 2 hours) so that the 
relative expressions of GroEL, ATP synthase F1 and thiol peroxidase could be assessed.  
Results in Figure 23 show that in a representative qRT-PCR example, only one DNA 
product was detected using each of the primer sets listed in Table 11.  The predicted size 
of the products (relative to the ladder) also appear to be as expected (see Table 11 for 
product sizes) with the rpoA product being the smallest (bottom left of Figure 23) and 
GroEL (top left of Figure 23) being the largest.   
qRT-PCR was performed in triplicate for each of the triplicate control and pantoprazole 
exposed samples at both 1 and 2 hours and gel electrophoresis used as described following 
each PCR.  In all other technical replicates of qRT-PCR, only one DNA product was 
detected for all four tested genes (data not shown).   
The presence of only one DNA product following each qRT-PCR was confirmed by 
analysing melt curve data generated by the Illumina software.  In all cases (triplicates of 
triplicates at both time points) only one peak was detected, with a mean melting 
temperature that was in the expected range.  The melting temperature of a product will 
depend on the length of the product and the guanine (G) and cytosine (C) content (i.e. a 
longer product with high G+C content will have a higher melting temperature than a 
shorter product with low G+C content).  A representative example of a melt curve for the 
ATP synthase F1 gene product can be seen in Figure 24. 
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Figure 23.  Agarose gel analysis of qRT-PCR products indicate that only one product is 
formed.  Following qRT-PCR for GroEL (wells 1-6), ATP synthase F1 (wells 8-13), rpoA 
(wells 15-20) or thiol peroxidase (wells 22-27) aliquots were removed from wells and 
analysed using gel electrophoresis.  Samples were loaded in the order control sample 1, 
control sample 2, control sample 3, PPI exposed sample 1, PPI exposed sample 2 and PPI 
exposed sample 3 in all four cases (wells 1-6, wells 8-13, wells 15-20 and wells 22-27).  
Wells 7, 14, 21 and 28 contain 1 Kb Plus DNA Ladder.   
 
If primer dimer formation was an issue with the experimental design then a second 
(smaller peak) would be expected at a lower temperature than the target gene product.  
This was absent in all analyses (data not shown) and so primer dimer formation was not an 
issue with the qRT-PCR experiments presented here.  Hence the only dsDNA found in the 
qRT-PCR was the primer specific product and the fluorescence signal emitted by SYBR 
green could therefore be used as an accurate measure of the amount of starting material.   
GroEL  ATP 
            Synthase 
 
 
 
 
 
 
 
 
 
RpoA   Thiol 
           Peroxidase 
GroEL  ATP 
            Synthase 
 
 
 
 
 
 
 
 
 
RpoA   Thiol 
           Peroxidase 
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Figure 24.  A representative example of melt curve analysis following qRT-PCR for ATP 
synthase F1 shows that only one product is formed.  Picture acquired using Illumina 
software. 
 
Because ImageMaster 2D Platinum software indicated that there was significant and highly 
significant changes to the proteome of C. jejuni strain 81-176 following exposure to 
1 mg/ml (or 1000 µg/ml) pantoprazole for 2 hours, qRT-PCR was performed to analyse the 
relative expression of selected genes following exposure to the same pantoprazole 
concentration for 1 and 2 hours.  The results of the qRT-PCR experiments are listed in 
Table 18.  After only 1 hour of pantoprazole exposure thiol peroxidase was expressed 
1.54 fold higher than for the no pantoprazole exposed control.  The expression of GroEL 
and the ATP synthase F1 genes was similar under both pantoprazole exposed and control 
conditions (relative expression values near 1) in the 1 hour exposure experiment.  
However, following extended exposure to pantoprazole the expression of the two oxidative 
stress related genes (GroEL and thiol peroxidase) were over four fold higher than in the no 
pantoprazole exposed control.  Up-regulation of the expression of the ATP synthase F1 
gene was also seen following 2 hours exposure to 1 mg/ml pantoprazole, but to a much 
lower degree than that seen for thiol peroxidase and GroEL (a 1.5 fold increase versus 
around a four fold increase). 
  
 101 | P a g e  
 
Table 18.  Results of qRT-PC show that all three selected genes were expressed at a 
higher level following 2 hours exposure to pantoprazole. 
 
Gene 
Relative Expression Following Pantoprazole Exposure 
1 Hour 2 Hours 
ATP Synthase F1 0.94 1.49 
GroEL 1.01 4.73 
Thiol Peroxidase 1.54 4.02 
 
3.3.4 Microarrays  
Microarray experiments were performed to identify any changes in gene expression 
following exposure to 2 mg/ml (or 2,000 µg/ml) pantoprazole for 2 hours.  The only gene 
which was found to be highly significant in its overexpression in response to exposure to 
pantoprazole for 2 hours was the gene Cj0561c.  Cj0561c encodes for a putative 
periplasmic protein or membrane transporter in C. jejuni, which is repressed by the known 
repressor CmeR (Guo et al., 2008, Dzieciol et al., 2011).  CmeR is best known as the 
repressor for the multi-drug efflux pump CmeABC which is involved in resistance to 
macrolides, fluoroquinolones and bile salts in C. jejuni.  For this reason, the raw data for 
all three components of the CmeABC pump, the repressor CmeR and Cj0561c were 
analysed in greater detail.   
The average values for the microarray experiments under pantoprazole exposed and 
control conditions are shown in Table 19.  No significant difference was found in the 
expression of cmeR, cmeB or cmeC and yet a significant difference (P = 0.03) was seen in 
the expression of cmeA and a highly significant difference (P = 0.00001) seen in the 
expression of Cj0561c.  No other genes were found to be expressed significantly or highly 
significantly differently in the microarrays.  The expression of cmeA was around two fold 
higher following exposure to pantoprazole and the expression of Cj0561c was around six 
fold higher.  The genes for the CmeABC pump are arranged in a single operon with the 
repressor cmeR positioned just upstream and cmeA, cmeB and cmeC are transcribed 
together (see Figure 25).  When the raw data for the expression of all three genes together 
is compared for pantoprazole exposed and control conditions, no significant difference in 
the expression of CmeABC is evident (P = 0.07).   
The bile salts cholate and taurocholate are known to block the binding of the repressor 
protein CmeR to the promotor regions of CmeABC and Cj0561c (see Figure 25) and so in 
the presence of bile, both CmeABC and Cj0561c are up-regulated (Guo et al., 2008, 
Dzieciol et al., 2011).  
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Table 19.  Statistical analysis of microarray results for selected related genes. 
 
Gene 
Number 
Gene 
Name 
Role 
Average 
Control 
Average 
PPI 
Exposed 
P 
Value 
Significance 
Cj0365c cmeC 
Multidrug 
Efflux 
Pump 
11,256 12,792 0.33 NS 
Cj0366c cmeB 15,764 15,091 0.80 NS 
Cj0367c cmeA 12,932 22,122 0.03 * 
Cj0368c cmeR Repressor   9,228   6,054 0.14 NS 
Cj0561c - Unknown 8,581 48,091 0.00 ** 
 
 
 
Figure 25.  Bile stops the repression of both CmeABC and Cj0561c by interfering with 
the binding of the CmeR protein to promoter regions.  The repressor cmeR can be 
transcribed into mRNA and translated into a protein which acts as a repressor by blocking 
the binding of RNA polymerase to the respective upstream promoters (P).  As such CmeR 
is capable of repressing the local CmeABC genes as well as the downstream Cj0561c 
gene.  Bile inhibits the binding of cmeR to both the promoters and results in up-regulation 
of both CmeABC and Cj0561c expression. 
 
3.3.5 kdpB Mutant Experiments  
The H
+
/K
+
-ATPase of parietal cells that is the target of PPIs is a P-type ATPase as is the 
bacterial Kdp ATPase.  The possibility that the kdp of C. jejuni was a target for PPI 
activity was investigated by making an insertional mutant.  Mutation of the kdpB gene 
caused no growth defect in C. jejuni (data not shown).  There was no significant difference 
found in the susceptibility to pantoprazole killing between the kdpB mutant and the parent 
strain (Table 20).  The MBC at 24 hours was the same for both strains and the difference 
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at 4 hours found to be not significant.  Hence, mutation of the kdpB gene does not 
significantly alter susceptibility to pantoprazole in C. jejuni. 
Table 20.  Mutation of the kdpB gene causes no significant change in the pantoprazole 
MBC. 
 
Time 
Mean Pantoprazole MBC (mg/ml) +/- SD 
P Value C. jejuni Strain 
11168-H kdpB Mutant 
4 Hours 2.5 +/- 1.4 3.5 +/- 1.27 0.051 
24 Hours 1.25 +/- 0.87 1.25 +/- 0.87 1.000 
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3.4 Discussion  
3.4.1 Proteomics 1  
Discussion of the results for the proteomics 1 experiments has been omitted, as these 
experiments were not validated by the use of biological replicates or confirmed with 
additional work. 
3.4.2 Proteomics 2  
3.4.2.1 Determining Pantoprazole Exposure Conditions  
Experiments were carried out only once in triplicate but results were in support of other 
observations (see Sections 2.3.2, 2.3.3 and 3.4.1).  Killing by pantoprazole is both time and 
concentration dependent.  The pantoprazole concentration chosen for triplicate proteomic 
analysis (1 mg/ml or 1,000 µg/ml) for a time of 2 hours was selected to ensure that there 
was no significant loss of viable bacteria in pantoprazole exposed samples.  This was 
indeed found to be the case, as serial dilutions performed on samples following the 
pantoprazole exposure had a similar number of CFU/ml in both control samples and in the 
PPI exposed samples (see Section 3.4.2.2). 
3.4.2.2 Proteomics 
The predicted isolelectric points of most C. jejuni proteins lies between 4 and 11 and when 
using proteomics to detect changes in the C. jejuni response to bile exposure, most of the 
proteins found to be differentially present fell within the pH 4-7 range (Fox et al., 2007).  
Hence gel strips in the range pH 4-7 were selected for use in this study and did 
successfully identify ten proteins which were differentially present under control 
conditions compared to pantoprazole exposed conditions.  None of the proteins identified 
as differentially present in proteomics 1 experiments were identified as differentially 
present in proteomics 2 experiments.  Results from proteomics 2 experiments are more 
robust than proteomics 1 because they were conducted in triplicate and gel images were 
analysed for differences using computer software (proteomics 1 experiments were carried 
out only once per pantoprazole exposure time and gels were assessed visually for 
differences).   
One of the proteins shown to be up-regulated in response to pantoprazole exposure was the 
ATP synthase F1 subunit, which forms part of an ATPase that is involved with regulating 
the proton motive force of C. jejuni (Fox et al., 2007).  It is possible that this ATPase is the 
target (or one of the targets) of PPIs in C. jejuni.  If pantoprazole binds to and inhibits the 
ATP synthase (as it does for the H
+
/K
+
-ATPase of parietal cells) then the bacterium may be 
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attempting to make more ATP synthases to maintain the proton motive force (in the same 
way as stomach acid release resumes only on assembly of new proton pumps).  The up-
regulation of the ATP synthase F1 subunit of the C. jejuni ATPase was confirmed using 
qRT-PCR. 
Bacteria have two different classes of proteins which are used for iron storage: ferritin and 
bacterioferritin.  Both have a non-haem iron core, but bacterioferritins have an additional 
protohaem.  Iron is an essential nutrient for all living organisms, lack of iron delays 
bacterial growth and so iron storage can be extremely advantageous.  In response to 
pantoprazole exposure two proteins were found to be up-regulated which are used by 
C. jejuni for iron storage (proteins 6 and 8 in Table 17).  The stress induced by C. jejuni 
during pantoprazole exposure may cause the bacterium to attempt to store more iron.  
Oxidative stress related proteins were identified in both proteomics 1 and proteomics 2 
experiments.  For this reason, two proteins involved in the oxidative stress response of 
C. jejuni were selected for gene expression analysis using qRT-PCR. 
3.4.3 Quantitative Real-time Polymerase Chain Reaction 
qRT-PCR is a very sensitive process which can easily be hindered by DNA contamination, 
technical error (the volumes used are very small) and primer dimer formation.  The 
analysis of PCR products on agarose gels and the employment of additional melt curves 
following qRT-PCR indicated that no DNA contamination occurred and that primer dimers 
did not interfere with the data obtained.  In qRT-PCR the cycle threshold (CT) is the 
number of cycles required for the accumulation of the fluorescence (due to the production 
of dsDNA in the case of SYBR green used in these experiments) to cross the threshold of 
background fluorescence.  So, the lower the CT value, the higher the concentration of 
starting material in the original sample.  Following exposure for 2 hours to (1 mg/ml or 
1,000 µg/ml) pantoprazole expression of the GroEL heat shock protein gene was found to 
be almost 5 times greater than in the control, expression of the thiol peroxidase gene was 
around 4 times greater and expression of the ATP synthase F1 gene was around 1.5× 
greater (Table 18).  These data confirm that protein spots identified by Image Master 2D 
Platinum as being differentially present were indeed altered in response to pantoprazole 
exposure. 
In a study investigating the C. jejuni response to ox-bile exposure GroEL, the ATP 
synthase F1 subunit and a ferritin were all found to be up-regulated using 2D proteomic 
analysis (Fox et al., 2007).  This is interesting in light of microarray data which indicate 
the increased expression of the Cj0561c and cmeA genes (see below and Figure 25). 
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3.4.4 Microarrays  
Cj0561c was the only gene which was highly significant (around a six fold increase) in its 
up-regulation when C. jejuni strain 81-176 was exposed to pantoprazole at 2 mg/ml (or 
2,000 µg/ml) for 2 hours and cmeA was the only gene to be significantly up-regulated 
(around a two fold increase).  As discussed previously (see Section 3.3.2.1), these 
conditions would have resulted in a loss of live bacteria in the pantoprazole exposed 
samples compared to the no pantoprazole control. 
CmeA is a periplasmic membrane fusion protein, CmeB is an inner membrane efflux 
transporter and CmeC is an outer membrane channel forming protein (Lin et al., 2003).  
Together they form the CmeABC pump which is involved in the extrusion of some 
conventional antibiotics, bile salts, detergents, dyes and heavy metals (Akiba et al., 2006).  
Bile resistance is hugely important for enteric pathogens like C. jejuni as they need to 
survive in the intestines where bile is present.  CmeR is known to be the repressor for the 
multi-drug efflux pump CmeABC and of the downstream gene Cj0561c (Guo et al., 2008).  
Cj0561c is a putative periplasmic protein the function of which is unknown.   
It has been shown that in the presence of bile, CmeR becomes inactivated in C. jejuni (see 
Figure 25) and expression of both CmeABC and Cj0561c becomes up-regulated (Guo et 
al., 2008, Dzieciol et al., 2011).  So bile salts are therefore both extruded via CmeABC and 
bile salts also act to block the repression of CmeABC so that CmeABC expression can be 
increased and the extrusion capability of C. jejuni maximised.   
Taurocholate is a bile salt that has been shown to effectively block the binding of CmeR to 
the promoter regions of CmeABC and Cj0561c (Shen et al., 2011).  Shen et al also 
demonstrated that in the presence of salicylate the CmeA, CmeB, CmeC and Cj0561c 
proteins appeared to be up-regulated (in varying amounts) even though there was no 
significant change in the expression of CmeR.  Salicylate is one of the main metabolites of 
the drug aspirin and the authors proposed that their results showed that salicylate also 
interfered with the binding of CmeR to the promoter regions.  In a study by Dzieciol et al it 
was shown that bile salts induced more effectively the Cj0561c gene than they did induce 
the CmeABC pump (Dzieciol et al., 2011).  Their results were similar to those shown here 
(see Table 19) in response to pantoprazole exposure and suggest perhaps that pantoprazole 
is both extruded via the CmeABC pump and that pantoprazole acts to block repression by 
CmeR.  This theory is supported by the observation that no statistical difference was found 
in the expression of CmeR (see Table 19). 
 107 | P a g e  
 
If pantoprazole interferes with the binding of CmeR to the promoter region of Cj0561c 
(perhaps in a manner similar to bile or salicylate) and presumably therefore also of 
CmeABC, then why do we not see increases in the expression of all three subunits cmeA, 
cmeB and cmeC?  What we have actually shown is that there is a statistically significant 
increase in cmeA expression, no statistically significant change in cmeB expression (rather 
the average values for the pantoprazole exposed samples is lower than that of the controls) 
and that there is a small and statistically not significant increase in cmeC expression (Table 
19).  The inconsistencies in these results could be explained by the expected loss of viable 
C. jejuni in the pantoprazole exposed samples compared to the control.  The effect of 
pantoprazole exposure on CmeR, CmeABC and Cj0561c is therefore unclear and the role 
of the CmeABC pump in response to exposure to pantoprazole will be further investigated 
in Chapter 5. 
3.4.5 kdpB Mutant Experiments  
The Kdp is best characterised in E.coli and is a P-type ATPase (as is the H
+
/K
+
-ATPase of 
parietal cells that is the target of PPIs).  The Kdp-ATPase is involved in maintaining 
bacterial turgor pressure and in pH homeostasis (Altendorf et al., 1998).  The Kdp of 
E. coli has three membrane bound subunits which are KdpA, KdpB and KdpC.  Expression 
of the kdpABC operon is controlled by the inner membrane bound protein KdpD and the 
soluble cytoplasmic protein KdpE (Walderhaug et al., 1992).  The kdpA gene encodes for 
the transmembrane subunit, the kdpB gene encodes for the catalytic ATPase subunit 
(which is the largest subunit) and kdpC encodes for an inner membrane protein.  Kdp is 
induced under low potassium conditions and is repressed under high potassium conditions, 
it is not essential for survival.   
KdpB is the largest subunit of the KdpABC ATPase and is the functional protein.  As 
stated in Section 3.2.7.1, the KdpB of C. jejuni was found on examination to contain two 
existing restriction enzyme sites within its sequence, both of which leave sticky ends, 
making insertional mutation a simpler process (no need to first create a restriction enzyme 
site).  Hence the kdpB gene was selected for insertional mutagenesis.  Pseudogenes are 
genomic DNA sequences which are similar to the sequences of functional genes, but are 
themselves functionless.  Many strains of C. jejuni have only pseudogenes or truncated 
open reading frames of the kdp operon but the kdpB gene appears to encode for a 
functional protein (Cameron et al., 2012).   
However, following successful formation of the deficient mutant, further study and 
research provided information that may have accounted for the mutant demonstrating no 
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differential susceptibility to pantoprazole.  According to Hofreuter et al C. jejuni strain   
81-176 has functional kdpA, kdpB and kdpC genes which encode for a potassium-
transporting ATPase and C. jejuni strains RM1221 and 11168 have only pseudogenes 
(Hofreuter et al., 2006).  Yet Cameron et al used C. jejuni 81-176 in their study and state 
that the potassium-transporting ATPase system they belong to is “degenerate” and that the 
kdp genes are pseudogenes.  C. jejuni strain 11168-H was selected for mutation, as this is 
the strain that is routinely used at the LSHTM for gene mutation and other laboratory 
experiments.  On inspection of the nucleotide sequence, the kdpB gene appeared to be 
functional, but whether or not the Kdp ATPase is functional (as stated by Hofreuter et al) 
or “degenerate” (as stated by Cameron et al), the kdpB gene of 11168-H is likely to be a 
pseudogene, as is the case for 11168.  Not only that, but the kdpB gene of C. jejuni 
contains an upstream homopolymeric tract (which is usually associated with hyper-variable 
or phase-variable gene expression) and so is likely to be unreliably transcribed even under 
normal culture conditions (Cameron et al., 2012).   
3.5 Summary and Conclusions  
Proteomics 1 experiments were carried out only once (rather than in triplicate) at each 
pantoprazole exposure time point and differences in the size and intensity of protein spots 
assessed visually.  The reliability of these results is therefore uncertain, but a number of 
proteins involved in LPS and bacterial membrane synthesis and proteins involved in the 
oxidative stress response of C. jejuni were identified as being differentially present under 
pantoprazole exposed and control conditions.  Proteomics 2 experiments were carried out 
in triplicate, differentially present proteins were identified using computer software and 
results are therefore more reliable.  Multiple proteins involved in the oxidative stress 
response of C. jejuni were again identified as being differentially present. 
The up-regulation of two oxidative stress proteins (thiol peroxidase and GroEL) in 
response to pantoprazole exposure was confirmed using qRT-PCR, as was the increase in 
the ATP synthase F1 subunit.  Only two genes were identified as being differentially 
expressed in response to pantoprazole exposure.  These were the Cj0561c gene and cmeA 
gene; both were up-regulated following pantoprazole exposure.  Mutation of the kdpB gene 
of C. jejuni resulted in no significant change to pantoprazole susceptibility and Kdp was 
thought to be an target of PPIs in C. jejuni. 
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Chapter 4 
 
Role of Oxidative Stress in 
the Killing of Campylobacter 
jejuni by Pantoprazole   
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4 INTRODUCTION  
4.1.1 Reactive Oxygen Species and Oxidative Stress  
During aerobic metabolism, the production of reactive oxygen species (ROS) such as 
superoxide (O2
-
), hydrogen peroxide (H2O2) and hydroxyl radicals (OH
•
) is unavoidable.  
As oxygen undergoes consecutive univalent reductions in order to be converted to water, 
all three of these ROS are produced.  ROS are able to damage bacterial DNA, lipids and 
proteins and so must be detoxified by bacteria.  Bacteria have various methods of dealing 
with this so called “oxidative stress”, including DNA repair mechanisms and various 
oxidative stress response enzymes.  If the levels of ROS exceed the organisms’ ability to 
detoxify them, then cell death can result, as levels of damage to lipids, proteins and DNA 
becomes unsalvageable.   
The response to oxidative stress is further complicated by the fact that ROS are not only 
generated during the reduction of oxygen, but also during the detoxification of other ROS 
as well (see Figure 26).  For example, SOD enzymes can be used to remove toxic 
superoxide, but in doing so they contribute to oxidative stress by producing additional 
hydrogen peroxide.  Hydrogen peroxide however can similarly be detoxified, by the 
activity of catalase or peroxidase enzymes (see Figure 26).   
Of these three aforementioned ROS then, the hydroxyl radical is the most potent oxidising 
agent, as no enzyme exists which detoxifies it.  Hydroxyl radicals are highly reactive and 
have a half-life of only nanoseconds.  In the presence of intracellular iron, hydrogen 
peroxide reacts to form hydroxyl radicals in a reaction that is known as the Fenton reaction 
(see Figure 26).  This reaction can occur easily in organisms which lack a catalase enzyme 
and also before hydrogen peroxide has been detoxified by catalase, in organisms which do 
have the enzyme. 
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Figure 26.  Oxidative stress and the roles of different oxidative stress inhibitors.  
Superoxide dismutase (SOD) enzymes can detoxify superoxide and produce hydrogen 
peroxide.  Catalase enzymes are capable of breaking down hydrogen peroxide into water 
and oxygen.  Hydrogen peroxide can also participate in the Fenton reaction in the 
presence of free iron and be broken down, forming the toxic hydroxyl radical.  The 
oxidative stress inhibitors bipyridyl and thiourea can be used to subvert the damage 
caused by hydroxyl radicals produced via the Fenton reaction at different stages of the 
reaction. 
 
4.1.2 Hydroxyl Radical Contributes to Cell Death  
In a study which aimed to determine the role of iron in bacterial susceptibility to the host 
defence of neutrophil attack, the observation was made that higher levels of intrinsic iron 
increased the susceptibility of S. aureus to killing by hydrogen peroxide (Repine et al., 
1981).  S. aureus cultures (following overnight incubation in broth with or without added 
iron) were exposed to varying concentrations of hydrogen peroxide for 60 minutes before 
viable counts were performed.  The bacteria which had been incubated overnight in the 
presence of extra iron, had higher intrinsic levels of iron and were susceptible to killing by 
lower concentrations of hydrogen peroxide than the no added iron control.  The authors 
highlighted that the Fenton reaction was the likely mechanism behind the results and used 
the potent hydroxyl radical quencher thiourea to reduce the number of hydroxyl radicals 
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produced via the Fenton reaction that were then free to damage DNA, lipids and proteins.  
In so doing, they increased the bacterial survival rates on exposure to hydrogen peroxide. 
In 1988 it was reported that the addition of bipyridyl, 5 minutes prior to hydrogen peroxide 
exposure, increased the survival rates of E. coli compared to the no bipyridyl control 
(Imlay et al., 1988).  Bipyridyl is a potent chelator of ferrous iron (Fe
2+
) and can be used in 
vitro to block the Fenton reaction from occurring, resulting in lower levels of hydroxyl 
radicals and less cell damage (see Figure 26).  The addition of thiourea in vitro does not 
stop the Fenton reaction from occurring, but it does provide an effective means of 
quenching the hydroxyl radicals formed, before they are able to cause damage to essential 
bacterial components.   
Thiourea and bipyridyl are therefore known as potent inhibitors of oxidative stress, each 
with an independent mechanism of action that can be used to manipulate the destructive 
potential of hydroxyl radicals formed via the Fenton reaction.  Use of either (or both) of 
these two agents results in less intracellular damage to bacteria as a result of hydroxyl 
radicals, which in turn causes an increase in bacterial survival. 
4.1.3 Oxidative Stress and Antibiotic Killing  
Antibiotics usually fall into one of two categories, those which inhibit active replication or 
growth of bacteria (bacteriostatic) and those which kill > 99.9% of a bacterial population 
(bactericidal).  Bacteriostatic agents often target ribosome function and bactericidal agents 
often target one of DNA replication/repair mechanisms, protein synthesis or cell wall 
synthesis.   
In 2007 a common mechanism of cell death, for three different classes of bactericidal 
antibiotics (aminoglycosides, β-lactams, and quinolones) was reported, that involved the 
generation of hydroxyl radicals via the Fenton reaction (Kohanski et al., 2007).  Both 
thiourea and bipyridyl were used by the authors to increase the survival of E. coli exposed 
to kanamycin (an aminoglycoside which targets protein synthesis), ampicillin (a β-lactam 
which targets cell wall synthesis) and norfloxacin (a quinolone which targets DNA 
replication).  The bacteriostatic antibiotics chloramphenicol, erythromycin, rifamycin, 
spectinomycin and tetracycline were also tested and these were found not to generate 
hydroxyl radicals and were therefore unaffected by the addition of either thiourea or 
bipyridyl.  This study was the first to argue that bactericidal agents, in addition to affecting 
their own specific targets, also contribute to cell death by inducing the production of toxic 
levels of hydroxyl radicals via the Fenton reaction (see Figure 27).   
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Figure 27.  Hydroxyl radicals contribute to cell death.  Kohanski et al proposed that 
bactericidal antibiotics caused cell death via their own specific targets and also by 
inducing the production of hydroxyl radicals via the Fenton reaction.  The contribution to 
cell death due to the induction of oxidative stress can be inhibited, at different stages, by 
bipyridyl and thiourea. 
 
Later other authors investigated the role of hydroxyl radical formation in the killing of 
bacteria by conventional antibiotics.  In 2009 it was reported that an E. coli mutant lacking 
SOD enzymes was more resistant to killing by norfloxacin than the control (Wang & Zhao, 
2009).  In the absence of extrinsically added hydrogen peroxide, hydrogen peroxide is 
generated mainly via the activity of SOD enzymes.  Hence, if the SOD activity is impaired, 
then the levels of hydrogen peroxide available to participate in the Fenton reaction would 
be expected to be lower and hence, the amount of hydroxyl radicals also lower.  It was 
proposed by Wang and Zhao that this was indeed the reason that SOD deficient mutants 
were less susceptible to killing by norfloxacin.  In further support of their argument, it was 
reported that an E. coli mutant lacking catalase activity (and hence having more hydrogen 
peroxide free to participate in the Fenton reaction) was more susceptible to killing by 
norfloxacin than the control.   
The role of hydroxyl radical formation in the antibiotic killing of bacteria other than E. coli 
has also been investigated.  The bactericidal class of antibiotics polymixins (small cationic 
peptides that target the cell membrane) were investigated using E. coli and Acinetobacter 
baumannii (A. baumannii) strains which were susceptible to and strains which were 
resistant to polymixins.  The authors reported that hydroxyl radical levels only increased in 
the susceptible strains and that whereas bipyridyl and thiourea could be used to increase 
bacterial survival in these susceptible strains on exposure to polymixins, the oxidative 
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stress inhibitors had no effect on the resistant strains (Sampson et al., 2012).  Thiourea was 
used to show that killing of Mycobacterium tuberculosis by various antibiotic 
combinations resulted in the production of ROS (Grant et al., 2012).  Thiourea and 
bipyridyl in combination were also used to show that killing of S. aureus by oxacillin, 
daptomycin and moxifloxacin was enhanced by oxidative stress (Liu et al., 2012).   
Other bactericidal antibiotics have been shown to induce the stress response of E. coli that 
in turn inhibits the TCA cycle, thereby inhibiting NADH production and affecting the 
electron transport chain.  Disrupting the electron transport chain can promote the 
production of superoxide, which is a precursor of the Fenton reaction (Sampson et al., 
2012). 
4.1.4 Oxidative Stress in Campylobacter jejuni  
C. jejuni is an obligate microaerophile as it uses oxygen as a terminal electron acceptor, 
but it is also extremely sensitive to high concentrations of oxygen.  It grows best at 5-10% 
oxygen (the percentage of oxygen present in atmospheric air is around 20%).  It has been 
established that addition of antioxidants (such as catalase) to growth media, enhances the 
growth of C. jejuni and suggested that C. jejuni might therefore be more susceptible to 
damage by free radicals than aero-tolerant bacteria (Kaakoush et al., 2007).  This 
suggestion seems reasonable as C. jejuni has only a single catalase enzyme (KatA) and a 
single SOD (SodB); in contrast the Gram negative enteric pathogen E. coli has three SODs 
and two catalase enzymes. 
Gentamicin is an aminoglycoside that can be used to treat severe/systemic Campylobacter 
infections (Suy et al., 2013) and ciprofloxacin is a fluoroquinolone that can be used in the 
treatment of severe campylobacteriosis (Joint-Formulary-Committee., 2015).  Gentamicin 
is a broad-spectrum bactericidal agent which binds irreversibly to 30S ribosomal subunits 
and thereby inhibits protein synthesis.  Ciprofloxacin is also a broad-spectrum bactericidal 
agent but inhibits DNA gyrase and thereby inhibits DNA synthesis.  These two 
conventional antibiotics would therefore be excellent candidates for testing the 
contribution that hydroxyl radicals make to the killing of C. jejuni. 
4.1.5 Chapter Aims  
We have shown in Chapter 2 that at certain concentrations, PPIs are able to kill C. jejuni 
in vitro.  Experiments presented in this chapter were performed to investigate the role of 
oxidative stress in the killing of C. jejuni by selected conventional antibiotics which are 
relevant to the treatment of campylobacteriosis and belong to classes that reportedly induce 
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hydroxyl radical production in other bacterial species.  The role of oxidative stress in the 
killing of C. jejuni by pantoprazole was also investigated using similar methods. 
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4.2 Materials and Methods  
4.2.1 Bacterial Strains and Culture Conditions  
The C. jejuni strains used in this chapter of the study are listed in Table 21.  All strains 
were stored at -80°C, revived, cultured and incubated as detailed in Section 2.2.1.  Strains 
from overnight growths were used in all individual experiments.   
Table 21.  Bacterial strains used in this chapter. 
 
Strain Features Origin/Reference 
C. jejuni 
11168-H 
Hypermotile derivative of 
strain 11168 
(Karlyshev et al., 2002) 
C. jejuni 
81-176 
Human clinically isolated 
strain 
(Korlath et al., 1985) 
 
 
4.2.2 Antibiotics, Oxidative Stress Inhibitors and Pantoprazole  
A 2 mg/ml stock solution of gentamicin 10 mg/ml solution (Sigma) was prepared by 
diluting with sterile water and stored in the fridge.  A stock solution of ciprofloxacin 
(Sigma) was prepared by dissolving in 1% acetic acid to give a 2 mg/ml solution.  This was 
then diluted with sterile water to a final concentration of 150 µg/ml, was wrapped in foil 
and stored in the fridge.  A 5 mM stock solution of 2,2’-bipyridyl (bipyridyl; Sigma) was 
prepared by dissolving in boiling water and a one molar stock solution of thiourea (BDH 
Laboratory Supplies) was prepared by dissolving in water.  Both of these were stored at 
room temperature.  All stock solutions were sterilised using a 0.2 µm filter (Corning) and 
further diluted when required in sterile water.  Pantoprazole sodium hydrate was prepared 
as described in Section 2.2.2.  Control cultures were performed routinely to ensure the 
sterility of water, oxidative stress inhibitors, PPI, the highest and the lowest dilution of all 
antibiotics used in each experiment.   
4.2.3 Thiourea and Bipyridyl Tolerance  
A bipyridyl and thiourea concentration that did not critically affect the survival of C. jejuni 
was determined.  Three ml MHB was added to 7 ml plastic bijous with loosened caps and 
allowed to equilibrate in the VAIN for 4 hours.  Then bipyridyl (final concentrations 
ranging from 500-50 µM), thiourea (final concentrations ranging from 150-37.5 mM) or 
water for oxidative stress inhibitor free controls was added to individual flasks.  A bacterial 
suspension was prepared by harvesting colonies from an overnight culture on MHA + B of 
C. jejuni 11168-H and correcting the OD600 in MHB to 0.2.  The flasks were inoculated 
with 400 µl each, mixed gently and incubated in the VAIN.  At 24 hours the OD600 was 
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determined (once for each replicate of the experiment) and serial dilutions performed in 
PBS to determine CFU/ml.   
4.2.4 Minimum Inhibitory Concentration and Minimum Bactericidal 
Concentration  
The MIC (for gentamicin and ciprofloxacin) and the MBC (for pantoprazole) were 
determined using the broth microdilution method described in Section 2.2.4.  The 
antibiotics were tested at concentrations ranging from 20-0.02 µg/ml and pantoprazole at 
concentrations ranging from 10-0.02 mg/ml (or 10,000-20 µg/ml) with sterile water being 
used for additional no drug controls.  The microtitre plates were covered with a sterile lid 
and wrapped in foil (to protect ciprofloxacin from light) before being incubated in the 
VAIN for 24 hours.  OD595 was measured using a Labsystems Ascent Multiscan plate 
reader. 
4.2.5 Oxidative Stress Inhibition  
A 1:100 dilution in fresh MHB of bacterial suspensions corrected to OD600 of 0.2 in MHB 
were prepared from plate cultures.  C. jejuni strains 11168-H and 81-176 were exposed to 
½ MIC ciprofloxacin (0.05 and 0.04 µg/ml respectively), ½ MIC gentamicin (0.25 and 
0.15 µg/ml respectively) or sub-lethal pantoprazole (250 µg/ml) in the presence and 
absence of bipyridyl at 75 µM and thiourea at 50 mM.  96 well microtitre plates were used 
to test in triplicate each antibiotic, each antibiotic in the presence of either bipyridyl or 
thiourea, pantoprazole alone, pantoprazole in the presence of either bipyridyl or thiourea, 
each antibiotic in the presence of pantoprazole and each antibiotic in the presence of 
pantoprazole and either bipyridyl or thiourea.  Positive controls were included which were 
free from any antibiotic, pantoprazole or oxidative stress inhibitors.  Plates were covered 
and incubated as described previously and OD595 nm determined at 24 hours. 
4.2.6 Replicates and Data Analysis  
Unless otherwise stated each assay was conducted in triplicate and was independently 
repeated at least three times.  Results are expressed as means +/- standard deviations (error 
bars) of replicate experiments.  The unpaired Students t test was used to determine 
statistical significance.  A P value of > 0.01 but < 0.05 was considered significant (*) and a 
P value of < 0.01 highly significant (**).  
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4.3 Results  
4.3.1 Thiourea and Bipyridyl Tolerance  
Thiourea has been used as an inhibitor of oxidative stress in various bacteria by other 
authors at concentrations of 50 and 100 mM (Liu et al., 2012), 100 mM (Wang & Zhao, 
2009), 300 mM (Sampson et al., 2012), but most commonly at 150 mM (Kohanski et al., 
2007, Grant et al., 2012, Keren et al., 2013).  Experiments were first performed to find a 
thiourea concentration that did not critically affect the survival of C. jejuni.  Results in 
Figure 28 show that C. jejuni was unable to tolerate 150 mM thiourea and a final 
concentration of 50 mM was used for further work in this study. 
Bipyridyl has been used as an inhibitor of oxidative stress by other authors at 
concentrations of 250 µM (Wang & Zhao, 2009), 500 µM (Kohanski et al., 2007), 600 µM 
(Sampson et al., 2012) and at 500 and 750 µM (Liu et al., 2012).  Results in Figure 29 
show that C. jejuni was unable to tolerate concentrations of bipyridyl above 150 µM and a 
final concentration of 75 µM was selected for further work in this study.  Results in 
Figures 28 and 29 also show that a reduction in OD is indicative of a corresponding 
reduction in surviving C. jejuni CFU/ml. 
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Figure 28.  Effect of the oxidative stress inhibitor thiourea on the survival of C. jejuni.  
C. jejuni strain 11168-H in MHB was exposed to a range of thiourea concentrations and 
incubated in the VAIN for 24 hours before OD was determined at 600 nm (a) and serial 
dilutions performed to calculate CFU/ml (b).  Levels of significance, as indicated by ** 
(P value < 0.01) relate to the individual test conditions compared to the no thiourea 
control. 
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Figure 29.  Effect of the oxidative stress inhibitor bipyridyl on the survival of C. jejuni.  
C. jejuni strain 11168-H in MHB was exposed to a range of bipyridyl concentrations and 
incubated in the VAIN for 24 hours before OD was determined at 600 nm (a) and serial 
dilutions performed to calculate CFU/ml (b).  Levels of significance, as indicated by ** 
(P value < 0.01) relate to the individual test conditions compared to the no bipyridyl 
control. 
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4.3.2 Minimum Inhibitory Concentration and Minimum Bactericidal 
Concentration  
Because oxidative stress inhibition experiments were to be carried out at ½ MIC 
gentamicin and ½ MIC ciprofloxacin, the MIC for both of these antibiotics was first 
determined for C. jejuni strain 81-176.  As ciprofloxacin was dissolved in acetic acid, the 
acetic acid concentration in serial dilutions which was itself sufficient to inhibit/kill 
C. jejuni was also determined.  C. jejuni was found to tolerate final concentrations of 
≤ 0.01% acetic acid.  Preparation of ciprofloxacin stock solution (150 µg/ml) in the manner 
described in Section 4.2.2 results in a final acetic acid concentration of 0.075%.  
Ciprofloxacin was then tested at a maximum final concentration of 20 µg/ml and this 
ensures that the residual acetic acid concentration was low enough to have no effect on 
C. jejuni survival.  The MICs for ciprofloxacin were found to be 0.1 and 0.08 µg/ml 
respectively for strains 11168-H and 81-176 and for gentamicin were 0.5 and 0.3 µg/ml 
respectively for the two strains.  As previously described (see Section 2.3.2) an MIC for 
pantoprazole could not be accurately determined but the MBC for both 11168-H and 81-
176 was found to be 1 mg/ml (or 1,000 µg/ml). 
The MIC is often ½ of the measured MBC (Sjostrom et al., 1997).  Gentamicin and 
ciprofloxacin were to be used at ½ MIC and so pantoprazole was used at a concentration of 
250 µg/ml in these experiments. 
4.3.3 Oxidative Stress Inhibition  
4.3.3.1 Gentamicin  
Gentamicin is an aminoglycoside that can be used to treat severe or systemic 
Campylobacter infections (Quinn et al., 2007) and killing by aminoglycosides has 
previously been shown to be inhibited by thiourea and bipyridyl (Kohanski et al., 2007, 
Wang & Zhao, 2009).  C. jejuni strain 81-176 was exposed to ½ MIC gentamicin in the 
absence and presence of either thiourea or bipyridyl to investigate whether the production 
of hydroxyl radicals via the Fenton reaction plays a role in the killing of C. jejuni by 
gentamicin.  Both thiourea (P = 0.011) and bipyridyl (P = 0.027) significantly increased 
C. jejuni survival (Figure 30) as demonstrated by an increase in OD, suggesting that 
killing of C. jejuni by gentamicin is partly mediated by the production of hydroxyl radicals.  
This shows that using similar methods to those used by others with E. coli the killing of 
C. jejuni by gentamicin induces hydroxyl radical production (as is true for E. coli).   
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Figure 30.  Both thiourea and bipyridyl protect C. jejuni from killing by gentamicin.  
C. jejuni strain 81-176 in MHB positive control was grown in the absence of any 
gentamicin, thiourea or bipyridyl.  C. jejuni was also grown in the presence of 0.15 µg/ml 
gentamicin for 24 hours before measuring OD600.  Thiourea (a) and bipyridyl (b) were 
used as inhibitors of oxidative stress at final concentrations of 50 mM and 75 µM 
respectively.  Addition of the oxidative stress inhibitors thiourea or bipyridyl results in a 
significant increase in bacterial survival, compared to the gentamicin only control, as 
indicated by * (P value > 0.01 but < 0.05). 
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4.3.3.2 Ciprofloxacin  
Ciprofloxacin is a fluoroquinolone that can be used to treat Campylobacter infections 
(Quinn et al., 2007).  It is also the drug of choice when treating gastroenteritis of unknown 
aetiology (Zilbauer et al., 2008) and killing by quinolones has previously been shown to be 
inhibited by thiourea and bipyridyl (Kohanski et al., 2007, Wang & Zhao, 2009, Grant et 
al., 2012, Liu et al., 2012).   
No increase in OD at 24 hours was observed for C. jejuni strain 81-176 exposed to ½ MIC 
ciprofloxacin in the presence of either thiourea (Figure 31a) or bipyridyl (Figure 31b).  
The same pattern was also observed using 11168-H (data not shown) suggesting that 
killing of Campylobacter by ciprofloxacin is not supplemented by the production of 
hydroxyl radicals. 
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Figure 31.  Neither thiourea nor bipyridyl protect C. jejuni from killing by ciprofloxacin.  
C. jejuni strain 81-176 in MHB positive control was grown in the absence of any 
gentamicin, thiourea or bipyridyl.  C. jejuni was also grown in the presence of 0.04 µg/ml 
ciprofloxacin for 24 hours before measuring OD600.  Thiourea (a) and bipyridyl (b) were 
used as inhibitors of oxidative stress at final concentrations of 50 mM and 75 µM 
respectively.  Addition of the oxidative stress inhibitors thiourea or bipyridyl does not 
result in any significant increase in bacterial survival, compared to the ciprofloxacin only 
control. 
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survival was seen with either inhibitor in the presence of pantoprazole, rather the OD at 
24 hours was reduced in both cases (last two bars on the far right of Figure 32).  This 
suggests that killing of C. jejuni by pantoprazole is not mediated by the production of 
hydroxyl radicals.  Sub-lethal levels of pantoprazole in combination with sub-MIC thiourea 
or bipyridyl results in reduced bacterial survival.  Co-exposure to thiourea and 
pantoprazole caused a highly significant reduction in bacterial survival compared to 
thiourea alone (P = 0.0001) or compared to pantoprazole alone (P = 0.0001).  Co-exposure 
to bipyridyl and pantoprazole caused a highly significant reduction in bacterial survival 
compared to bipyridyl alone (P = 0.0002) or compared to pantoprazole alone (P = 0.0001).   
 
 
Figure 32.  Neither thiourea nor bipyridyl protect C. jejuni from killing by pantoprazole.  
C. jejuni strain 11168-H in MHB positive control was grown in the absence of thiourea 
(Thio), bipyridyl (Bipy) or pantoprazole (Panto).  C. jejuni was also grown in the presence 
of thiourea, bipyridyl or pantoprazole at final concentrations of 50 mM, 75 µM or 
250 µg/ml respectively for 24 hours before measuring OD600.  Thiourea and bipyridyl were 
used as inhibitors of oxidative stress, in the presence of pantoprazole at the concentrations 
stated above. 
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4.4 Discussion  
4.4.1 Thiourea and Bipyridyl Tolerance  
The oxidative stress inhibitors thiourea and bipyridyl have been used in other studies at a 
variety of concentrations with various Gram negative and Gram positive organisms.  Some 
studies state that both thiourea and bipyridyl inhibit bacterial growth (Kohanski et al., 
2007, Wang & Zhao, 2009, Liu et al., 2012, Sampson et al., 2012), other studies use only 
one of the inhibitors and agree that growth inhibition occurs (Cole et al., 2006, Keren et 
al., 2013), whereas others state that no growth inhibition occurs (Repine et al., 1981, 
Olekhnovich et al., 2014).  The discrepancy even exists between studies using the same 
bacterial species, for example S. aureus is reportedly not inhibited by thiourea in one study 
(Olekhnovich et al., 2014) and S. aureus is reportedly inhibited by both thiourea and 
bipyridyl in another (Liu et al., 2012).  Where studies report that thiourea and/or bipyridyl 
affect bacterial growth, then a concentration which is below the MIC is often used.  In 
some cases a concentration of ½ MIC is suggested (Wang & Zhao, 2009).   
Thiourea has been used most often at a concentration of 150 mM in other studies 
(Kohanski et al., 2007, Grant et al., 2012, Keren et al., 2013) and the lowest concentration 
reportedly used was 50 mM (Liu et al., 2012).  Bipyridyl has been used in other studies at 
concentrations as low at 250 µM (Wang & Zhao, 2009) and as high as 750 µM (Liu et al., 
2012).  Results in Figures 28 and 29 show that both thiourea and bipyridyl have a dose 
dependent inhibitory effect on C. jejuni.  This is in support of another study which reports 
that bipyridyl affects the survival of C. jejuni (Cole et al., 2006).   
C. jejuni growth was highly significantly inhibited by 150 mM thiourea and so a 
concentration of 50 mM was used in further experiments, as this was the lowest reported 
concentration used by others and 50 mM thiourea did not significantly affect C. jejuni 
growth.  C. jejuni growth was highly significantly inhibited by concentrations as low as 
100 µM bipyridyl and so a concentration that was lower than those reportedly used by 
others had to be used in further C. jejuni experiments.  C. jejuni appears to be highly 
sensitive to these two agents (particularly to the iron chelator bipyridyl).  As a 
consequence, bipyridyl was used in these experiments at a concentration much lower than 
those used in other studies.  It has been suggested that using thiourea and bipyridyl at low 
concentrations would lead to incomplete protection against killing due to incomplete 
prevention of hydroxyl radical accumulation (Wang & Zhao, 2009).  This was likely a 
factor in the experiments presented in this chapter and it is possible that oxidative stress 
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could not be inhibited to the same degree for C. jejuni as was achieved by other authors 
using the chemical inhibitors thiourea and bipyridyl at higher concentrations.   
The possibility that exposure to pantoprazole increases the permeability of the outer 
membrane of C. jejuni is discussed in further detail in Chapter 5.  This possibility 
however may account for the increased susceptibility to other agents when C. jejuni is 
exposed to them in combination with pantoprazole.  It is possible that in the presence of 
pantoprazole, increased membrane permeability causes a higher intracellular concentration 
at a set extracellular concentration to develop. 
4.4.2 Minimum Inhibitory Concentration and Minimum Bactericidal 
Concentration  
Whilst investigating the anti-Helicobacter activity of a PPI, Sjostrom et al reported that the 
bactericidal activity was more pronounced over time and following acid activation, 
suggesting that one or more of the sulfenamide derivatives was responsible for the anti-
bacterial activity (Sjostrom et al., 1997).  Killing of C. jejuni by pantoprazole has been 
shown to be both concentration and time dependent (see Table 8) and the anti-
Campylobacter activity of pantoprazole is probably also due to one or more of the 
sulfenamide derivatives.  Hence an exposure time of 24 hours was selected for 
investigation of the anti-Campylobacter activity of pantoprazole and for the conventional 
antimicrobials ciprofloxacin and gentamicin.  The MIC of ciprofloxacin was found to be 
similar for the two strains of C. jejuni tested, as was the MIC of gentamicin.  These were 
notably in the µg/ml range (as is common for conventional antibiotics).  The pantoprazole 
concentration which is required to kill is therefore notably much higher (in the mg/ml 
range). 
4.4.3 Oxidative Stress Inhibition  
4.4.3.1 Gentamicin and Ciprofloxacin  
Aminoglycosides and quinolones have been shown by others to induce hydroxyl radical 
accumulation and the aminoglycoside gentamicin and the quinolone ciprofloxacin are both 
antibiotics that can be used in the treatment of Campylobacter infections.  Hence 
ciprofloxacin and gentamicin were selected for use in these experiments.  Experiments 
were performed using either thiourea (a quencher of hydroxyl radicals) or bipyridyl (an 
iron chelator) as inhibitors of oxidative stress, to investigate if hydroxyl radical 
accumulation contributed to the killing of C. jejuni by these two antibiotics.   
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As has been reported by others, using other bacterial genera such as E. coli (Kohanski et 
al., 2007, Wang & Zhao, 2009, Foti et al., 2012) and A. baumannii (Sampson et al., 2012), 
killing of C. jejuni by gentamicin was found to be mediated by the production of hydroxyl 
radicals.  Killing of C. jejuni by ciprofloxacin was found not to be mediated by the 
production of hydroxyl radicals.  In one of the key studies relevant to this work, addition of 
bipyridyl caused an increase in bacterial survival (compared to the antibiotic alone) of 
around 4 log for an aminoglycoside but only of 2 log for a quinolone (Kohanski et al., 
2007).  This suggests that hydroxyl radicals contributed more to the killing of E. coli by 
aminoglycosides than to killing by quinolones.  This, in combination with the lower 
concentrations of bipyridyl and thiourea that could be used in C. jejuni experiments may 
account for why the two antibiotic classes did not equally induce hydroxyl radical 
production.   
It is also worth noting that in many other studies, shorter time points were used and 
antibiotics added at much higher concentrations than were employed here (sometimes as 
high at 10× the MIC (Grant et al., 2012)).  In a study which reportedly dismissed the 
findings of Kohanski et al, the killing of E. coli by a quinolone was shown to be 
significantly decreased, on the addition of thiourea, at some concentrations of norfloxacin, 
but not at other norfloxacin concentrations (Keren et al., 2013). 
4.4.3.2 Pantoprazole  
The killing of C. jejuni by pantoprazole was shown not to be mediated by the production of 
hydroxyl radicals.  Instead of demonstrating an increase in bacterial survival (as would be 
expected if killing was mediated by hydroxyl radical production) a highly significant 
decrease in C. jejuni survival was found on exposure to sub-lethal levels of pantoprazole 
and thiourea and on exposure to sub-lethal levels of pantoprazole and bipyridyl. 
It has been suggested that published works on oxidative stress and hydroxyl radical killing, 
that have made use of the iron chelator bipyridyl, may have overlooked effects on other 
bacterial processes that are dependent on iron and that the presence of bipyridyl does more 
than just block hydroxyl radical production via the Fenton reaction (Liu et al., 2012).   
Results in Figure 32 show that the killing of C. jejuni by pantoprazole can be enhanced if 
the C. jejuni is exposed to pantoprazole and thiourea, even when the concentrations of the 
individual agents are sub-lethal.  The same is true for pantoprazole in combination with 
bipyridyl.  Thiourea is a hydroxyl radical quencher and bipyridyl is a chelator of ferrous 
iron and yet the presence of either chemical increases the anti-Campylobacter activity of 
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pantoprazole.  This may be due to C. jejuni being unable to successfully extrude via efflux 
two compounds which are identified as potential toxins, thereby increasing the 
susceptibility to the anti-Campylobacter activity of pantoprazole.  The role of efflux in 
response to C. jejuni exposure to pantoprazole will be further investigated in Chapter 5. 
4.5 Summary and Conclusions  
Development of therapeutic agents requires the identification of unique target sites that are 
essential to the pathogen (Smith et al., 1999).  In recent years, the development rate of new 
antibiotics has slowed considerably, whilst resistance rates have continued to increase.  
The effectiveness of our current arsenal of antibiotics therefore is diminishing and it may 
prove useful and cost effective to investigate means of potentiating the efficacy of 
currently used antibiotics.  This may include methods of inducing bacterial oxidative stress 
or supressing the bacterial protective responses to oxidative stress (Belenky & Collins, 
2011).   
The killing of C. jejuni by gentamicin was shown to be mediated by the production of 
hydroxyl radicals and the induction of oxidative stress in the bacterium.  The killing of 
C. jejuni by ciprofloxacin and pantoprazole however was shown not to be mediated by the 
production of hydroxyl radicals.  The co-exposure to sub-lethal levels of ciprofloxacin (a 
conventional antibiotic) and bipyridyl (an iron chelator which inhibits C. jejuni growth in a 
dose dependent manner) was shown to cause a significant reduction in C. jejuni growth 
(compared to the antibiotic alone).  The same was true for C. jejuni co-exposed to sub-
lethal levels of pantoprazole and bipyridyl and for C. jejuni co-exposed to sub-lethal levels 
of pantoprazole and thiourea.  The effect of co-exposure to pantoprazole and conventional 
antibiotics will be further investigated in Chapter 5.  
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Chapter 5 
 
Effect of Pantoprazole on 
the Susceptibility of 
Campylobacter jejuni to 
Conventional Antibiotics   
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5 INTRODUCTION  
5.1 Antibiotic Resistance  
Antibiotic resistance is a growing problem worldwide and as such poses an important risk 
to public health.  Factors contributing to the problem are many and varied but increased 
resistance may be linked to increased use of antibiotics in animal husbandry and veterinary 
practice where they are used both as growth promoters and as therapeutic agents.  This 
activity can cause selective pressure on organisms, which then develop resistance and 
resistant organisms can be transferred to humans and then possibly go on to cause difficult 
to treat infections.   
New anti-bacterial agents could be developed either by modifying the chemical structures 
of existing antibiotics, using high throughput chemical screening methods or by identifying 
new bacterial targets that are essential for growth/replication and can be chemically 
inhibited.  Yet the numbers of new antibiotics being discovered and brought to market has 
slowed dramatically in recent years.   
5.1.1 Resistance Mechanisms  
Resistance to antibiotics can develop in a number of different ways.  Genetic material such 
as plasmids can be transferred horizontally or vertically; latent genetic elements such as 
transposons may become activated and resistance may result from DNA mutagenesis in the 
host genome.  Mobile genetic elements such as plasmids may encode for a number of 
different resistance mechanisms and therefore have the ability to transfer resistance to 
multiple agents at the same time. 
5.1.2 Antibiotic Resistance in Campylobacter  
Campylobacteriosis is most commonly a self-limiting infection that does not require 
treatment with antibiotics.  However, in severe, systemic, recurring infections or infections 
in immunocompromised individuals, antibiotic treatment may be required.  
Fluoroquinolones like ciprofloxacin and macrolides like erythromycin are drugs of choice 
in the treatment of C. jejuni infection.  It is however known that antibiotic resistance is 
rising in Campylobacter spp. and this is of concern due to the sheer number of infections 
caused worldwide.  Infections caused by resistant strains of Campylobacter are linked with 
longer duration of symptoms, increased healthcare costs and higher risk of systemic or 
serious illness (Helms et al., 2005).  Developing antibiotic resistance in Campylobacter 
spp. poses a significant risk to public health with up to 70% of C. coli isolates and around 
 132 | P a g e  
 
12% of C. jejuni isolates now being reportedly resistant to erythromycin (Quinn et al., 
2007)  
The horizontal transfer of both plasmid and chromosomal DNA occurs in C. jejuni both in 
vitro and during chick colonization, which indicates that natural transformation could have 
an important role in genome plasticity and in the spread of new factors such as antibiotic 
resistance, even in the absence of selective pressure (Avrain et al., 2004). 
5.1.2.1 The CmeABC of Campylobacter  
Although there are as many as 13 putative efflux transporters encoded for in the genome of 
C. jejuni strain 11168, CmeABC (Campylobacter multidrug efflux) is the most important 
and best characterised efflux pump of C. jejuni (Su et al., 2014).  CmeABC was first 
identified in C. jejuni as a multidrug efflux pump in 2002 (Lin et al., 2002, Pumbwe & 
Piddock, 2002) and is a resistance-nodulation-cell division (RND) type efflux pump.  RND 
efflux pumps are found in many Gram negative organisms and they move compounds from 
the cytoplasm, to the outside of the cell, by moving protons inside the cell.  CmeABC is 
tripartite, chromosomally encoded and extrudes various dyes, detergents, bile salts and 
antibiotics in an energy-dependent process (Quinn et al., 2007).   
The cmeA gene encodes for a periplasmic membrane fusion protein, cmeB for an energy-
dependent inner membrane efflux transporter and cmeC for an outer membrane channel 
forming protein.  CmeABC is regulated by the Tet-R like local repressor cmeR (see 
Figure 33).  Insertional mutagenesis of cmeR (see Figure 33) has been shown to cause 
overexpression of both Cj0561c and cmeB (Guo et al., 2008).  Overexpression of 
CmeABC confers increased resistance to agents which can be more effectively extruded by 
CmeABC (Shen et al., 2011). 
Conversely, insertional mutagenesis of the largest subunit (CmeB) of the CmeABC 
tripartite pump confers increased susceptibility to selected agents, because they could not 
be extruded from the cell to the same extent as in the wild-type.  A cmeB mutant was 
shown by Lin et al to be more sensitive to various bile acids and a range of structurally 
diverse conventional antibiotics including rifampicin, ciprofloxacin, erythromycin and 
gentamicin (Lin et al., 2002).  These antibiotics have been listed according to the impact of 
the mutation on susceptibility i.e. the largest fold difference in susceptibility between the 
cmeB mutant and the wild-type was seen for rifampicin and the lowest for gentamicin.  
Pumbwe and Piddock made a kanamycin insertion mutant of cmeB in C. jejuni strain 
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11168 and also showed that the mutant was more susceptible to various agents, including 
ciprofloxacin, erythromycin, detergents and dyes (Pumbwe & Piddock, 2002). 
 
 
 
Figure 33.  The cmeR gene controls expression of both CmeABC and Cj0561c.  The 
repressor cmeR can be transcribed into mRNA and translated into a protein which is 
capable of repressing the local CmeABC genes, as well as the downstream Cj0561c gene, 
by binding to their upstream promoters (P).  A cmeB mutant has been used in this study 
which has had a kanamycin resistance cassette (kan
R
) inserted into the cmeB gene.  The 
cmeR gene can also be mutated causing overexpression of CmeABC and Cj0561c. 
 
Results in Section 3.3.4 showed that Cj0561c was the only gene highly significantly up-
regulated (around ten fold increase) when C. jejuni strain 81-176 was exposed to 
pantoprazole at 2 mg/ml (2,000 µg/ml) for 2 hours.  It is known that expression of Cj0561c 
is controlled by the repressor CmeR (Guo et al., 2008) and that CmeR also regulates the 
expression of CmeABC (see Figure 33).  The microarray results also showed that there 
was a small (only two fold) increase in the expression of CmeABC following exposure to 
pantoprazole.   
It has been shown in C. jejuni, that in the presence of bile, CmeR is unable to bind to and 
repress the expression of both CmeABC and Cj0561c (see Figure 25) and so both of these 
products are up-regulated in the presence of bile (Guo et al., 2008, Dzieciol et al., 2011).  
The statistically significant up-regulation of Cj0561c and the two fold increase in 
CmeABC expression seen in response to pantoprazole exposure suggests either that 
pantoprazole acts in a similar manner to bile (i.e. actively preventing the binding of CmeR 
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to the CmeABC and Cj0561c promotors) or that the C. jejuni is actively down-regulating 
(perhaps as a result of identifying the pantoprazole as a potential toxic molecule which 
should be extruded) the expression of the CmeR protein, thereby up-regulating the 
expression of CmeABC and Cj0561c. 
5.1.2.2 Fluoroquinolone Resistance in Campylobacter  
As discussed in Section 5.1.2.1 the CmeABC pump contributes to fluoroquinolone 
resistance in Campylobacter.  Fluoroquinolone resistance can also result following target 
modiﬁcation (mutations to GyrA) (Luo et al., 2003).  The gyrA gene encodes for the 
A subunit of DNA gyrase (a key enzyme involved in DNA replication and transcription).  
A single point mutation in the quinolone resistance-determining region of gyrA is sufﬁcient 
to signiﬁcantly increase the resistance of Campylobacter to ﬂuoroquinolones (Luo et al., 
2005).  A T86I substitution in GyrA confers high-level resistance to ﬂuoroquinolones, 
while T86K, A70T, or D90N substitutions are associated with moderate resistance to 
ﬂuoroquinolones (Payot et al., 2006).  Strains with GyrA mutations conferring 
ﬂuoroquinolone resistance must retain a functional CmeABC pump as without CmeABC, 
GyrA mutants are unable to maintain the resistance phenotype (Yan et al., 2006). 
5.1.2.3 Macrolide Resistance in Campylobacter  
As discussed in Section 5.1.2.1 the CmeABC pump also contributes to macrolide 
resistance in Campylobacter.  However high-level macrolide resistance in Campylobacter 
is associated with an A2075G mutation in the peptidyl transferase region in domain V of 
the 23S ribosomal ribonucleic acid (rRNA) gene, which is the target of macrolides 
(Hannula & Hanninen, 2008). 
5.1.2.4 Tetracycline Resistance in Campylobacter  
Tetracycline is a broad-spectrum inhibitor of protein synthesis and is a bacteriostatic agent.  
Resistance to tetracycline usually results from the acquisition of the plasmid known as 
pTet in Campylobacter spp.  C. jejuni strain 81-176 is known to contain pTet and is 
therefore resistant to tetracycline, whereas C. jejuni strain 11168-O does not contain the 
plasmid and is susceptible to tetracycline (Hofreuter et al., 2006).  Both of these strains are 
used extensively in the experimental work detailed in this thesis.  pTet encodes for the tetO 
gene which offers ribosomal protection to C. jejuni and renders it unsusceptible to the 
activity of tetracyclines.  There is also evidence to suggest that the CmeABC pump also 
contributes to tetracycline resistance in Campylobacter as cmeB mutants have been shown 
to be more susceptible to tetracycline (Lin et al., 2002, Pumbwe & Piddock, 2002).   
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5.1.3 Rifampicin  
Rifampicin is a semi-synthetic derivative of rifamycin (a fermentation product of 
Streptomyces mediterranei) which inhibits RNA polymerase, thereby inhibiting RNA 
synthesis (Drapeau et al., 2010).  It is bactericidal, but unlike vancomycin, it has good 
bioavailability when taken orally (Joint-Formulary-Committee., 2015).  It has a broad-
spectrum of activity inclusive of some Gram positive and Gram negative pathogens 
although it is not recommended for use in single therapy because of rapid emergence of 
high-level resistance in vivo and in vitro (Zavascki et al., 2013).   
5.1.4 Vancomycin  
Vancomycin is a structurally unique glycopeptide antibiotic that is poorly absorbed when 
taken orally and is therefore more commonly administered intravenously.  It is effective 
against Gram positive bacteria and is commonly used in the treatment of S. aureus and 
C. difficile infections (Joint-Formulary-Committee., 2015).  Vancomycin blocks cell wall 
synthesis by binding to peptidoglycan precursors and as such is a bactericidal agent.  
Although the cell walls of both Gram negative and Gram positive organisms contain 
peptidoglycan, vancomycin is selective for Gram positive organisms because its large 
molecular weight and complex structure prevent it from penetrating the outer membrane of 
Gram negative organisms (Neu & Gootz, 1996).  In essence, vancomycin would 
successfully interfere with the cell wall synthesis of Gram negative organisms if 
vancomycin could gain access to the cell cytoplasm through the bacterial membrane.  
Vancomycin has been used in experiments described in this thesis to investigate the ability 
of pantoprazole to induce susceptibility of a Gram negative bacterium to the bactericidal 
action of the drug, by interfering with the permeability of the outer membrane. 
5.1.5 Chapter Aims  
Broth microdilution MIC and MBC methods, similar to those used in earlier chapters, were 
extensively employed to investigate if in vitro exposure to pantoprazole affected C. jejuni 
susceptibility to selected conventional antibiotics, which could be prescribed in the 
treatment of campylobacteriosis.  C. jejuni susceptibility (in the presence of pantoprazole) 
to selected conventional antibiotics, which would not be used to treat campylobacteriosis, 
was also investigated.  Selected experiments were also performed using a cmeB insertional 
mutant which was a very kind gift from Sherif Abouelhadid at the LSHTM.  The 
susceptibility of the cmeB mutant to conventional antibiotics, to pantoprazole and to 
conventional antibiotics in the presence of additional pantoprazole was assessed. 
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5.2 Materials and Methods  
5.2.1 Bacterial Strains and Culture Conditions  
The C. jejuni strains used in this chapter of the study are listed in Table 22.  All strains 
were stored at -80°C, revived, cultured and incubated as detailed in Section 2.2.1.  Strains 
from overnight growths were used in all individual experiments.   
Table 22.  Bacterial strains used in this chapter. 
 
Strain Features Origin/Reference 
C. jejuni 
11168-H 
Hypermotile derivative of 
strain 11168 
(Karlyshev et al., 2002) 
C. jejuni 11168-H 
cmeB mutant 
kan
R 
inserted into the B 
subunit gene of the Cme 
pump 
Sherif Abouelhadid, 
LSHTM 
C. jejuni 
81-176 
Human clinically isolated 
strain 
(Korlath et al., 1985) 
 
 
5.2.1.1 cmeB Mutant  
The same kan
R
 used in Section 3.2.7 was also used to make an insertional mutant in the 
cmeB gene of C. jejuni 11168-H using a method similar to that previously described for the 
kdpB mutant.  Briefly, a 1 kb region of the cmeB gene (encoding a single BclI site) was 
amplified using PCR and the amplicon cloned into pJET to form construct pI.  BclI was 
used to cut the plasmid and the kan
R
 (which had been retrieved from pJMK30 using 
BamHI) was inserted to form construct pIK.  pIK was introduced into C. jejuni in the same 
way as for the kdpB mutant and selected colonies checked for the presence of the kan
R
 
insert using PCR.  The C. jejuni cmeB mutant was transported on a Transwab® Amies 
Charcoal swab (Medical Wire and Equipment) from the LSHTM, inoculated onto MHA + 
B + kan agar immediately upon arrival and incubated for 24 hours.  A well isolated single 
colony was selected and subcultured to a fresh MHA + B + kan agar plate and the 
overnight culture used to make a Microbank™ bead stock for storage at -80°C.  Forward 
primer with the sequence (5′-GACGTAATGAAGGAGAGCCA-3′) and reverse primer 
with the sequence (5′-CTGATCCACTCCAAGCTATG-3′) were used to check that the size 
of the product included the 1.4 kb kan
R
. 
5.2.2 Antibiotics and Pantoprazole  
Pantoprazole sodium hydrate was prepared as described in Section 2.2.2.  A 400 µg/ml 
stock solution of gentamicin 10 mg/ml solution (Sigma) was prepared by diluting with 
sterile water.  A stock solution of ciprofloxacin (Sigma) was prepared by dissolving in 
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1% acetic acid to give a 2 mg/ml solution.  This was then diluted with sterile water to a 
final concentration of 400 µg/ml and was wrapped in foil to protect it from the light.  
Erythromycin (Sigma) was dissolved in 10% ethanol to 2 mg/ml and the concentration 
then adjusted to 400 µg/ml using sterile water, to prepare the stock solution.  Rifampicin 
(Sigma) was dissolved in DMSO to 25 mg/ml and the concentration then adjusted to 
4 mg/ml using sterile water for the stock solution.  Vancomycin (Sigma) was dissolved in 
water to 2 mg/ml for the stock solution. 
All antibiotic stock solutions were sterilised using a 0.2 µm filter (Corning), stored in the 
fridge and further diluted when required in sterile water.  Control cultures were performed 
routinely on MHA incubated aerobically to ensure the sterility of water, pantoprazole, the 
highest and the lowest dilution of all antibiotics used in each experiment.   
5.2.3 cmeB Mutant Experiments  
5.2.3.1 Susceptibility of cmeB Mutant to Conventional Antibiotics  
The cmeB insertional mutant and the parent strain 11168-H were exposed to halving 
dilutions of the bactericidal agents’ gentamicin and rifampicin and to the bacteriostatic 
agent erythromycin in a broth microdilution method similar to those described previously, 
with one notable exception.  Antibiotics were serially diluted once per experiment and 
equal volumes removed into two fresh sterile 96 well microtitre plates (one for each 
strain).  An equal volume of sterile water was added to all wells and double the volume of 
bacterial strains in MHB was added to all wells.  Gentamicin and erythromycin solutions 
were used at 400 µg/ml and rifampicin adjusted to 2 mg/ml.  Antibiotic free positive 
controls were also included.  Gentamicin and erythromycin were tested at final 
concentrations of 100-0 µg/ml and rifampicin at 500-0 µg/ml.  96 well microtitre plates 
were incubated for 24 hours before reading the OD600 to help determine the MIC.  MIC 
was also assessed visually using a light box.  MBC was determined by spotting 10 µl 
aliquots onto MHA + B plates and incubating plates for 48 hours.  Aliquots were also 
removed from the two wells either side of the MIC and these serially diluted in PBS and 
dilutions plated on MHA + B to calculate surviving CFU/ml. 
5.2.3.2 cmeB Mutant Pantoprazole Minimum Bactericidal Concentration  
A broth microdilution MBC experiment as detailed in Section 2.2.4 was performed using 
overnight growths of C. jejuni 11168-H and the cmeB mutant harvested into MHB.  
Pantoprazole was tested at final concentrations ranging 1,000-0 µg/ml with sterile water 
being used for the no pantoprazole control. 
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5.2.3.3 Effect of Additional 100 µg/ml Pantoprazole on cmeB Mutant 
Antibiotic Susceptibility  
400 µg/ml stock solutions of gentamicin, ciprofloxacin and erythromycin were adjusted to 
25 µg/ml and 4 mg/ml rifampicin adjusted to 125 µg/ml.  Halving dilutions of each of 
these four antibiotics were made in sterile 96 well microtitre plates.  50 µl of each dilution 
was removed into two rows of a fresh 96 well microtitre plate.  50 µl of water was added to 
one row and 50 µl pantoprazole (at 400 µg/ml) added to the other row.  The cmeB mutant 
of C. jejuni 11168-H was grown overnight on MHA + B + kan agar.  Colonies were 
harvested into MHB to an OD600 of 0.2 and a 1 in 100 dilution made from this into fresh 
MHB.  This was equal to around 3.5×10
6
 CFU/ml.  100 µl of the prepared bacterial 
suspension was added to each well, mixed gently, the 96 well microtitre plate wrapped in 
foil and incubated for 24 hours.  Positive controls with no antibiotics and no pantoprazole 
and controls in the presence of pantoprazole alone (final concentration 100 µg/ml) were 
also performed.  As in Section 5.2.3.1 MIC was assessed visually using a light box by 
reading the OD600   10 µl aliquots were spotted onto MHA + B plates to determine MBC 
and serial dilutions performed on aliquots removed from selected wells to calculate 
surviving CFU/ml. 
5.2.3.4 cmeB Mutant Pantoprazole Minimum Inhibitory Concentration  
A broth microdilution MIC experiment was performed as described in Section 2.2.4.  
Pantoprazole was tested at final concentrations ranging 500-0 µg/ml with sterile water 
being used for the no pantoprazole control. 
5.2.3.5 Effect of 10 µg/ml Pantoprazole on cmeB Mutant Antibiotic 
Susceptibility  
The method described in Section 5.2.3.3 was used, with pantoprazole solution made to 
40 µg/ml and so tested at a final concentration of 10 µg/ml.  Rifampicin was not tested in 
combination with pantoprazole in this manner, only gentamicin, ciprofloxacin and 
erythromycin. 
5.2.4 Effect of Pantoprazole on Wild-type Campylobacter jejuni Antibiotic 
Susceptibility  
A 1:100 dilution in fresh MHB of bacterial suspension corrected to OD600 of 0.2 in MHB 
was prepared from overnight plate cultures of C. jejuni strain 81-176.  Bacteria were 
exposed to sub-lethal pantoprazole (250 µg/ml), ½ MIC gentamicin (0.15 µg/ml), to a 
combination of the two (gentamicin at 0.15 µg/ml and pantoprazole at 250 µg/ml), ½ MIC 
ciprofloxacin (0.04 µg/ml) and a combination of the two (ciprofloxacin at 0.04 µg/ml and 
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pantoprazole at 250 µg/ml) in 96 well microtitre plates.  A positive control was included 
which was free from any gentamicin, ciprofloxacin or pantoprazole.  Plates were incubated 
for 24 hours before OD595 was determined and 50 µl aliquots removed from wells and 
plated over the entire surface of MHA + B plates.  Plates were then incubated for 48 hours 
before being examined for the growth of Campylobacter.   
An Erythromycin MIC experiment was performed using C. jejuni strains 81-176 and 
11168-H in a manner similar to that described in Section 5.2.3.1.  Erythromycin was 
serially diluted once and split between two fresh 96 well plates.  An equal volume of water 
was added to one plate (to act as the erythromycin alone exposed control) and pantoprazole 
added to the other at a final concentration of 250 µg/ml.   
In a similar manner C. jejuni strain 81-176 was exposed to rifampicin at 500, 250 and 
125 µg/ml with and without the addition of sub-lethal pantoprazole (250 µg/ml) for 
24 hours before 50 µl aliquots were removed and plated onto MHA + B plates.  Plates 
were then incubated for 48 hours before being examined for the growth of Campylobacter.   
In a similar manner C. jejuni strains 81-176 and 11168-H were exposed to vancomycin at 
500, 250 and 125  and 62.5 µg/ml with and without the addition of sub-lethal pantoprazole 
(at 100 or 250 µg/ml) for 24 hours before 10 µl aliquots were removed and spotted onto 
MHA + B plates.  Plates were then incubated for 48 hours before being examined for the 
growth of Campylobacter.   
5.2.5 Replicates and Data Analysis  
Unless otherwise stated each assay was conducted in triplicate and was independently 
repeated at least three times.  Results are expressed as means +/- standard deviations (error 
bars) of replicate experiments.  The unpaired Students t test was used to determine 
statistical significance.  A P value of > 0.01 but < 0.05 was considered significant (*) and a 
P value of < 0.01 highly significant (**).  
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5.3 Results  
5.3.1 cmeB Mutant Experiments  
Initial experiments were performed using the C. jejuni cmeB insertional mutant from the 
LSHTM and the parent strain 11168-H to determine if there was a difference in 
susceptibility to selected conventional antibiotics relevant to the treatment of C. jejuni 
infections.   
5.3.1.1 Susceptibility of cmeB Mutant to Conventional Antibiotics  
5.3.1.1.1 Gentamicin and Erythromycin  
Results in Figure 34a show that the cmeB mutant and the parent strain were similarly 
susceptible to gentamicin.  At all concentrations of gentamicin tested, the P values 
comparing the OD for the cmeB mutant and those for the parent strain 11168-H were 
> 0.05, indicating that there was no statistically significant difference in gentamicin 
susceptibility between the two strains.  The MICs for gentamicin can be found in Table 23 
where the mean MIC for triplicate experiments was 0.2 µg/ml, for both strains and the 
range was also the same for both strains.   
Table 23.  The MICs of gentamicin and erythromycin for the parent strain 11168-H and 
the cmeB mutant.   
 
C. jejuni 
Strain 
Antibiotic MIC (µg/ml) 
Gentamicin Erythromycin 
Mean +/- SD Range Mean +/- SD Range 
11168-H 0.20 +/- 0.15 0.40-0.10 1.60 +/- 0.00 1.60-1.60 
cmeB Mutant 0.20 +/- 0.17 0.40-0.10 0.20 +/- 0.00 0.20-0.20 
 
Results in Figure 34b however, show that the cmeB mutant was more susceptible to 
erythromycin than the parent strain.  There was a significant difference in OD results for 
11168-H exposed to 1.6 µg/ml erythromycin versus 0.8 µg/ml (P = 0.0223) indicating that 
the MIC for 11168-H was 1.6 µg/ml erythromycin.  The erythromycin MIC for the cmeB 
mutant however was found to be 0.2 µg/ml (P value for 0.2 µg/ml erythromycin versus 
0.1 µg/ml = 0.0001).  The difference in susceptibility to erythromycin was clear and 
consistent in all three replicates of the experiment (see standard deviations and ranges 
listed in Table 23).   
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  b 
 
Figure 34.  The cmeB mutant of C. jejuni displays differential susceptibility (compared 
to the parent strain) to erythromycin but not gentamicin.  C. jejuni strain 11168-H and 
the cmeB insertion mutant were exposed to varying concentrations of gentamicin (a) or 
erythromycin (b) for 24 hours before MIC was determined by measuring OD600.  Levels of 
significance, as indicated by * (P value > 0.01 but < 0.05) or ** (P value < 0.01) 
compared the bacterial survival at a given antibiotic concentration between the two 
strains. 
 
The differential susceptibility of the cmeB mutant (versus the parent strain) to 
erythromycin was also confirmed by comparing the ODs for the two strains at 
concentrations < MIC of the parent strain but ≥ the MIC of the cmeB mutant (e.g. 0.8, 0.4 
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and 0.2 µg/ml erythromycin).  The P values for these comparisons were 0.0159, 0.0001 
and 0.0001 respectively (see Figure 34b).   
Aliquots were removed from selected wells of microtitre plates following antibiotic 
exposures and serially diluted to calculate surviving CFU/ml.  Following exposure to 
0.4 µg/ml erythromycin, an average of 1.3×10
7
 CFU/ml were recovered for the parent 
strain 11168-H, compared to < 100 CFU/ml for the cmeB mutant.  Similarly, following 
exposure to 0.2 µg/ml erythromycin, an average of 1.8×10
7
 CFU/ml were recovered for the 
parent strain compared to 1.1×10
5
 CFU/ml for the cmeB mutant.  Culture results therefore 
support the OD results shown in Figure 34b and the cmeB mutant is indeed significantly 
more susceptible to the action of erythromycin than the parent strain. 
5.3.1.1.2 Rifampicin  
C. jejuni is usually inherently resistant to rifampicin, as a result of the CmeABC pump (Lin 
et al., 2002, Hannula & Hanninen, 2008).  However, because Lin et al reported that 
mutation of cmeB conferred susceptibility to rifampicin (Lin et al., 2002) further 
experiments were performed to assess parent strain and cmeB mutant susceptibility to 
rifampicin.   
The cmeB mutant was found to be more susceptible to rifampicin than the parent strain 
(Table 24).  Significant and highly significant differences in the susceptibility of the cmeB 
mutant (versus the parent strain) to rifampicin were found by comparing the ODs for both 
strains at 31.3, 15.6, 7.8, 3.9, 2.0, 1.0 and 0.5 µg/ml rifampicin (see Figure 35). 
Table 24.  The MIC of rifampicin for the parent strain 11168-H and the cmeB mutant.   
 
C. jejuni Strain 
Rifampicin MIC (µg/ml) 
Mean +/- SD Range 
11168-H 52.1 +/- 18.1 62.5-31.3 
cmeB Mutant 0.8 +/- 0.3 1.0-0.5 
 
Wild-type resistance to rifampicin was reflected in the MBC results, as the MBC for the 
parent strain was found to be > 500 µg/ml.  However the MBC for the cmeB mutant was 
found to be 15.6 µg/ml.  Following exposure to 31.3 µg/ml rifampicin, an average of 
1.1×10
8
 CFU/ml were recovered for 11168-H, compared to < 100 CFU/ml for the cmeB 
mutant.  Similarly, following exposure to 15.6 µg/ml rifampicin, an average of 5.6×10
8
 
CFU/ml were recovered for the parent strain compared to < 100 CFU/ml for the cmeB 
mutant.  Differential susceptibility was still evident at much lower concentrations of 
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rifampicin.  A 2 log difference in survival was seen following exposure to 0.5 µg/ml 
rifampicin, with 1.3×10
9
 CFU/ml of 11168-H being recovered versus 3.4×10
7
 CFU/ml of 
the cmeB mutant.   
 
 
Figure 35.  The cmeB mutant of C. jejuni displays differential susceptibility (compared 
to the parent strain) to rifampicin.  C. jejuni strain 11168-H and the cmeB insertion 
mutant were exposed to varying concentrations of rifampicin for 24 hours before MIC was 
determined by measuring OD600.  Levels of significance, as indicated by * (P value > 0.01 
but < 0.05) or ** (P value < 0.01) compared the bacterial survival at a given antibiotic 
concentration between the two strains. 
 
Culture results therefore support the OD results shown in Figure 35 and the cmeB mutant 
used in this study is indeed more susceptible to the action of rifampicin than the parent 
strain.  Results for the no antibiotic positive controls (seen in the last set of blue and red 
bars in Figure 34 and Figure 35) show that the cmeB mutation caused no growth defect in 
the strain, as there was no significant difference seen in the ODs for the mutant versus the 
parent strain for the no antibiotic positive controls in the experiments. 
5.3.1.2 cmeB Mutant Pantoprazole Minimum Bactericidal Concentration  
An MBC experiment similar to the MBC experiments used previously for wild-type strains 
(see Section 2.2.4) was used to assess the susceptibility to pantoprazole of the cmeB 
mutant versus the parent strain.  The MBC at 24 hours for the parent strain 11168-H was 
found to be 1 mg/ml (or 1,000 µg/ml), which is similar to those previously reported in 
Table 8 for wild-type strains with functional CmeABC pumps.  However the MBC for the 
cmeB mutant was found to be four times lower, at 250 µg/ml and so the cmeB mutant is 
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demonstrably more susceptible to the antimicrobial activity of pantoprazole than the 
C. jejuni parent strain.   
5.3.1.3 Effect of Additional 100 µg/ml Pantoprazole on cmeB Mutant 
Antibiotic Susceptibility  
Because the cmeB mutant was more susceptible to some conventional antibiotics and to 
pantoprazole than the parent strain, experiments were performed exposing the mutant and 
parent strain to combinations of pantoprazole and selected conventional antibiotics.  
Pantoprazole was added at a fixed final concentration of 100 µg/ml (sub-lethal for both the 
mutant and parent strain) and antibiotics serially diluted in doubling dilutions. 
For both ciprofloxacin and rifampicin, the MIC was the same in all three replicates of the 
experiment (0.024 and 0.97 µg/ml respectively, see Table 25) and clearly defined MICs 
can therefore be seen in Figure 36b and d.  Comparing the ODs at one concentration 
(0.024 and 0.97 µg/ml respectively for ciprofloxacin and rifampicin) with the ODs 
achieved for the next lowest antibiotic dilution (0.012 and 0.48 µg/ml respectively for 
ciprofloxacin and rifampicin) gives highly significant results for both agents.  The MICs 
for gentamicin and erythromycin were found to be 0.195 µg/ml in some replicates of the 
experiment and 0.098 µg/ml in others, which is reflected in the standard deviations shown 
in Table 25 and the large error bars seen in Figure 36a and c for 0.098 µg/ml antibiotic.   
Table 25.  Addition of 100 µg/ml pantoprazole inhibits the growth of the cmeB mutant 
and hinders determining an MIC for pantoprazole + selected conventional antibiotics. 
 
Antibiotic 
cmeB Mutant Mean MIC (µg/ml) +/- SD 
Antibiotic Alone 
With 100 µg/ml 
Pantoprazole 
Gentamicin 0.13 +/- 0.06 < 0.006 
Ciprofloxacin 0.02 +/- 0.00 < 0.006 
Erythromycin 0.13 +/- 0.06 < 0.006 
Rifampicin 0.97 +/- 0.00 < 0.030 
 
In Section 5.3.1.2 the MBC of pantoprazole for the cmeB mutant was found to be 
250 µg/ml and so a sub-lethal concentration of 100 µg/ml was selected for use in these 
conventional antibiotic and PPI co-exposure experiments.  However it is evident that there 
was a highly significant difference between the ODs for the no antibiotic controls (with 
and without the presence of 100 µg/ml pantoprazole) as seen in the last set of blue and red 
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bars on the far right of all of the graphs in Figure 36.  This indicates that the presence of 
pantoprazole alone, at a concentration of 100 µg/ml is highly significant in its ability to 
inhibit the growth of the cmeB mutant.   
  a 
  b 
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  c 
  d 
 
Figure 36.  Presence of sub-lethal 100 µg/ml pantoprazole significantly affects growth of 
the cmeB mutant.  An MIC experiment was performed using a broth microdilution method 
before OD600 was measured.  The C. jejuni cmeB mutant was exposed to various 
concentrations of gentamicin (a), ciprofloxacin (b), erythromycin (c) or rifampicin (d) in 
the absence of pantoprazole (blue bars) and in the presence of pantoprazole (red bars).  
Levels of significance, as indicated by ** (P value < 0.01) compared the bacterial survival 
at a given antibiotic concentration between the no pantoprazole control and with 
additional 100 µg/ml pantoprazole. 
 
5.3.1.4 cmeB Mutant Pantoprazole Minimum Inhibitory Concentration  
Because the cmeB mutant was found to be inhibited (see Figure 36) by concentrations of 
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broth microdilution MIC experiment, using the cmeB mutant, was performed for 
pantoprazole.  The ODs achieved following exposure to each pantoprazole concentration 
were compared to the values obtained for the concentration one dilution lower (see Figure 
37 for concentrations along the X axis).  The only highly significant difference was seen 
when comparing the ODs achieved following exposure to 125 µg/ml pantoprazole with 
those achieved following exposure to 63 µg/ml (P = 0.00001).  No significant differences 
(P > 0.01 but ≤ 0.05) were found across the range.  The pantoprazole MIC for the cmeB 
mutant was therefore found to be 125 µg/ml in these experiments.  We have already shown 
that 100 µg/ml pantoprazole significantly inhibits the growth of the cmeB mutant (Figure 
36) and so it is likely that the pantoprazole concentration which is sufficiently low enough 
to allow the cmeB mutant to grow lies somewhere between 63 and 100 µg/ml. 
 
 
Figure 37.  Standard broth microdilution can be used to determine the pantoprazole 
MIC for the cmeB mutant.  The cmeB mutant in MHB was exposed to varying 
concentrations of pantoprazole for 24 hours before MIC was determined by measuring 
OD600.  Level of significance, as indicated by ** (P value < 0.01) compared the bacterial 
survival at a given concentration with survival at the next lowest dilution. 
 
5.3.1.5 Effect of 10 µg/ml Pantoprazole on cmeB Mutant Antibiotic 
Susceptibility  
Because growth of the cmeB mutant was inhibited by much lower concentrations of 
pantoprazole than wild-type C. jejuni, experiments were performed exposing the cmeB 
mutant to selected conventional antibiotics in combination with 10 µg/ml pantoprazole (in 
a manner similar to that used in Section 5.3.1.3).  Again, a clear MIC was defined in all 
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three replicates of the experiment for ciprofloxacin (see Figure 38b) and the MICs for 
gentamicin and erythromycin again varied between two subsequent dilutions (0.195 or 
0.098 µg/ml).  This contributed to the higher standard deviations shown in Table 26 and 
the large error bars seen in Figure 38a and c for 0.098 µg/ml gentamicin and erythromycin 
respectively. 
However there was a highly significant difference between the ODs for the no antibiotic 
controls (with and without the presence of 10 µg/ml pantoprazole) as seen in the last set of 
blue and red bars on the far right of the graphs in Figure 38a and c.  A significant 
difference in the OD achieved following exposure to 10 µg/ml pantoprazole alone can also 
be seen in Figure 38b.  This indicates that the presence of pantoprazole alone, at a 
concentration of 10 µg/ml is still significantly able to inhibit growth of the cmeB mutant. 
Table 26.  Addition of 10 µg/ml pantoprazole still inhibits the growth of the cmeB 
mutant and hinders determining an MIC for pantoprazole + conventional antibiotics. 
 
Antibiotic 
cmeB Mutant Mean MIC (µg/ml) +/- SD 
Antibiotic Alone 
With 10 µg/ml 
Pantoprazole 
Gentamicin 0.16 +/- 0.06 < 0.006 
Ciprofloxacin 0.02 +/- 0.00 < 0.006 
Erythromycin 0.13 +/- 0.06 < 0.006 
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  b 
  c 
Figure 38.  Presence of 10 µg/ml pantoprazole inhibits cmeB mutant growth.  An MIC 
experiment was performed using a broth microdilution method before OD600 was 
measured.  The C. jejuni cmeB mutant was exposed to various concentrations of 
gentamicin (a), ciprofloxacin (b) or erythromycin (c) in the absence of pantoprazole (blue 
bars) and in the presence of 10 µg/ml pantoprazole (red bars).  Levels of significance, as 
indicated by * (P value > 0.01 but < 0.05) or ** (P value < 0.01) compared the bacterial 
survival at a given antibiotic concentration between the no pantoprazole control and with 
additional 10 µg/ml. 
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5.3.1.6 2 µg/ml Pantoprazole Significantly Inhibits cmeB Mutant Growth  
Because 10 µg/ml pantoprazole was found to be highly significant (Figure 38a and c) or 
significant (Figure 38b) in its inhibition of the cmeB mutant growth, data from the 
pantoprazole MIC experiment in Section 5.3.1.4 was re-examined.  Results in Figure 37 
show that the ODs achieved following exposure to ≤ 63 µg/ml pantoprazole were higher 
(all ODs above 0.3) than those achieved at higher concentrations of pantoprazole (at 500, 
250 and 125 µg/ml pantoprazole all ODs were below 0.2).  So at pantoprazole 
concentrations of ≤ 63 µg/ml, the cmeB mutant is able to grow.  However, when the ODs 
for each individual concentration ≤ 63 µg/ml pantoprazole are compared to the ODs for the 
no pantoprazole positive control, highly significant and significant reductions in OD were 
found between 63 and 2 µg/ml pantoprazole (see Table 27).  Hence concentrations of 
pantoprazole ≥ 2 µg/ml significantly inhibit the growth of the cmeB mutant. 
Table 27.  The ODs achieved following exposure to various pantoprazole concentrations 
have been compared to those achieved for the no pantoprazole positive control. 
 
 Pantoprazole Concentration (µg/ml) for which Data have been 
Compared to the no Pantoprazole Control 
63 31 16 8 4 2 1 
P value 0.002 0.004 0.002 0.003 0.007 0.027 0.071 
Significance 
Level 
** ** ** ** ** * NS 
 
Highly significant (**) and significant (*) were assigned for P values of < 0.01 and > 0.01 
but < 0.05 respectively.  P values > 0.05 were designated not significant (NS). 
 
5.3.2 Effect of Pantoprazole on Wild-type Campylobacter jejuni Antibiotic 
Susceptibility  
5.3.2.1 Gentamicin, Ciprofloxacin and Erythromycin  
Because the cmeB mutant displayed such pronounced susceptibility to pantoprazole and 
the CmeABC pump has been shown to be involved in the extrusion of conventional 
antibiotics (Guo et al., 2008) experiments were performed combining sub-lethal 
pantoprazole with sub-MIC gentamicin and sub-MIC ciprofloxacin using wild-type 
C. jejuni.  C. jejuni strains 81-176 and 11168-H, have functioning CmeABC pumps and 
were the strains used in these experiments. 
A highly significant decrease in the OD for C. jejuni exposed to pantoprazole and 
gentamicin in combination (compared to both pantoprazole alone and gentamicin alone) 
was seen (Figure 39a).  A highly significant decrease in the OD for C. jejuni exposed to 
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pantoprazole and ciprofloxacin in combination was also seen, but in comparison to 
pantoprazole alone only (not compared to ciprofloxacin alone). 
To confirm that the highly significant reduction in OD, which was seen when C. jejuni was 
exposed to gentamicin in the presence of pantoprazole, corresponded to a reduction in 
surviving bacteria, aliquots were removed from wells and plated onto non-selective agar 
(Figure 39b-d).  A confluent growth of C. jejuni was recovered (Figure 39b) following 
exposure to 250 µg/ml pantoprazole alone, which is therefore clearly sub-lethal.  A semi-
confluent growth of C. jejuni was recovered following exposure to sub-MIC gentamicin 
(Figure 39c) yet only a few colonies were cultured (Figure 39d) following co-exposure to 
both agents at the same concentrations used in Figure 39b and c.   
In a similar manner the highly significant reduction in OD, which was seen when C. jejuni 
exposed to ciprofloxacin in the presence of pantoprazole was also confirmed to correspond 
to a reduction in surviving bacteria (pictures not shown).  An average of 7.5×10
6
 CFU/ml 
were recovered following exposure to ciprofloxacin (0.125 µg/ml) alone, compared to 
1.4×10
5
 CFU/ml recovered following exposure to 0.125 µg/ml ciprofloxacin with 
additional 250 µg/ml pantoprazole. 
The MIC of erythromycin for C. jejuni strain 81-176 consistently showed a one fold 
reduction (on addition of 250 µg/ml pantoprazole versus erythromycin only control).  An 
average of 3.6×10
3
 CFU/ml of C. jejuni strain 81-176 were recovered following 24 hour 
exposure to 1 µg/ml erythromycin alone versus < 100 CFU/ml recovered following 
24 hour exposure to 1 µg/ml erythromycin in the presence of additional 250 µg/ml 
pantoprazole.  C. jejuni strain 11168-H also demonstrated the same one fold reduction in 
erythromycin MIC when 250 µg/ml pantoprazole was added. 
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  a 
 
b 
 
250 µg/ml Pantoprazole 
c 
0.15 µg/ml Gentamicin 
d 
250 µg/ml Pantoprazole 
with added 
0.15 µg/ml Gentamicin 
 
Figure 39.  Pantoprazole enhances killing of C. jejuni by gentamicin and ciprofloxacin.  
C. jejuni strain 81-176 was exposed to pantoprazole (Panto) at 250 µg/ml, gentamicin 
(Gent) at 0.15 µg/ml, a combination of both (Panto + Gent), ciprofloxacin (Cipro) at 
0.04 µg/ml and a combination of both (Panto + Cipro) for 24 hours before measuring 
OD595 (a).  50 µl was aliquoted and spread onto MHA + B plates and plates incubated for 
48 hours following the exposures to pantoprazole (b), gentamicin (c) or a combination of 
both (Panto + Gent; d).  Levels of significance, as indicated by ** (P value < 0.01) 
showed that significantly less bacteria survive exposure to pantoprazole and gentamicin in 
combination than survive either exposure to gentamicin alone or pantoprazole alone.  
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5.3.2.2 Rifampicin  
Because the cmeB mutant displayed such pronounced susceptibility to pantoprazole and 
the CmeABC pump is known to be involved in resistance to rifampicin (Lin et al., 2002), 
experiments were performed combining sub-lethal pantoprazole with rifampicin using 
wild-type C. jejuni.   
C. jejuni strain 81-176 displayed a dose depended response to killing by rifampicin (see the 
series of three images on the left of Figure 40) but this was at concentrations notably much 
higher than those required for antibiotics to which C. jejuni would be considered 
susceptible to.  For example, a similar number of colonies can be cultured from a 50 µl 
aliquot following C. jejuni 81-176 exposure to 0.15 µg/ml gentamicin as can be cultured 
following C. jejuni 81-176 exposure to 250 µg/ml rifampicin (see Figures 39c and 40b 
respectively).   
C. jejuni 81-176 exposed to rifampicin in the presence of additional 250 µg/ml 
pantoprazole is however killed more effectively than C. jejuni exposed to rifampicin alone 
(Figure 40), although 250 µg/ml pantoprazole is itself sub-lethal to C. jejuni 81-176 (see 
Figure 39b).   
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Figure 40.  Presence of a sub-lethal pantoprazole concentration enhances rifampicin 
killing.  C. jejuni strain 81-176 in MHB was exposed to rifampicin at 500 (a), 250 (b) or 
125 (c) µg/ml and rifampicin alone and with added 250 µg/ml pantoprazole for 24 hours 
before 50 µl aliquots were spread onto MHA + B plates.  Plates were incubated for 
48 hours before being examined for the growth of Campylobacter. 
 
5.3.2.3 Vancomycin  
Vancomycin is a bactericidal agent which inhibits cell wall synthesis in Gram positive 
bacteria and would therefore not be expected to be effective against the Gram negative 
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organism C. jejuni.  The vancomycin MBC for both strains of C. jejuni tested was found to 
be > 500 µg/ml and these results were therefore as expected.  Although vancomycin (up to 
a maximum concentration of 500 µg/ml) was unable to kill C. jejuni in vitro, results in 
Figure 41 suggest that vancomycin is capable of inhibiting C. jejuni growth.  A highly 
significant increase in the OD achieved following C. jejuni exposure to 125 µg/ml 
vancomycin (compared to the OD achieved following exposure to 250 µg/ml vancomycin) 
was seen in the absence of pantoprazole (blue bars).  The vancomycin MIC for C. jejuni 
strain 81-176 was therefore found to be 250 µg/ml.  Again, this concentration is notably 
much higher than those required for conventional antibiotics to which C. jejuni would be 
considered susceptible to. 
 
 
Figure 41.  Presence of pantoprazole significantly increases susceptibility to 
vancomycin.  C. jejuni strain 81-176 in MHB was exposed to varying concentrations of 
vancomycin (with and without the presence of 100 µg/ml (green bars) or 250 µg/ml 
pantoprazole (panto) (red bars)) for 24 hours before OD600 was measured.  Levels of 
significance, as indicated by * (P value > 0.01 but < 0.05) or ** (P value < 0.01) relate to 
the individual test conditions compared to the no PPI control. 
 
At vancomycin concentrations below the MIC, significant and highly significant decreases 
in OD were found with the addition of either 100 or 250 µg/ml pantoprazole (Figure 41).  
Of particular interest was that a significant decrease in OD was seen at 125 µg/ml 
vancomycin when 100 µg/ml pantoprazole was also present (when compared to the no 
vancomycin control for 100 µg/ml pantoprazole) and that a highly significant decrease in 
OD was seen at 62.5 µg/ml vancomycin when 100 µg/ml pantoprazole was also present 
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(again when compared to the no vancomycin control for 100 µg/ml pantoprazole).  
Vancomycin in the presence of 100 µg/ml pantoprazole therefore inhibits the growth of 
C. jejuni; even though the presence of 100 µg/ml pantoprazole does not itself significantly 
inhibit C. jejuni growth (see the last set of blue and green bars on the far right of 
Figure 41). 
The presence of 250 µg/ml pantoprazole itself was highly significant in its ability to inhibit 
the growth of C. jejuni (see the last set of blue and red bars on the far right of Figure 41) 
even though this concentration is known to be below the cidal level (see Table 8 and 
Figure 39b).   
The MBC of vancomycin alone was > 500 µg/ml and in the presence of additional 
100 µg/ml pantoprazole the MBC remained unchanged at > 500 µg/ml.  However in the 
presence of a confirmed sub-MBC concentration of 250 µg/ml pantoprazole, the 
vancomycin MBC was found to be 250 µg/ml in 12 replicates and 500 µg/ml in three 
replicates.  The median MBC of vancomycin (in the presence of 250 µg/ml pantoprazole) 
was therefore 300 µg/ml.   
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5.4 Discussion  
5.4.1 cmeB Mutant Experiments  
5.4.1.1 Susceptibility of cmeB Mutant to Conventional Antibiotics  
Results in Table 23 and Figure 34a show that there was no significant difference in the 
cmeB mutant susceptibility to gentamicin when compared to that of the parent strain.  
Previously it has been reported that mutation of cmeB leads to a two fold increase in 
susceptibility to gentamicin (Lin et al., 2002) but these authors mutated the cmeB of 
C. jejuni strain 81-176 and not 11168-H, as was the strains used in this study.  Both 
C. jejuni strains 11168 and 81-176 have functional CmeABC pumps.  It is however worth 
noting that in their study, the authors reported that the cmeB mutant showed fold 
differences in the range of 256-2 fold for a variety of agents and therefore the reported 
increase in susceptibility to gentamicin was very small.  Also noteworthy is that although 
the authors used broth microdilution in MHB (as was used in this study), they calculated 
MIC following two days incubation at 42°C (and not following one day incubation at 37°C 
as was used in this study).  This may account for the discrepancy in cmeB mutant 
gentamicin susceptibility results.  The cmeB mutant used by Pumbwe and Piddock was 
made using kan
R
 inserted into strain 11168, but they unfortunately did not report on 
gentamicin susceptibility (Pumbwe & Piddock, 2002).   
Following exposure to 0.4 µg/ml erythromycin, 1.3×10
7
 CFU/ml of 11168-H were 
recovered, compared to the cmeB mutant which had no live colonies recovered.  
Erythromycin is a bacteriostatic agent and the parent strain 11168-H is able to withstand 
exposure to 0.4 µg/ml and actively grow in its presence to give a 2 log increase in CFU/ml 
from the initial inoculum.  Similarly, following exposure to 0.2 µg/ml erythromycin, the 
cmeB mutant demonstrated a 2 log reduction in survival rate compared to that of the parent 
strain.  Both Lin et al and Pumbwe and Piddock reported that their individual cmeB 
mutants displayed an increased susceptibility to erythromycin.  The cmeB mutant used in 
this study also showed an increased susceptibility to erythromycin (see Figure 34b) and is 
therefore in support of these two previous works.   
The CmeABC pump must therefore play a role in the extrusion of erythromycin in wild-
type strains of C. jejuni.  The CmeABC pump is the most important mechanism of energy-
dependent efflux in wild-type C. jejuni and disruption of this pump clearly has the ability 
to increase susceptibility to conventional antibiotics that may be used in the treatment of 
infections caused by C. jejuni. 
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It has been previously shown that insertional mutation of cmeB renders the C. jejuni 
mutant susceptible to rifampicin, a bactericidal antibiotic which C. jejuni is usually 
inherently resistant to (Lin et al., 2002).  Experiments were therefore performed using the 
cmeB mutant from the LSHTM to investigate if disruption of the CmeABC pump could 
truly induce rifampicin susceptibility.  Results in Table 24 and Figure 35 show that the 
cmeB mutant was indeed more susceptible to rifampicin than the parent strain and these 
results are in support of Lin et al.   
The CmeABC pump must therefore also be involved in the extrusion of rifampicin in wild-
type strains of C. jejuni.  Disruption of this pump clearly has the ability to induce 
susceptibility to conventional antibiotics that may otherwise not normally be used in the 
treatment of infections caused by C. jejuni. 
5.4.1.2 cmeB Mutant Pantoprazole Minimum Bactericidal Concentration  
The MBC for the cmeB mutant was only ¼ of the MBC for the parent strain (250 µg/ml 
compared to 1,000 µg/ml) and so the cmeB mutant is clearly more susceptible to the 
antimicrobial activity of pantoprazole than the parent strain.  This perhaps suggests that the 
CmeABC pump is involved in the extrusion of pantoprazole in wild-type C. jejuni.  To our 
knowledge, this is the first report that disruption of the CmeABC pump confers increased 
susceptibility to agents from the PPI family.   
5.4.1.3 Effect of Additional 100 µg/ml Pantoprazole on cmeB Mutant 
Antibiotic Susceptibility  
The experiments failed to determine if the cmeB mutant was differentially susceptible to 
conventional antibiotics in the presence of additional 100 µg/ml pantoprazole because 
100 µg/ml pantoprazole was shown to be highly significant in its ability to inhibit the 
growth of the cmeB mutant (Figure 36).  This result was unexpected as 100 µg/ml is less 
than ½ of the pantoprazole MBC for the cmeB mutant and it has been stated that the MIC 
is often ½ of the measured MBC (Sjostrom et al., 1997).  Because significant growth 
inhibition of the cmeB mutant was apparent at a concentration less than ½ of the 
pantoprazole MBC and that the cmeB mutant was susceptible to lower concentrations of 
pantoprazole than wild-type C. jejuni, a standard broth microdilution MIC experiment was 
performed. 
5.4.1.4 cmeB Mutant Pantoprazole Minimum Inhibitory Concentration  
A pantoprazole MIC could not be accurately determined for wild-type strains of C. jejuni 
because the inhibitory concentration appeared to be close to concentrations of pantoprazole 
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where yellow benzimidazole intermediates made visual and automated MIC determination 
difficult (see Figure 8).  The cmeB mutant was however shown to be inhibited by lower 
concentrations of pantoprazole than the parent strain and this concentration was low 
enough that an MIC could be determined using OD readings.  The pantoprazole MIC for 
the cmeB mutant was shown to be 125 µg/ml (Figure 37).  At concentrations of 
pantoprazole ≤ 500 µg/ml there were no issues with yellow colour development or PPI 
solubility that made visual MIC determination difficult and affected the OD of solutions 
used in earlier experiments (see Section 2.3.2).   
The cmeB mutant is demonstrably more susceptible to killing by pantoprazole than the 
parent strain and other wild-type strains (see Table 8 and Section 5.3.1.2).  Hence it is 
clear that the CmeABC pump is not only important for the extrusion of detergents, dyes, 
bile salts and conventional antibiotics, but also important in the extrusion of the PPI 
pantoprazole. 
5.4.1.5 Effect of 10 µg/ml Pantoprazole on cmeB Mutant Antibiotic 
Susceptibility  
Experiments failed to determine if the cmeB mutant was differentially susceptible to 
selected conventional antibiotics in the presence of additional 10 µg/ml pantoprazole 
because 10 µg/ml pantoprazole was shown to be highly significant in two experiments and 
significant in one set of experiments in its ability to inhibit the growth of the cmeB mutant 
(Figure 38).  For this reason, the experiment was not performed using rifampicin (as was 
the case in Section 5.3.1.3 where 100 µg/ml pantoprazole was utilised).   
Re-examination of the pantoprazole MIC data shown in Figure 37 showed that growth of 
the cmeB mutant was highly significantly and significantly inhibited by concentrations as 
low as 2 µg/ml pantoprazole (see Table 27). 
5.4.2 Effect of Pantoprazole on Wild-type Campylobacter jejuni Antibiotic 
Susceptibility  
5.4.2.1 Gentamicin, Ciprofloxacin and Erythromycin  
The ODs of cultures exposed to sub-MIC gentamicin in the presence of additional 
250 µg/ml pantoprazole were shown to be highly significant in their reduction, when 
compared to those for gentamicin alone or pantoprazole alone (Figure 39a).  The proton 
motive force is important for the uptake of gentamicin into bacterial cells.  The highly 
significant increase in bacterial killing on exposure to both gentamicin and pantoprazole 
concurrently suggest that pantoprazole does not adversely affect the proton motive force of 
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C. jejuni.  Culture results confirmed that the reduction in OD corresponded to a reduction 
in recoverable C. jejuni (Figure 39d).  Combinations of OD and culture results also 
showed that the same was true for ciprofloxacin and erythromycin.  These three agents can 
be prescribed in the treatment of campylobacteriosis and we have shown that antibiotic 
killing can be improved in the presence of sub-lethal concentrations of pantoprazole.   
The ability of PPIs to contribute to growth inhibition or killing by conventional antibiotics 
has previously been reported for organisms unrelated to C. jejuni, e.g. in S. aureus 
(Aeschlimann et al., 1999, Vidaillac et al., 2007) and for P. aeruginosa and S. aureus 
(Singh et al., 2012).  Enhanced activity of conventional antibiotics in the presence of PPIs 
has also previously been reported for the related organism H. pylori (Bamba et al., 1997, 
Midolo et al., 1997, Trautmann et al., 1999, Tanaka et al., 2002).  H. pylori eradication 
triple therapy regimes often combine two antibiotics (e.g. metronidazole, clarithromycin or 
tetracycline) prescribed alongside a PPI (Mills et al., 2004).  We know that by making the 
stomach environment less acidic, sensitivity to conventional antibiotics can be increased 
(Sachs et al., 1995).  We also know that PPIs exhibit a direct anti-bacterial effect on 
H. pylori and so the benefits of treating H. pylori infections with an antibiotic and PPI 
combination are multifactorial (Spengler et al., 2004). 
5.4.2.2 Rifampicin 
Results in Figure 40 show that resistance to rifampicin can be lessened by exposing wild-
type C. jejuni to rifampicin in the presence of additional 250 µg/ml pantoprazole.  The 
numbers of CFU/ml recovered following co-exposure to pantoprazole and rifampicin are 
lower than those recovered following exposure to pantoprazole alone (see Figure 39b) and 
are also lower than those recovered following exposure to rifampicin alone (Figure 40).   
It has been previously reported that inherent wild-type C. jejuni resistance to rifampicin 
can be overcome by the mutation of cmeB (Lin et al., 2002) and results by these authors 
have been confirmed in this study (see Table 24 and Figure 35).  This study has provided 
evidence that C. jejuni growth can be inhibited by pantoprazole (Figure 10), that (at 
concentrations higher than inhibitory concentrations) pantoprazole is bactericidal (Table 8) 
and that the CmeABC pump must be involved in the extrusion of pantoprazole 
(Figure 38).  Perhaps in wild-type C. jejuni exposed to two bactericidal agents which are 
extruded via CmeABC pump, the pumps are unable to extrude the agents as quickly, the 
agents are able to exert their bactericidal effect more easily and therefore bacterial killing 
is more pronounced on exposure to both agents.  This may also account for the increased 
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susceptibility seen in Chapter 4 when C. jejuni was exposed to thiourea and pantoprazole 
concurrently and also bipyridyl and pantoprazole concurrently. 
5.4.2.3 Vancomycin 
Vancomycin (up to a maximum concentration of 500 µg/ml) was unable to kill C. jejuni in 
vitro and this was expected, as the large size and complex structure of vancomycin makes 
it unable to penetrate the cell membrane of Gram negative bacteria.  However results in 
Figure 41 suggest that vancomycin is capable of inhibiting C. jejuni growth.  This result 
was unexpected but may be a result of prolonged exposure (24 hours) to high 
concentrations of vancomycin (100s of µg/ml).  Vancomycin is a bactericidal agent and 
would therefore not be expected to cause growth inhibition, with no subsequent killing, in 
a susceptible strain.  It is however clear in this instance that exposure to vancomycin alone 
is insufficient to kill C. jejuni even though vancomycin is a bactericidal agent. 
However results indicate that in the presence of additional 100 µg/ml pantoprazole, 
vancomycin is significantly better at inhibiting the growth of C. jejuni (Figure 41 green 
bars) compared to vancomycin alone or pantoprazole alone.  In the presence of 250 µg/ml 
pantoprazole we see C. jejuni growth inhibition (but not killing) as a result of the 
pantoprazole activity.  Killing of C. jejuni occurs following exposure to 500 µg/ml 
vancomycin and 250 µg/ml pantoprazole concurrently and this killing must be a result of 
vancomycin activity as 250 µg/ml pantoprazole is sub-lethal.  We suggest that exposure to 
sub-lethal concentrations of pantoprazole causes damage to the outer membrane of 
C. jejuni, allowing some of the vancomycin entry to kill C. jejuni. 
5.5 Summary and Conclusions  
It would be hugely beneficial to return to the golden age of antibiotic development with 
new families of antibiotics being discovered and novel targets being identified and 
inhibited successfully.  It would also be desirable to develop selective target antibiotics so 
infectious bacteria can be eliminated without harming bacteria that make up the natural 
flora. 
Broth microdilution MIC and MBC methods, similar to those used in earlier chapters were 
extensively employed in the experiments detailed in this chapter.  However with the 
notable exception that in these experiments only one serial dilution was made per antibiotic 
agent utilised.  Equal volumes of these dilutions were then removed into duplicate wells of 
fresh 96 well microtitre plates and supplemented with equal volumes of sterile water 
before adding twice the volume of bacterial suspension in broth.  This results in a 1 in 4 
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dilution of the antibiotic agent (which can easily be adjusted for by changing the 
concentration of the stock solution) but still finally uses equal volumes of bacterial 
suspension in broth and diluent.  In previous chapters two separate serial dilutions were 
performed and one set of dilutions used for one condition and the second set of dilutions 
for the other.  This previously used method introduces more risk of error compared to the 
adapted method used in this chapter.  The adapted method benefits from a reduced risk of 
error and therefore less chance of large standard deviations or error bars. 
We have shown that the cmeB mutant is four times more susceptible to killing by 
pantoprazole than the parent strain (MBC of 250 µg/ml versus. 1,000 µg/ml respectively).  
We have also shown that, at concentrations of pantoprazole well below the cidal level, 
growth of the cmeB mutant is significantly inhibited (down to 2 µg/ml pantoprazole). 
Wild-type C. jejuni is demonstrably more effectively killed by conventional antibiotics, in 
combination with pantoprazole, that are relevant to the treatment of campylobacteriosis 
(gentamicin, ciprofloxacin and erythromycin).  In addition, antibiotics not usually used in 
the treatment of campylobacteriosis are enhanced in their inhibitory and cidal activity 
when used in combination with pantoprazole.  Our results lead us to conclude that 
pantoprazole damages the outer cell membrane of C. jejuni, making it more permeable to 
large molecules such as vancomycin, which usually cannot access the Gram negative cell 
wall. 
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6 GENERAL DISCUSSION  
The benzimidazoles are a diverse group of chemicals that are easily modified and the 
activities of the different chemical structures are far reaching.  Benzimidazole derivatives 
have previously been shown to have anti-parasitic, anti-cancer, anti-viral and anti-fungal 
activities (Kazimierczuk et al., 2002, Andrzejewska et al., 2004, Navarrete-Vazquez et al., 
2006).  The PPI family are the most commonly used drugs belonging to the benzimidazole 
group and the anti-Helicobacter activity of PPIs has long since been established.  PPIs are 
also known to be extremely safe for use in humans (even at very high doses) and are 
available as oral agents. 
This project aimed to investigate the effect of direct exposure of C. jejuni to PPIs.  Results 
similar to those reported by others using other bacterial genera were obtained.  Exposure to 
PPI affects C. jejuni growth/survival, motility, morphology, biofilm formation and 
invasion potential of cultured epithelial cells.  Proteomics identified a number of proteins 
as being differentially present under pantoprazole exposed and control conditions that were 
involved in the oxidative stress response of C. jejuni.  The up-regulation of two oxidative 
stress proteins (thiol peroxidase and GroEL) in response to pantoprazole exposure was 
confirmed using qRT-PCR, as was the increase in the ATP synthase F1 subunit.  Only two 
genes (Cj0561c and cmeA) were identified as being differentially expressed in response to 
pantoprazole exposure using microarrays.  Both were up-regulated in response to 
pantoprazole and the importance of the CmeABC pump in the susceptibility of C. jejuni to 
pantoprazole has been here demonstrated.   
Bacterial transport mechanisms like influx/efflux are used to acquire essential nutrients, 
maintain the pH gradient across the cytoplasmic membrane as well as to extrude toxic 
compounds (Kaatz et al., 1993).  The cmeB mutant was demonstrably more susceptible to 
killing by pantoprazole than the parent strain and other wild-type strains.  Hence it is clear 
that CmeABC is not only important for the extrusion of detergents, dyes, bile salts and 
conventional antibiotics, but also important in the extrusion of the PPI pantoprazole.  
Microarray results showed a significant increase in some of the genes controlled by CmeR 
but there was no statistically significant decrease seen in the expression of CmeR and so, 
during exposure to pantoprazole, the repressor of CmeABC and Cj0561c is still being 
produced by C. jejuni.  It is therefore possible that pantoprazole acts on C. jejuni in a 
manner similar to that of bile, i.e. pantoprazole is identified as a potentially toxic agent, 
that should be extruded via CmeABC but the pantoprazole itself is also capable of 
interfering with the activity of the CmeR (see the scenario proposed in Figure 42). 
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Figure 42.  Possible role for pantoprazole in C. jejuni.  In the presence of pantoprazole 
the cmeR gene is transcribed successfully and the functional protein produced but 
pantoprazole interferes with the binding of the repressor to the promoters and the Cj0561c 
gene and the CmeABC genes are successfully transcribed. 
 
Although the oxidative stress response of C. jejuni appeared to be important during 
pantoprazole exposure, the killing by pantoprazole was shown not to be mediated by the 
production of hydroxyl radicals.  Had more time been available it may have proved 
insightful to use both thiourea and bipyridyl together in oxidative stress inhibition 
experiments.  The addition of both bipyridyl and thiourea may have meant that any 
hydroxyl radicals formed via the Fenton reaction (due to incomplete protection by 
bipyridyl, as a result of using a low concentration) could be scavenged by the thiourea and 
therefore oxidative stress might better have been inhibited.  The use of both agents in 
combination is quite unusual but in one study, both bipyridyl and thiourea were used to 
inhibit oxidative stress (Liu et al., 2012).   
The identification of the significant up-regulation of the F1 protein subunit of the ATP 
synthase of C. jejuni (which was confirmed using qRT-PCR) may indicate that 
pantoprazole is binding to and inhibiting this bacterial ATPase, hence the bacterium is 
attempting to counteract this by producing more functional ATPases.  Although the ATP 
synthase of E. coli is known to be non-essential for survival (Santana et al., 1994) the 
enzyme is important for bacterial energy production, C. jejuni flagellar motion and is up-
regulated in the C. jejuni response to bile (Fox et al., 2007).  H. pylori has an ATP 
synthase which has similar homology to the ATP synthase of C. jejuni (Slonczewski et al., 
2009).  Whether the ATP synthase is the (or one of the) targets of PPIs in C. jejuni and 
H. pylori requires further investigation. 
It is possible that the relatively small genome of the campylobacterales contributes to the 
“taxonomic boundary” of the anti-bacterial activity of PPIs that was originally proposed by 
Iwahi et al.  Whereas the disruption of the ATP synthase of E. coli may prove to be non-
 166 | P a g e  
 
lethal (perhaps as a result of a wide range of available alternative enzymes produced by the 
bacterium from its relatively large genome), disruption of the ATP synthase of C. jejuni 
may be much more problematic (perhaps as a result of a lack of available alternative 
enzymes which are not encoded for in the relatively small genome). 
Bacterial resistance to antibiotics is a growing problem and poses a great risk to public 
health around the world.  The development of new antibiotics is currently scarce, as is the 
identification of new potential targets for novel antibiotic development.  It was hoped that 
modern proteomic and genomic analysis might identify new bacterial targets for which 
inhibiting agents could be designed, but this has shown limited success in recent years (Liu 
et al., 2012).  Potentiation of currently used antibiotics has been proposed as a cost-
effective option that might be extremely advantageous and may benefit patient care 
(Belenky & Collins, 2011).  This may be achieved by developing small molecules that 
enhance the efficacy of conventional antibiotics (Liu et al., 2012) or by enhancing 
additional damage to bacteria by inducing the production of ROS (Brynildsen et al., 2013).  
Consumer preference is also moving towards natural antibiotics (Castillo et al., 2011) and 
increasing awareness of the wider implications of disrupting the natural host flora during 
antibiotic treatment means that targeted (and perhaps pathogen specific) treatments are also 
being sought.   
Campylobacter is the most common cause of bacterial gastroenteritis in Europe and in 
many other areas of the world.  Antibiotic resistance in the genus is on the rise and patients 
infected with multi-resistant strains have been shown to have a longer duration of illness, 
are at greater risk of developing invasive disease and have higher associated healthcare 
costs (Quinn et al., 2007).  The CmeC portion of the CmeABC pump was found to be 
antigenic in chickens and has been proposed that the outer-membrane components of Gram 
negative multi-drug efflux pumps may be immune targets that can be successfully used as 
treatment enhancing intervention strategies (Lin et al., 2003).  The enhanced killing of 
C. jejuni, in the presence of sub-lethal concentrations of PPI, by conventional antibiotics 
suggest there may be potential benefits to prescribing PPIs in combination with antibiotics 
for the treatment of campylobacteriosis. 
The in vitro antimicrobial activity of pantoprazole against strains of C. jejuni has been here 
demonstrated, as has the detrimental effect on bacterial motility, ability to form a 
protective biofilm, ability to invade epithelial cells and to enhance susceptibility to and 
killing by some conventional antibiotics.  Data presented herein therefore suggest that 
exposure to pantoprazole adversely affects a number of factors that might be expected to 
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result in reduced pathogenicity of the organism.  Lack of functional flagella prevents the 
organism colonising the host and non-motile C. jejuni do not cause disease.  This may be 
especially true in those patients taking higher doses of PPIs on empty stomachs.  Due to a 
lack of available information on the subject, the major difficulty in interpreting these 
results is in estimating the PPI concentrations that might be clinically achievable in vivo 
(see Table 3).   
In the past it has been suggested that people taking PPIs are at higher risk of developing 
enteric infections like campylobacteriosis than people not taking PPIs (Tam et al., 2009).  
In light of the results presented in this study, that may be seen as quite a dichotomy.  Yet in 
a more recent study it has been suggested that the predisposition to GI infections may lie, 
not directly with the taking of PPIs, but rather as a result of the GI troubles that lead to the 
prescription of PPIs as a treatment (Brophy et al., 2013).  These results suggest that, for 
some patients taking large doses of PPIs, the residual PPI concentration in the GI tract may 
be sufficient to reduce the pathogenicity of C. jejuni and that for some people, the taking of 
PPIs may actually be “protective” against C. jejuni causing disease in that individual. 
The actual mechanism (or mechanisms) responsible for the killing of C. jejuni by PPIs is 
not yet clear, but from our results, a number of potential mechanisms can be speculated 
upon.  On exposure to PPI the morphology of C. jejuni changes from spiral to coccal, 
which has previously been associated with a non-culturable state.  The proteomic data 
gathered suggests several targets involved in bacterial electron transport inside the cell may 
be inhibited, which have been shown to be lethal when deficient.  The ability of 
vancomycin to exert its killing effect shows that the outer membrane is leaky and hence 
more permeable to large molecules which are conventionally excluded.  This effect must 
be the result of pantoprazole exposure.  In order for C. jejuni to be killed by PPIs, the 
effect must be greater than the ability of the Cme efflux system to extrude the drug.  Some, 
or all, of these mechanisms may act together to exert bactericidal action on C. jejuni.  
Finally, we have successfully demonstrated that the safe for human consumption drugs 
PPIs can be used to increase the efficacy of currently used conventional antibiotics.  We 
suggest that benzimidazole derivatives may be good candidates for drug repurposing and 
further development in this field. 
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7 APPENDIX 1 – MEDIA AND BUFFERS 
7.1 Growth Media  
All sterilisations were carried out by heating to 121°C for 15 minutes in an autoclave.  
Media was then cooled before use. 
 
MHA – Mueller-Hinton agar 
MHA (Oxoid) 15.2 g 
Distilled water 400 ml 
25 ml per 90 mm petri dish 
 
MHA + B – Mueller-Hinton agar with 7% horse blood 
MHA (Oxoid) 15.2 g 
Distilled water 400 ml 
Allowed to cool before adding: 
Defibrinated horse blood (E+O) 28 ml 
25 ml per 90 mm petri dish 
 
SSA – Semi-solid agar 0.4% 
MHB (Oxoid) 8.4 g 
Agar Bacteriological Agar No. 1 (Oxoid) 1.6 g 
Distilled water 400 ml 
30 ml per 90 mm petri dish 
 
STA – Soft top agar 0.8% 
MHB (Oxoid) 1.84 g 
Agar Bacteriological Agar No. 1 (Oxoid) 0.64 g 
Distilled water 80 ml 
10 ml per aliquot 
 
MHB – Mueller-Hinton broth 
MHB (Oxoid) 2.1 g 
Distilled water 
 100 ml 
SOB – Super optimal broth 
Yeast extract (Sigma) 0.5 g 
Tryptone (Sigma) 2 g 
NaCl (Sigma) 58.4 mg 
KCl (Sigma) 18.6 mg 
MgSO4 (Sigma) 240.8 mg 
Distilled water 100 ml 
 
TSB – Tryptic soy broth 
TSB (LabM) 3 g 
Distilled water 100 ml 
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7.2 Buffers and Solutions   
Ammonium bicarbonate 200 mM stock 
Ammonium bicarbonate 7.905 g 
Distilled water 500 ml 
Diluted 1:2 with distilled water for use at 100 mM and also then mixed with an equal 
volume of Acetonitrile for 50% acetonitrile/100 mM ammonium bicarbonate 
 
Farmer’s reducing agent – FA  
20% Sodium thiosulphate 50 ml 
1% Potassium ferricyanide 50 ml 
 
5% Coomassie Blue G-250 (Biorad)* 5× stock 
Coomassie Blue G-250 2.5 g 
Double-distilled water 50 ml 
 
Coomassie dye stock solution 
Coomassie Blue G-250 5% 5× stock solution 50 ml – see * 
85% Phosphoric acid  30 ml 
Ammonium sulfate 250 g 
Double-distilled water 2.5 l 
 
Coomassie working solution 
Coomassie Blue G-250 5% 5× stock solution 400 ml – see * 
Methanol  100 ml 
 
SDS equilibration buffer** stock solution 
1.5 M Tris-Cl at pH 8.8 6.7 ml 
7 M Urea 72.07 g 
87% Glycerol 69 ml 
Sodium doecyl sulfate 4.0 g 
Bromophenol blue 2 mg 
Double-distilled water 124.3 ml 
 
Equilibration buffer with DDT 
SDS equilibration buffer 10 ml – see ** 
D-dopachrome tautomerase – DDT 100 mg 
 
Equilibration buffer with iodoacetamide 
SDS equilibration buffer 10 ml – see ** 
Iodoacetamide 250 mg 
 
Fixative 
10% Acetic acid 300 ml 
40% Ethanol 1.2 l 
Double-distilled water 1.5 l 
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Rehydration Buffer 
2% CHAPS 
7 M Urea 
0.3% DTT 
2 M Thiourea 
1% IPG buffer 
Bromophenol blue 
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8 APPENDIX 2 – NUCLEOTIDE SEQUENCES AND 
PRIMER DESIGN  
8.1 kdpB 
ATGTCTAAAAAACAAAATAAACTCATTACAAAAGAAATTTTAAATAATGCCA
TAAAAGGAGCATTTTTAAAATTTGATCCACGCTTTATGGTAAAAAATCCTGTT
ATGTTTATGGTGGAAGTTGGATTGATTCTTACTTTGATTTTAAGTATTTTTCCTA
CTTTGTTTAATGGAAATTCTGATGAAAGAATTTATAACATCTTAATCACTTTTA
TTTTATTTATAACCTTGCTTTTTGCAAATTTTGCAGAAAGTATTGCAGAAGGAA
GGGGTAAAGCCCAAGCAGCTACCTTAAGACAAAGCAAAAAGGATTCTAAAGC
TAGACGCATAAAAAGTGATGGCAGTGAAGAAATGCTTAATTCTAGCGAGTTAA
AAATAGGTGATATAGTTTTAGTTAAAGCAGGTGAACTTATACCTAATGATGGA
GAAATTATAGAAGGTGCTGCAAGTGTTGATGAATCAGCTATTACAGGTGAAAG
TGCTCCTGTTATGCGTGAAGCGGGCGGTGATTTTTCTTCTGTTACAGGTGGGAC
TACGGTTTTAACTGATTTTTTAAAGATTAAAATTTTAGTTGGAGCTGGGGAAAG
TTTTTTAGATAAAATGATCAATCTTGTAGAAGGTGCTGCGCGTCAAAAAACTC
CAAATGAAATTGCTCTTAATACTCTTTTAATTGTTCTTAGTTTGAGTTTTTTGGT
GGTGGTTGTAAGTTTATATCCTTTTATGCAATTTTTAGGCGTGAGTTTGCCTATT
TCGTGGTTAGTAGCATTGCTTGTATGTCTTATTCCTACAACTATAGGGGGGCTT
TTATCAGCTATAGGAATAGCAGGTATGGATAGGGTAACGCGTTTTAATGTGAT
CGCACTTTCAGGCAAGGCTGTTGAAAGTTGTGGTGATGTTGATACTATGATTTT
GGATAAAACAGGAACGATTACTTTTGGAAACCGTTTGGCAAATGAATTTTATG
AAGTCCAAGGTATAAGTAAAGAAGAAATGATTAAAGCTTGTGTTTTATCCTCT
TTAAAAGATGAAACTCCAGAAGGTAAAAGCATAGTTGCATTGGCTCAAAAAAT
GGGTTATGAATTAGAAGGTAATGATATTAAAGAATTTATCGAATTTAGCGCTC
AAAATAGAATGAGTGGTGTGGATTTACAAGATAATACAAAAATTCGCAAAGGT
GCTTTTGATGCTATAAGAGCTTATATAAGCGAAATGAATGGAAAAATTCCTAG
CGATTTAGAAACTAAGGTAATGGAAATTTCAAATCTTGGTGGCACTCCTTTGGT
AGTGTGTAAAAATGAAAAAATTTTAGGAGTGATTTATCTAAAGGATACAGTAA
AACCAGGACTTAAAGAGCGCTTTGATGAGCTTAGAAAAATGGGCATAAAAAC
TTTAATGTGTACTGGAGACAATCCTTTAACAGCAGCTACTATAGCTAAAGAAG
CAGGGCTTGATGGATTTATAGCAGAATGCAAGCCTGAAGATAAAATAGAAGC
CATTAAAAAAGAACAAGCTCAAGGTAAGATAGTAGCCATGACAGGAGATGGA
ACCAATGATGCTCCGGCTCTTGCACAAGCTGATGTAGGTATAGCTATGAACTC
AGGAACTCAGGCGGCCAAAGAAGCAGCCAATATGATAGATCTTGATTCTAATC
CTACTAAAATTTTAGAAGTGGTTGAAATAGGAAAAGGTTTGCTTATTACTAGA
GGCAGTCTTACAACTTTTAGTATGGCAAATGATATTGCTAAGTATTTTACTATT
TTACCTGCTATGTTTAGTGTGGTTTTACCTCAAATGCAAATTTTAAATATTATGC
ATTTGGCTACCCCGCAAAGCGCTATTTTATCAGCACTTATTTTTAATGCTATTAT
TATACCTTTGCTCATACCTATTGCTATGCGTGGAGTTAAATTTAAGCCTATGAA
AAGTGAGCATTTGCTTTTAAGAAATTTGAGTATTTATGGTTTAGGTGGTATGAT
AGCACCTTTTATAGGGATAAAAATAATTGATATTCCTACAGCTTGGATACTTAG
AATTTTAGGAGTGTGA 
 
Figure 43.  Sequence of the kdpB gene of C. jejuni 81116.  The nucleotide sequence of 
the kdpB gene is shown with existing BclI and BglII sites (highlighted in green and blue 
respectively).  Gene specific forward (kdpB GS-F) and reverse (kdpB GS-R) primers were 
selected to target the areas highlighted in yellow.  The sequences of these were 5’-
TAATGCCATAAAAGGAGC-3’ and 5’-ATTCTAAGTATCCAAGC-3’ respectively. 
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8.2 KanR 
GATAAACCCAGCGAACCATTTGAGGTGATAGGTAAGATTATACCGAGGTATGA
AAACGAGAATTGGACCTTTACAGAATTACTCTATGAAGCGCCATATTTAAAAA
GCTACCAAGACGAAGAGGATGAAGAGGATGAGGAGGCAGATTGCCTTGAATA
TATTGACAATACTGATAAGATAATATATAATATATCTTTACTACCAAGACGATA
AATGCGTCGGAAAAGTTAAACTGCGAAAAAATTGGAACCGGTACGCTTATATA
GAAGATATCGCCGTATGTAAGGATTTCAGGGGGCAAGGCATAGGCAGCGCGC
TTATCAATATATCTATAGAATGGGCAAAGCATAAAAACTTGCATGGACTAAT
GCTTGAAACCCAGGACAATAACCTTATAGCTTGTAAATTCTATCATAATTGTG
GTTTCAAAATCGGCTCCGTCGATACTATGTTATACGCCAACTTTGAAAACAACT
TTGAAAAAGCTGTTTTCTGGTATTTAAGGTTTTAGAATGCAAGGAACAGTGAA
TTGGAGTTCGTCTTGTTATAATTAGCTTCTTGGGGTATCTTTAAATACTGTAGA
AAAGAGGAAGGAAATAATAAATGGCTAAAATGAGAATATCACCGGAATTGAA
AAAACTGATCGAAAAATACCGCTGCGTAAAAGATACGGAAGGAATGTCTCCT
GCTAAGGTATATAAGCTGGTGGGAGAAAATGAAAACCTATATTTAAAAATGAC
GGACAGCCGGTATAAAGGGACCACCTATGATGTGGAACGGGAAAAGGACATG
ATGCTATGGCTGGAAGGAAAGCTGCCTGTTCCAAAGGTCCTGCACTTTGAACG
GCATGATGGCTGGAGCAATCTGCTCATGAGTGAGGCCGATGGCGTCCTTTGCT
CGGAAGAGTATGAAGATGAACAAAGCCCTGAAAAGATTATCGAGCTGTATGC
GGAGTGCATCAGGCTCTTTCACTCCATCGACATATCGGATTGTCCCTATACGAA
TAGCTTAGACAGCCGCTTAGCCGAATTGGATTACTTACTGAATAACGATCTGG
CCGATGTGGATTGCGAAAACTGGGAAGAAGACACTCCATTTAAAGATCCGCGC
GAGCTGTATGATTTTTTAAAGACGGAAAAGCCCGAAGAGGAACTTGTCTTTTC
CCACGGCGACCTGGGAGACAGCAACATCTTTGTGAAAGATGGCAAAGTAAGT
GGCTTTATTGATCTTGGGAGAAGCGGCAGGGCGGACAAGTGGTATGACATTG
CCTTCTGCGTCCGGTCGATCAGGGAGGATATCGGGGAAGAACAGTATGTCGA
GCTATTTTTTGACTTACTGGGGATCAAGCCTGATTGGGAGAAAATAAAATATT
ATATTTTACTGGATGAATTGTTTTAGTACCTAGATTTAGATGTCTAAAAAGCTT 
 
Figure 44.  Sequence of the kanamycin resistance cassette found in pJMK30.  The 
nucleotide sequence of the kanamycin resistance cassette encodes for an aminoglycoside 
3’-phosphotransferase (aph-3) which can be excised using BamHI to give sticky ends.  
Gene specific forward (kan
R
 F-out) and reverse (kan
R
 R-out) primers were selected to 
target the areas highlighted in yellow.  The sequences of these were 5’-
TGGGTTTCAAGCATTAGTCCATGCAAG-3’ and 5’-GTGGTATGACATTGCCTTCTG 
CG-3’ respectively.  
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9 APPENDIX 3 – METABOLOMICS  
9.1 Materials and Methods  
A suspension of C. jejuni 81-176 in MHB was prepared from 48 hour plate cultures and 
corrected to an OD595 of 1.5.  One ml of this was added to each of two vented cap 75 cm
2
 
tissue culture flasks (Corning).  37 ml of fresh sterile MHB was added to each flask and 
2 ml of sterile water added to one flask to act as the PPI free control and 2 ml of 
pantoprazole in water was added to the other (to give a final pantoprazole concentration of 
2 mg/ml or 2,000 µg/ml).  Flasks were mixed well and incubated for 4 hours before 
plunging flasks into ice buckets, mixing regularly for 5 minutes.  Cooled 40 ml samples 
were then transferred from tissue culture flasks into cooled sterile 50 ml falcon tubes 
(Corning) and left on ice for a further 5 minutes.  Tubes were then centrifuged at 1,000 × g 
for 10 minutes at 4°C.  A large proportion of supernatant was removed, leaving around 
1 ml in which to resuspend pellets.  This was then transferred to 1.5 ml sterile Eppendorfs 
and centrifuged again at 2,500 × g for 5 minutes at 4°C.  All of the supernatant was then 
removed and the pellets re-suspended in 200 μl of iced chloroform/methanol/water mixture 
(ratio 1:3:1).  Eppendorfs were then vortexed at 4°C for 1 hour before being centrifuged at 
13,000 × g for 3 minutes at 4°C.  180 μl supernatant was then removed into fresh 
Eppendorfs and stored at -80°C until analysis by LCMS was carried out on three biological 
replicates. 
9.2 Results  
Only metabolites with an identity confidence score of between seven and ten (ten being the 
highest achievable) have been selected for inclusion in Table 28.  Metabolites with low 
confidence scores have not been matched with known authentic standards which are 
included as internal controls before each batch of analysis.  The detected mass and 
retention time of metabolites with low confidence scores is such that the identity cannot be 
accurately established.  All metabolites found in the control samples are given a score of 
1.00.  Metabolites with fold differences (either higher or lower) for which the P value was 
found to be significant (≤ 0.05) have been included in the table.  Undetected levels are 
designated as 0.00 but values in other sample sets cannot be statistically compared to 
undetected levels and so these have been disregarded from statistical analysis.  Therefore 
all metabolites with a detection level of 0.00 in either the control samples or the PPI 
exposed samples have been omitted.  Hence, the chemical structure identity of the PPI is 
missing from the table, because the score for the control samples was found to be 0.00.  
Metabolites which were detected in higher levels in the pantoprazole exposed samples are 
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shown in blue and metabolites detected in lower levels in the pantoprazole exposed 
samples are shown in orange. 
 
Table 28.  Metabolites with high confidence in their identity, which were detected in 
significantly different amounts between control and pantoprazole exposed C. jejuni. 
 
Putative 
Metabolite 
Confidence Related 
Pathway 
Control PPI 
Exposed 
T Test 
Chyrsophanol 8-O-
beta-D-glucoside 
7 Aromatic 
polyketides 
1.00 97.46 0.01 
Cyrysophanol 7 Chyrsophanol 
biosynthesis 
1.00 34.92 0.00 
Trp-Gly-His 7 Basic peptide 1.00 14.51 0.02 
Pyridoxamine 8 Vitamin B6 
metabolism 
1.00 11.46 0.02 
Solanidine 7 Steroidal 
glycoalkaloid 
1.00 10.38 0.02 
Isopyridoxal 7 Vitamin B6 
metabolism 
1.00 6.59 0.02 
L-2,3-
Dihydrodipicolinate 
8 Lysine 
biosynthesis 
1.00 5.68 0.03 
Methyloxaloacetate 8 C5-branched 
dibasic acid 
1.00 5.64 0.02 
Cys-Lys-Pro-Pro 7 Basic peptide 1.00 3.77 0.03 
3-
methoxyanthranilate 
8 Tryptophan 
metabolism 
1.00 3.20 0.03 
Xanthine 10 Purine 
metabolism 
1.00 2.35 0.03 
D-mannose 8 Fructose and 
mannose 
1.00 2.29 0.02 
Urocanate 8 Histidine 
metabolism 
1.00 2.09 0.03 
But-2-ene-1,2,3-
tricarboxylate 
8 Propanoate 
metabolism 
1.00 2.04 0.04 
Hexadecanoic acid 8 Fatty acid 
biosynthesis 
1.00 1.95 0.03 
octanoic acid 7 Fatty acid 
biosynthesis 
1.00 0.38 0.04 
Ile-Phe-Thr-Pro 7 Hydrophobic 
peptide 
1.00 0.10 0.02 
nonanoic acid 7 Fatty acids 
and 
conjugates 
1.00 0.05 0.04 
chavicol 7 Volatile 
cinnamoic 
1.00 0.04 0.02 
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